ClinicalTrials.gg
CompletedNCT05514509EBONIUpdated Oct 1, 2026Results posted

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

A Phase 4 interventional study of APRETUDE and Cabotegravir tablet in HIV Infections, sponsored by ViiV Healthcare. Completed at 22 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Updated Oct 1, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
14th of 36
295 · median 200
Started
2022
with 2 others
Phase 4
3 of 36
1 open now
Registered
26th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 26th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP). The study objectives are also to identify barriers and facilitators to implementation. The first of two participant types in the study are the Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available CAB PrEP via prescription from the PrEP provider. The second are Staff Study Participants (SSPs) who are site staff involved in the administrative and clinical aspects of offering and administering PrEP to PSPs at the clinical site.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Long acting injectables
  • Implementation science
  • HIV
  • PrEP
  • HIV Disparities
  • Ending the Epidemic
  • Engaging Black Women on APRETUDE by Optimizing Novel Implementation Strategies (EBONI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age, at the time of signing the .
  • negative at screening. Type of HIV-1 test is per standard of care.
  • No prior history of receiving oral CAB or CAB LA injections.
  • PrEP provider deems CAB PrEP use to be appropriate per the applicable CAB PrEP prescribing information prior to enrollment in the study.
  • Female at birth or self-identified Transgender Female.
  • Self-identified as African American/Black
  • Capable of giving signed informed consent

Exclusion criteria

Exclusion criteria:

  • indeterminate or positive test result during screening.
  • A participant of concurrent interventional clinical or implementation science study at any time during the study.
  • Cis-gender or Transgender male
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
295 participants (actual)

Study arms

  • Active comparator
    Standard Implementation (SI)

    The SI arm evaluated cabotegravir long-acting injectable (CAB LA) for pre-exposure prophylaxis (PrEP) delivery using standard toolkits made available with the commercial release of CAB LA for providers and patients to use as needed, along with implementation monitoring.

    Drug: APRETUDE · Drug: Cabotegravir tablet

  • Experimental
    Enhanced Implementation (EI)

    The EI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. EI sites received supports like patient-provider discussion tools, informational tools, and provider education.

    Drug: APRETUDE · Drug: Cabotegravir tablet

  • Experimental
    Enhanced Collaborative Implementation (ECI)

    The ECI arm evaluated CAB LA delivery using the standard toolkits plus enhanced supports to use as needed, along with implementation monitoring. ECI sites received supports like a sexual health assessment, provider education, videos, informational tools, persistence support, and peer ambassadors.

    Drug: APRETUDE · Drug: Cabotegravir tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12

    The IAM was used to assess among SSPs the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for Black women at our clinic/practice 2. APRETUDE seems suitable for Black women at our clinic/practice 3.APRETUDE seems applicable for Black women at our clinic/practice 4.APRETUDE seems like a good match for Black women at our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving Optional oral Lead in \[OLI\])

    Time frame: At Month 12

Secondary outcomes

  1. Mean IAM Score Assessed for SSPs Over Time

    Timeframe for evaluation of this outcome measure is Baseline (BL), M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI)

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  2. Change From Baseline in IAM Score Assessed for SSPs

    This outcome assesses the change in IAM score for SSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

    Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)

  3. Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at Baseline

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ at baseline are displayed in this outcome measure. In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

    Time frame: At Baseline (Month 1)

  4. Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 4

    SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

    Time frame: At Month 4

  5. Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 12

    SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

    Time frame: At Month 12

  6. Number of SSPs With Responses to APRETUDE Staffing Sufficiency Assessed by ISQs at Months 4 and 12

    SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs evaluated staff sufficiency to manage the current or anticipated number of APRETUDE patients on an ongoing basis.

    Time frame: At Month 4 and Month 12

  7. Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured Interview (SSI) at Month 4

    Semi-structured interview (SSI) guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4

  8. Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI at Month 12

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 12

  9. Mean IAM Score Assessed for PSPs

    The IAM was used to assess the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for me, 2. APRETUDE seems suitable for my lifestyle, 3. APRETUDE seems applicable in my life, 4. APRETUDE seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5, with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  10. Change From Baseline in IAM Score Assessed for PSPs

    This outcome assesses the change in IAM for PSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI) compared to BL.

    Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)

  11. Number of SSPs With Responses to Perceived Appropriateness of APRETUDE for Different Patient Characteristics Assessed by ISQ

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSP perceptions on the appropriateness of APRETUDE for patients, including specific patient groups or characteristics influencing appropriateness.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  12. Number of SSPs Reporting That APRETUDE is More Appropriate for Specific Demographic Groups Assessed by ISQ

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. The number of SSPs reporting in the ISQ that APRETUDE is more appropriate for specific patient demographic groups is displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  13. Number of SSPs Reporting Specific Demographic Groups for Which APRETUDE May be More Appropriate Assessed by ISQ

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions of the appropriateness of APRETUDE for specific patient demographics groups as reported in the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  14. Number of SSPs Reporting Appropriateness of APRETUDE Via Level of Concern Surrounding Patient Beliefs and Experiences Assessed by ISQ

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this outcome measure, appropriateness of APRETUDE for patients was reported by SSPs by rating in the ISQ their level of concern (ranging from "Not at all concerned" to "Extremely concerned") surrounding patients' belief in the efficacy of APRETUDE and experience with pain.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  15. Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Baseline

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the appropriateness of APRETUDE gathered during SSIs at baseline are displayed. This outcome measure presents common concepts identified from qualitative analysis of PSPs' perceived appropriateness of APRETUDE. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Baseline (Month 1)

  16. Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Month 12

    Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Month 12

  17. Number of Cis- and Trans Black Women Who Complete a Sexual Health Assessment in ECI Arm

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by gender. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  18. Number of PSPs Who Complete a Sexual Health Assessment in ECI Arm

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by clinic type to represent differences across clinical settings. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  19. Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm

    Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

    Time frame: Up to Month 12

  20. Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting

    Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

    Time frame: Up to Month 12

  21. Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm

    Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

    Time frame: Up to Month 12

  22. Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting

    Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

    Time frame: Up to Month 12

  23. Mean Feasibility of Intervention Measure (FIM) Score for PrEP Training Assessed for SSPs

    The FIM was used to assess the feasibility of the PrEP training provided only to EI and ECI arms using a four-item measure (1. The PrEP training would be easily implemented as part of my continuing education 2. It would be possible to incorporate the PrEP training into my continuing education efforts 3. The PrEP training was doable as a continuing education activity 4. The PrEP training was easy to use) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI); and was not assessed at baseline as sites had not had time to utilize the tool.

    Time frame: At Month 4 and Month 12

  24. Change in FIM Score for PrEP Training Assessed for SSPs

    This outcome assesses the change in FIM score for PrEP Training for SSPs over time. The change in FIM score was calculated as the longitudinal mean change from Month 4 to Month 12. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) compared to M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 12 compared to Month 4

  25. Number of SSPs With Responses to Feasibility and Ease of Clinical Tool Implementation Assessed by SSP Questionnaire Responses at Baseline

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of study tools gathered through the ISQ at BL, M4, and M12 are displayed. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents SSPs'perception of ease of implementation of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool.

    Time frame: At Baseline (Month 1)

  26. Number of SSPs With Responses to Planned Frequency of Use for PrEP Options Communication and Sexual Health Assessment Tools Assessed by SSP Questionnaire Responses at Baseline

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the planned frequency of use of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool among SSPs' clinics.

    Time frame: At Baseline (Month 1)

  27. Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 4

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

    Time frame: At Month 4

  28. Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 12

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

    Time frame: At Month 12

  29. Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 4

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

    Time frame: At Month 4

  30. Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 12

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

    Time frame: At Month 12

  31. Number of SSPs With Responses to Current Use of the PrEP Options Communication Tool

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4 and Month 12

  32. Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 4

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

    Time frame: At Month 4

  33. Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 12

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

    Time frame: At Month 12

  34. Number of SSPs With Responses to Current Use of the Sexual Health Assessment Tool

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4 and Month 12

  35. Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 4

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons the Sexual Health Assessment Tool was not used by a clinic/practice.

    Time frame: At Month 4

  36. Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 12

    Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons why the Sexual Health Assessment Tool was not used by a clinic/practice.

    Time frame: At Month 12

  37. Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 4

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

    Time frame: At Month 4

  38. Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 12

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

    Time frame: At Month 12

  39. Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Study Arm

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on if study tools were fit for use were gathered. Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

    Time frame: Up to Month 12

  40. Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Study Arm

    Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

    Time frame: Up to Month 12

  41. Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Study Arm

    PrEP training and tools were only available to selected arms (EI and/or ECI). Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients" (ECI only).

    Time frame: Up to Month 12

  42. Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Clinic Characteristics

    Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

    Time frame: Up to Month 12

  43. Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Clinic Characteristics

    Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

    Time frame: Up to Month 12

  44. Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Clinic Characteristics

    Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients (ECI only)".

    Time frame: Up to Month 12

  45. Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Study Arm

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

    Time frame: Up to Month 12

  46. Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Study Arm

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

    Time frame: Up to Month 12

  47. Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

    Time frame: Up to Month 12

  48. Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

    Time frame: Up to Month 12

  49. Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

    Time frame: Up to Month 12

  50. Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question: "Who discussed the results of the assessment with you? (ECI only)".

    Time frame: Up to Month 12

  51. Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

    Time frame: Up to Month 12

  52. Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

    Time frame: Up to Month 12

  53. Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies by patient gender subgroups.

    Time frame: Up to Month 12

  54. Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials by patient gender subgroups.

    Time frame: Up to Month 12

  55. Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

    Time frame: Up to Month 12

  56. Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question regarding the sexual health assessment: "Who discussed the results of the assessment with you? (ECI only)".

    Time frame: Up to Month 12

  57. Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

    Time frame: Up to Month 12

  58. Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups

    PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

    Time frame: Up to Month 12

  59. Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies Assessed by SSI by Study Arm

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies.

    Time frame: Up to Month 12

  60. Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies by Patient Subgroups

    PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies by patient gender subgroups.

    Time frame: Up to Month 12

  61. Number of Injections Occurring Within the Target Window From Target Date

    This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as +/- 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  62. Number of PSPs With Responses to Ease of Target Appointment Date Understanding Across Traditional and Non-traditional Settings

    PSP perceptions of barriers and facilitators to fidelity to APRETUDE injection windows were gathered via the ISQ. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs responses to the following question: "How easy was it to understand the Target Appointment Date?"

    Time frame: At Baseline (Month 1)

  63. Number of PSPs With Responses to Missed APRETUDE Injection Visits Assessed Traditional and Non-traditional Settings

    Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Have you missed any of your APRETUDE injection visits in the last 6 months?".

    Time frame: At Month 4 and Month 12

  64. Number of PSPs With Responses to Planned/Unplanned Nature of Missed Injection Visits Across Traditional and Non-traditional Settings

    Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Was missing your APRETUDE injection visits planned or unplanned?".

    Time frame: At Month 4 and Month 12

  65. Number of PSPs With Responses to Initiation of Oral PrEP Following Missed Visits Across Traditional and Non-traditional Settings

    Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Did you start oral PrEP after missing any of your injection visit?".

    Time frame: At Month 4 and Month 12

  66. Number of PSPs With Responses to Ease or Difficulty of Initiating Oral PrEP After a Missed Visit Across Traditional and Non-traditional Settings

    Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How easy or difficult was it to start oral PrEP after a missed injection visit?".

    Time frame: At Month 4 and Month 12

  67. Number of PSPs With Responses to Acceptability of Initiating Oral PrEP After a Missed Visit Assessed Across Traditional and Non-traditional Settings

    Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How acceptable was it to start oral PrEP after a missed injection visit?".

    Time frame: At Month 4 and Month 12

  68. Number of PSPs With Responses to Target Appointment Date Understanding and Access Across Traditional and Non-traditional Settings

    Data below were collected via SSIs or interviews, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs understanding and access to the target appointment date. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Baseline (Month 1)

  69. Number of PSPs With Responses to APRETUDE Adherence and Barriers/Facilitators to Injection Fidelity Across Traditional and Non-traditional Settings

    Data below were collected via SSIs or interviews, and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSP responses to the APRETUDE adherence and the specified barriers and facilitators to injection fidelity.

    Time frame: At Month 12

  70. Number of SSPs With Responses to APRETUDE Patient Management Challenges and Injection Fidelity Across Traditional and Non-traditional Settings

    Data below were collected by ISQ and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses for the specified items regarding patient management challenges and injection fidelity for APRETUDE.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  71. Number of SSPs With Responses to Injection Visits, Adherence, and Missed Doses Across Traditional and Non-traditional Settings Assessed by SSI

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Data displayed represent injection fidelity topics discussed by SSPs while describing the APRETUDE implementation process. SSIs were not conducted with SSPs at baseline. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Month 4

  72. Number of SSPs With Responses to Perceived Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings Assessed by SSI

    Data below were collected via SSIs, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents topics surrounding managing adherence and missed doses as discussed by SSPs during SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Month 12

  73. Number of Clinics With Responses to Implementation Monitoring Calls (IMC) Assessed Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings

    IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to barriers and facilitators to fidelity to APRETUDE injection windows as discussed during IMC calls. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: Up to Month 12

  74. Number of PSPs Completing Target Number of Injections by Patient Subgroups

    Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

    Time frame: Up to Month 12

  75. Number of SSPs With Responses to APRETUDE Implementation and Patient Management Assessed by Questionnaires

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified APRETUDE implementation and patient management. Only a selection of items are applicable for BL timepoint.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  76. Number of SSPs With Responses to Clinic Climate and Change Readiness Assessed by Questionnaires

    Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs response to the specified items regarding to the clinic climate and change readiness as implementation barriers and facilitators.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  77. Number of SSPs With Responses to Perceived Benefits of Bi-monthly Injections Assessed by Questionnaires

    Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs perception of the bi-monthly injection benefits.

    Time frame: At Month 12

  78. Number of PSPs With Responses to Prior Knowledge of HIV/PrEP Assessed by Questionnaires

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified questions regarding prior knowledge of HIV/PrEP. For each timepoint assessed for this outcome measure only specific questions were applied.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  79. Number of PSPs With Responses to HIV Knowledge and Misconceptions Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified items regarding HIV knowledge and misconceptions.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  80. Number of PSPs With Responses on Social Support, Stigma, and Personal Attitudes Towards PrEP Use Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement regarding the social and personal perceptions (support, stigma, attitude) towards PrEP use.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  81. Number of PSPs With Responses on Community Attitude Towards PrEP Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs response to the following question: "In general, what kind of attitude do you think your community has toward PrEP?".

    Time frame: At Baseline (Month 1)

  82. Number of PSPs With Responses to Worry Regarding APRETUDE Disclosure Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs response to the following question: "How often are you worried that people may find out that you are taking APRETUDE?".

    Time frame: At Month 4 and Month 12

  83. Number of PSPs With Responses to Sources of Pre-enrollment APRETUDE Information Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the sources of information for APRETUDE pre-enrollment. This outcome measure presents the PSPs response to the following question: "If you have questions about APRETUDE, where do you find information?" The answer "the study app/website" was inconsistently displayed to study arms at different time points due to a programming error.

    Time frame: At Month 4 and Month 12

  84. Number of PSPs With Responses to Perceived Benefits of In-person APRETUDE Injection Visits

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the PSPs perception of the benefits of in-person APRETUDE injection visits.

    Time frame: At Month 12

  85. Number of PSPs With Responses to Overall Feelings to APRETUDE Assessed by Questionnaires

    Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Overall, how are you feeling about getting APRETUDE?".

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  86. Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 4

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

    Time frame: At Month 4

  87. Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

    Time frame: At Month 12

  88. Number of Clinics With Responses to Facilitators and Barriers to Implementation Assessed by IMCs

    IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to overall SSP perceptions of facilitators and barriers to APRETUDE implementation discussed during IMC calls. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to qualitative data collection.

    Time frame: Up to Month 12

  89. Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Baseline

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Baseline (Month 1)

  90. Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

    Time frame: At Month 12

  91. Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs

    The AIM was used to assess among PSPs the acceptability of APRETUDE using a four-item measure (1. I believe APRETUDE will meet my approval for preventing HIV, 2. APRETUDE for the prevention of HIV is appealing to me, 3. I think I will like APRETUDE for the prevention of HIV, 4. I welcome APRETUDE for the prevention of HIV) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI)

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  92. Mean FIM Score Assessed for PSPs

    The FIM was used to assess among PSPs the feasibility of APRETUDE using a four-item measure (1. Receiving APRETUDE injections every 2 months seems workable in my life, 2. Receiving APRETUDE injections every 2 months seems possible for me, 3. Receiving APRETUDE injections every 2 months seems doable in my life, 4. Receiving APRETUDE injections every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  93. Mean AIM Score Assessed for SSPs

    The AIM was used to assess the acceptability of APRETUDE using a four-item measure (1. APRETUDE in our clinic/practice meets my approval, 2. APRETUDE in our clinic/practice is appealing to me, 3. I like APRETUDE in our clinic/practice, 4. I welcome APRETUDE in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  94. Mean FIM Score Assessed for SSPs

    The FIM was used to assess the feasibility of APRETUDE using a four-item measure (1. APRETUDE seems implementable in our clinic/practice, 2. APRETUDE seems possible in our clinic/practice, 3. APRETUDE seems doable in our clinic/practice, 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  95. Number of SSPs With Responses to Feasibility of APRETUDE Implementation

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding feasibility of APRETUDE implementation.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  96. Number of SSPs With Responses to Clinic Capacity for APRETUDE Patient Management

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding clinic capacity for APRETUDE patient management (i.e. "Number of APRETUDE patients that the clinic can manage per week").

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  97. Mean Number of Staff Needed to Incorporate APRETUDE Into Clinics Per Week

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This endpoint presents the results on mean number of staff needed to incorporate APRETUDE into clinics per week.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  98. Number of SSPs With Responses to Staff Time/Full-time Equivalent Hours (FTE) Requirements Per Week

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to staff time/FTE requirements per week to incorporate APRETUDE.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  99. Number of SSPs With Responses to Clinic/Practice Methods for Patient Tracking

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods for patient tracking.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  100. Number of SSPs With Responses to Clinic/Practice Methods to Remind Patients of an Upcoming Appointment

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods to remind patients of an upcoming appointment

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  101. Number of SSPs With Responses to Clinic/Practice Approaches for Offering Injection Appointments

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice approaches for offering injection appointments.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  102. Number of SSPs With Responses to Perceived Ease/Difficulty of Implementing APRETUDE in Clinics

    The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived ease/difficulty of implementing APRETUDE in clinics.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  103. Number of SSPs With Responses to Acceptability of APRETUDE Implementation

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to acceptability of APRETUDE implementation.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  104. Number of SSPs With Responses to Perceived Positive Perception of Implementing APRETUDE

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived positive perception of implementing APRETUDE.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  105. Number of SSPs With Responses to Patient Time in Waiting Room and Exam Room for APRETUDE Injection Visits

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to patient time in waiting room and exam room for APRETUDE injection visits.

    Time frame: At Month 12

  106. Number of SSPs With Responses to Post-injection Observation Period for Patients After APRETUDE

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to post-injection observation period for patients after APRETUDE.

    Time frame: At Month 12

  107. Number of PSPs With Responses to Convenience Level of Clinic Hours

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to convenience level of clinic hours.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  108. Number of PSPs With Responses to Sources of First Injection Appointment Reminders at Baseline

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to sources of first injection appointment reminders at baseline.

    Time frame: At Baseline (Month 1)

  109. Number of PSPs With Responses to Sources of Injection Appointment Reminders at Month 12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to sources of injection appointment reminders at Month 12.

    Time frame: At Month 12

  110. Number of PSPs With Responses to Preferred Appointment Reminder Types at Baseline

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to preferred appointment reminder types at baseline (Month 1).

    Time frame: At Baseline (Month 1)

  111. Number of PSPs With Responses to Most Helpful Types of Appointment Reminders at M4 and M12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to most helpful types of appointment reminders at M4 and M12.

    Time frame: At Month 4 and Month 12

  112. Number of PSPs With Responses to Need for Additional Care for Injection Visits

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to need for additional care for injection visits.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  113. Number of PSPs With Responses to Anticipated Time Off Work for APRETUDE Injections at Baseline

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to anticipated time off work for APRETUDE injections at baseline.

    Time frame: At Baseline (Month 1)

  114. Number of PSPs With Responses to Time Taken Off Work for Injections at M4 and M12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to time off work for APRETUDE injections at M4 and M12.

    Time frame: At Month 4 and Month 12

  115. Number of PSPs With Responses to Amount of Time Off Work Taken for Injections at M4 and M12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to amount of time off work taken for injections at M4 and M12.

    Time frame: At Month 4 and Month 12

  116. Number of PSPs With Responses to Status of Time Off Work for Injections at M4 and M12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to status of time off work for injections at M4 and M12.

    Time frame: At Month 4 and Month 12

  117. Number of PSPs With Responses to Frequency of Worry About Forgetting APRETUDE Injections

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to frequency of worry about forgetting APRETUDE injections.

    Time frame: At Month 4 and Month 12

  118. Number of PSPs With Responses to Perceived Ease/Difficulty of Scheduling Injection Appointments

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of scheduling injection appointments.

    Time frame: At Month 4 and Month 12

  119. Number of PSPs With Responses to Perceived Ease/Difficulty of Rescheduling Injection Appointments

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of rescheduling injection appointments.

    Time frame: At Month 4 and Month 12

  120. Number of PSPs With Responses to Acceptability of Attending the Clinic Every 2 Months

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to how easy or difficult it has been to get to the clinic every 2 months at M4 and M12.

    Time frame: At Month 4 and at Month 12

  121. Number of PSPs With Responses to Length of Journey to the Clinic/Practice at M12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to "Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?" at M12.

    Time frame: At Month 12

  122. Number of PSPs With Responses to Concerns About APRETUDE

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to concerns about APRETUDE.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  123. Number of PSPs With Responses to Specific Concerns About APRETUDE at Baseline

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at baseline (M1).

    Time frame: At Baseline (Month 1)

  124. Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 4

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M4.

    Time frame: At Month 4

  125. Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 12

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M12.

    Time frame: At Month 12

  126. Number of PSPs With Responses to Acceptability of Bi-monthly Clinic Visits for Injections

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of bi-monthly clinic visits for injections.

    Time frame: At Baseline (Month 1), Month 4 and Month 12

  127. Number of PSPs With Responses to Acceptability of HIV and STI Testing Frequency

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of HIV and STI testing frequency.

    Time frame: At Month 4 and Month 12

  128. Number of PSPs With Responses to Local Reactions Following an APRETUDE Injection

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to local reactions following an APRETUDE injection.

    Time frame: At Month 4 and Month 12

  129. Number of PSPs With Responses to Acceptability of Local Reactions

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of local reactions following an APRETUDE injection.

    Time frame: At Month 4 and Month 12

  130. Number of PSPs With Responses on Return to Daily Activities Post-injection

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses on return to daily activities post-injection (e.g., going back to work, social events, exercise, driving).

    Time frame: At Month 4 and Month 12

  131. Number of PSPs Indicating How Bothered by Pain They Were During APRETUDE Injections

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents data indicating how bothered by pain PSPs were during injection.

    Time frame: At Month 4 and Month 12

  132. Number of PSPs With Responses to Acceptability of Injection-related Pain

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of injection-related pain.

    Time frame: At Month 4 and Month 12

  133. Number of PSPs With Responses to Pain Reduction Strategies Post-injection

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to pain reduction strategies post-injection.

    Time frame: At Month 4 and Month 12

  134. Mean Rating of Pain/Discomfort Following First APRETUDE Injection

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following first APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

    Time frame: At Month 4 and Month 12

  135. Mean Rating of Pain/Discomfort Following Most Recent APRETUDE Injection

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following the most recent APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

    Time frame: At Month 4 and Month 12

  136. Number of SSPs With Influences on and Facilitators/Barriers of Acceptability of APRETUDE Assessed by SSI

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions of the acceptability of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of acceptability of APRETUDE.

    Time frame: At Month 4 and Month 12

  137. Number of SSPs With Influences on and Facilitators/Barriers of Feasibility of APRETUDE

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSP perceptions of the feasibility of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of feasibility of APRETUDE.

    Time frame: At Month 12

  138. Number of PSPs With Influences of Acceptability of APRETUDE at Baseline

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of acceptability of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Baseline (Month 1)

  139. Number of PSPs With Influences of Acceptability of APRETUDE at Month 12

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of acceptability of APRETUDE at M12.

    Time frame: At Month 12

  140. Number of PSPs With Influences of Feasibility of APRETUDE at Baseline

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of feasibility of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

    Time frame: At Baseline (Month 1)

  141. Number of PSPs With Influences of Feasibility of APRETUDE at Month 12

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of feasibility of APRETUDE at M12.

    Time frame: At Month 12

  142. Number of PSPs Who Had Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Baseline

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of use of oral cabotegravir pills as oral lead-in to APRETUDE injections was gathered using the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs who had OLI before APRETUDE injection.

    Time frame: At Baseline (Month 1)

  143. Number of SSPs Reporting Use of Oral lead-in Before APRETUDE Injection on Baseline ISQ

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs who chose OLI before APRETUDE injection at baseline (M1).

    Time frame: At Baseline (Month 1)

  144. Number of SSPs Who Chose Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Month 4 and 12

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs who chose OLI before APRETUDE injection at M4 and M12.

    Time frame: At Month 4 and Month 12

  145. Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI

    SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions on reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). SSIs were not conducted with SSPs at BL. This outcome measure presents the SSPs with responses on reasons for decision to use OLI assessed by SSI at M4 and M12.

    Time frame: At Month 4 and Month 12

  146. Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Baseline

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at baseline (M1).

    Time frame: At Baseline (Month 1)

  147. Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 4

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M4.

    Time frame: At Month 4

  148. Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 12

    The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M12.

    Time frame: At Month 12

  149. Number of PSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons for using oral cabotegravir pills as OLI to APRETUDE injections were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs' experiences with and reasons for using OLI or direct-to-injection (DTI) approach, assessed by SSIs.

    Time frame: At Baseline (Month 1)

  150. Number of PSPs With Responses on Decision Making for Use of OLI Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs on reasons for decision to use OLI, assessed by surveys.

    Time frame: At Baseline (Month 1)

  151. Number of PSPs With Responses on Reasons for Decision for Use of OLI Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses on reasons for decision for use of OLI, assessed by surveys.

    Time frame: At Baseline (Month 1)

  152. Number of PSPs With PrEP History

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. Timeframe for evaluation of this outcome measure is BL.

    Time frame: At Baseline (Month 1)

  153. Number of PSPs With Responses to Consistency in Oral PrEP Use in Past 6 Months

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to consistency in Oral PrEP use in past 6 months.

    Time frame: At Baseline (Month 1)

  154. Number of PSPs With Responses to Oral PrEP Duration

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to Oral PrEP duration.

    Time frame: At Baseline (Month 1)

  155. Number of PSPs Who Completed a SHA and Initiate APRETUDE

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP use of the sexual health assessment (available only to the ECI arm) was gathered via the ISQ. Timeframe for evaluation of this outcome measure is at Baseline (BL) and M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs who completed a SHA and initiate APRETUDE. All PSPs enrolled in the study initiated APRETUDE.

    Time frame: At Baseline (Month 1) and Month 12

  156. Number of PSPs With Responses to Experiences With Oral PrEP Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to experiences with Oral PrEP, assessed by surveys.

    Time frame: At Baseline (Month 1)

  157. Number of PSPs With Responses to Oral PrEP Side Effects Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to Oral PrEP side effects, assessed by surveys.

    Time frame: At Baseline (Month 1)

  158. Number of PSPs With Responses to Frequency of Worry About Oral PrEP Disclosure Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to frequency of worry about Oral PrEP disclosure, assessed by surveys.

    Time frame: At Baseline (Month 1)

  159. Number of PSPs With Responses to Reasons for Choosing APRETUDE Assessed by Surveys

    The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to reasons for choosing APRETUDE, assessed by surveys.

    Time frame: At Baseline (Month 1)

  160. Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Baseline

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection. This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at baseline (M1).

    Time frame: At Baseline (Month 1)

  161. Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Month 12

    SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at M12.

    Time frame: At Month 12

07

Results

Posted Oct 1, 2026

Participant flow

A total of 24 clinics were randomized to Standard implementation(SI), EI(Enhanced Implementation) and ECI(Enhanced Collaborative Implementation) arms. In these clinics, a total of 163 patient study participants (PSPs) were enrolled and all of them received study treatment and 132 Staff Study Participants (SSPs) were enrolled that included healthcare providers, nurses, staff performing injections, clinic administrators, social workers, case managers, pre-exposure prophylaxis(PrEP) educators, etc.

Participant flow — Overall Study
MilestoneStandard Implementation (SI)Enhanced Implementation (EI)Enhanced Collaborative Implementation (ECI)
Started9611584
Psp566344
Ssp405240
Completed778563
Not completed193021
Withdrew: Adverse event111
Withdrew: Lost to follow-up899
Withdrew: Physician decision123
Withdrew: Withdrawal by subject9148
Withdrew: Site terminated by sponsor040

Outcome measures

PrimaryMean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12

The IAM was used to assess among SSPs the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for Black women at our clinic/practice 2. APRETUDE seems suitable for Black women at our clinic/practice 3.APRETUDE seems applicable for Black women at our clinic/practice 4.APRETUDE seems like a good match for Black women at our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving Optional oral Lead in \[OLI\])

Time frame:
At Month 12
Reported as:
Mean · Scores on a scale
Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 12
Scores on a scaleSI - SSPEI - SSPECI - SSP
Mean Intervention Appropriateness Measure (IAM) Score Assessed for SSPs at Month 124.4 ± 0.904.7 ± 0.494.3 ± 0.69
SecondaryMean IAM Score Assessed for SSPs Over Time

Timeframe for evaluation of this outcome measure is Baseline (BL), M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI)

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean IAM Score Assessed for SSPs Over Time
Scores on a scaleSI - SSPEI - SSPECI - SSP
Baseline4.4 ± 0.844.6 ± 0.554.6 ± 0.66
Month 44.3 ± 0.864.5 ± 0.614.3 ± 0.70
Month 124.4 ± 0.904.7 ± 0.494.3 ± 0.69
SecondaryChange From Baseline in IAM Score Assessed for SSPs

This outcome assesses the change in IAM score for SSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

Time frame:
At Month 4 and Month 12 compared to Baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in IAM Score Assessed for SSPs
Scores on a scaleSI - SSPEI - SSPECI - SSP
Month 4 compared to Baseline-0.3 ± 0.89-0.1 ± 0.58-0.3 ± 0.60
Month 12 compared to Baseline-0.3 ± 1.200.0 ± 0.65-0.5 ± 0.76
SecondaryNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at Baseline

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ at baseline are displayed in this outcome measure. In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at Baseline
ParticipantsSI - SSPEI - SSPECI - SSP
Identifying eligible individuals for APRETUDE — Extremely concerned360
Identifying eligible individuals for APRETUDE — Moderately concerned151
Identifying eligible individuals for APRETUDE — Somewhat concerned776
Identifying eligible individuals for APRETUDE — Slightly concerned8158
Identifying eligible individuals for APRETUDE — Not at all concerned211925
Staff resourcing to ensure appropriate clinic flow — Extremely concerned230
Staff resourcing to ensure appropriate clinic flow — Moderately concerned235
Staff resourcing to ensure appropriate clinic flow — Somewhat concerned745
Staff resourcing to ensure appropriate clinic flow — Slightly concerned101010
Staff resourcing to ensure appropriate clinic flow — Not at all concerned193220
Number of exam rooms for injections — Extremely concerned233
Number of exam rooms for injections — Moderately concerned423
Number of exam rooms for injections — Somewhat concerned134
Number of exam rooms for injections — Slightly concerned655
Number of exam rooms for injections — Not at all concerned273925
Clinic staff to administer injections — Extremely concerned432
Clinic staff to administer injections — Moderately concerned312
Clinic staff to administer injections — Somewhat concerned234
Clinic staff to administer injections — Slightly concerned897
Clinic staff to administer injections — Not at all concerned233625
SecondaryNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 4

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 4
ParticipantsSI - SSPEI - SSPECI - SSP
Identifying eligible individuals for APRETUDE — Extremely concerned210
Identifying eligible individuals for APRETUDE — Moderately concerned300
Identifying eligible individuals for APRETUDE — Somewhat concerned337
Identifying eligible individuals for APRETUDE — Slightly concerned477
Identifying eligible individuals for APRETUDE — Not at all concerned172124
Staff resourcing to ensure appropriate clinic flow — Extremely concerned201
Staff resourcing to ensure appropriate clinic flow — Moderately concerned022
Staff resourcing to ensure appropriate clinic flow — Somewhat concerned7410
Staff resourcing to ensure appropriate clinic flow — Slightly concerned768
Staff resourcing to ensure appropriate clinic flow — Not at all concerned132017
Number of exam rooms for injections — Extremely concerned002
Number of exam rooms for injections — Moderately concerned000
Number of exam rooms for injections — Somewhat concerned314
Number of exam rooms for injections — Slightly concerned4710
Number of exam rooms for injections — Not at all concerned222422
Clinic staff to administer injections — Extremely concerned111
Clinic staff to administer injections — Moderately concerned210
Clinic staff to administer injections — Somewhat concerned438
Clinic staff to administer injections — Slightly concerned739
Clinic staff to administer injections — Not at all concerned152420
SecondaryNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 12

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by ISQs at Month 12
ParticipantsSI - SSPEI - SSPECI - SSP
Identifying eligible individuals for APRETUDE — Extremely concerned300
Identifying eligible individuals for APRETUDE — Moderately concerned423
Identifying eligible individuals for APRETUDE — Somewhat concerned414
Identifying eligible individuals for APRETUDE — Slightly concerned357
Identifying eligible individuals for APRETUDE — Not at all concerned121818
Staff resourcing to ensure appropriate clinic flow — Extremely concerned202
Staff resourcing to ensure appropriate clinic flow — Moderately concerned304
Staff resourcing to ensure appropriate clinic flow — Somewhat concerned336
Staff resourcing to ensure appropriate clinic flow — Slightly concerned564
Staff resourcing to ensure appropriate clinic flow — Not at all concerned131716
Number of exam rooms for injections — Extremely concerned103
Number of exam rooms for injections — Moderately concerned302
Number of exam rooms for injections — Somewhat concerned425
Number of exam rooms for injections — Slightly concerned356
Number of exam rooms for injections — Not at all concerned151916
Clinic staff to administer injections — Extremely concerned304
Clinic staff to administer injections — Moderately concerned302
Clinic staff to administer injections — Somewhat concerned227
Clinic staff to administer injections — Slightly concerned454
Clinic staff to administer injections — Not at all concerned141915
SecondaryNumber of SSPs With Responses to APRETUDE Staffing Sufficiency Assessed by ISQs at Months 4 and 12

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs evaluated staff sufficiency to manage the current or anticipated number of APRETUDE patients on an ongoing basis.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to APRETUDE Staffing Sufficiency Assessed by ISQs at Months 4 and 12
ParticipantsSI - SSPEI - SSPECI - SSP
Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — No135
Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff to manage only the current number of APRETUDE patients11714
Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff for current and anticipated APRETUDE patients15209
Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Unsure2210
Month 4 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Missing000
Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — No204
Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff to manage only the current number of APRETUDE patients101012
Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Yes, the clinic has sufficient staff for current and anticipated APRETUDE patients11119
Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Unsure347
Month 12 - Sufficient staff to manage current and anticipated APRETUDE patients on an ongoing basis — Missing010
SecondaryNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured Interview (SSI) at Month 4

Semi-structured interview (SSI) guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured Interview (SSI) at Month 4
ParticipantsSI - SSPEI - SSPECI - SSP
Importance for women576
Changes in perceptions of appropriateness845
Barrier: Insurance issues (Access)7711
Barrier: Injection aversion (Initiation)8910
Barrier: Injection schedule (Initiation)658
Barrier: Patient beliefs (Initiation)754
Barrier: Comfort with oral PrEP (Initiation)133
Barrier: Challenges with Visits (Maintenance)8812
Barrier: Injection Side Effects (Maintenance)101111
Barrier: Lack of resources (Maintenance)446
Facilitator: Absence of daily pill regimen (Initiation)191213
Facilitator: Perceived protection from HIV (Initiation)751
Facilitator: Privacy (Initiation)921
Facilitator: Minimal Side Effects (Maintenance)432
Patient Selection for APRETUDE222223
Patient Selection Strategies201719
Patient Selection Criteria478
SecondaryNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI at Month 12

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI at Month 12
ParticipantsSI - SSPEI - SSPECI - SSP
Enthusiasm about APRETUDE10812
Belief in appropriateness1485
Patient Selection-Assessment of sexual-behavioral history896
Patient Selection-Discussions using shared decision-making635
Patient Selection-Results of STI-HIV testing731
Patient identification-Consider specific criteria746
Patient identification-Discuss with sexually active patients637
Patient identification-Utilize routine sexual history assessments552
Patient identification-Discuss with all patients623
Patient identification-Employ an open nonjudgmental approach331
Patient identification-Train providers340
Facilitator: Need for injectable option101010
Facilitator: For anyone having sex1156
Facilitator: Needed for high-risk people462
Facilitator: Needed for women-Black women433
Facilitator: General need for APRETUDE225
Patient lifestyle barriers402
SecondaryMean IAM Score Assessed for PSPs

The IAM was used to assess the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for me, 2. APRETUDE seems suitable for my lifestyle, 3. APRETUDE seems applicable in my life, 4. APRETUDE seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5, with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean IAM Score Assessed for PSPs
Scores on a scaleSI - PSPEI - PSPECI - PSP
Baseline4.3 ± 0.834.2 ± 0.744.6 ± 0.52
Month 44.6 ± 0.604.3 ± 0.594.7 ± 0.52
Month 124.7 ± 0.494.3 ± 0.654.7 ± 0.54
SecondaryChange From Baseline in IAM Score Assessed for PSPs

This outcome assesses the change in IAM for PSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI) compared to BL.

Time frame:
At Month 4 and Month 12 compared to Baseline (Month 1)
Reported as:
Mean · Scores on a scale
Change From Baseline in IAM Score Assessed for PSPs
Scores on a scaleSI - PSPEI - PSPECI - PSP
Month 4 compared to BL0.2 ± 0.890.0 ± 0.600.1 ± 0.55
Month 12 compared to BL0.2 ± 0.600.1 ± 0.610.1 ± 0.64
SecondaryNumber of SSPs With Responses to Perceived Appropriateness of APRETUDE for Different Patient Characteristics Assessed by ISQ

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSP perceptions on the appropriateness of APRETUDE for patients, including specific patient groups or characteristics influencing appropriateness.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Perceived Appropriateness of APRETUDE for Different Patient Characteristics Assessed by ISQ
ParticipantsSI - SSPEI - SSPECI - SSP
BL - People who have been sexually active with 1 or more partners in the last 6 months345037
BL - People who have sex without a condom395037
BL - People who engage in anal sex364836
BL - People who have a sexual partner living with HIV375139
BL - People who are in monogamous relationships211714
BL - People who have sex with a person/people who inject drugs354737
BL - People who have sex with someone who has recently been in jail/prison324234
BL - People who currently have or recently (within the past 6 months) have had an STI other than HIV364536
BL - People who are currently adherent on daily oral PrEP302126
BL - Adherent daily oral PrEP users preferring a long-acting option343836
BL - People who are non-adherent on daily oral PrEP273231
BL - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1)252326
BL - People who could benefit from PrEP but do not want to use daily oral PrEP344336
BL - People who have previously used and discontinued oral PrEP283832
BL - People who feel stigmatized about taking oral PrEP314535
BL - People who request APRETUDE spontaneously223326
BL - People who experience stigma around using HIV prevention283832
BL - People who are concerned about taking pills every day334335
BL - People who experience stress of anxiety over adherence of a daily pill regimen324534
BL - People who live in areas with high HIV prevalence354335
BL - People who inject drugs334036
BL - People who have more chaotic lifestyles233131
BL - People who have more structured lifestyles222721
BL - People who have difficulty planning or organizing202929
BL - People who have stable income and stable housing232422
BL - People who experience homelessness or are unstably housed253529
BL - People who have psychiatric comorbidities222824
BL - People who are incarcerated, temporarily incarcerated, or recently released from incarceration273125
BL - Other201
M4 - People who have been sexually active with 1 or more partners in the last 6 months283137
M4 - People who have sex without a condom273135
M4 - People who engage in anal sex292833
M4 - People who have a sexual partner living with HIV293136
M4 - People who are in monogamous relationships191418
M4 - People who have sex with a person/people who inject drugs273235
M4 - People who have sex with someone who has recently been in jail/prison262830
M4 - People who currently have or recently (within the past 6 months) have had an STI other than HIV283134
M4 - People who are currently adherent on daily oral PrEP212221
M4 - Adherent daily oral PrEP users preferring a long-acting option263033
M4 - People who are non-adherent on daily oral PrEP242630
M4 - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1)202324
M4 - People who could benefit from PrEP but do not want to use daily oral PrEP272933
M4 - People who have previously used and discontinued oral PrEP252830
M4 - People who feel stigmatized about taking oral PrEP262833
M4 - People who request APRETUDE spontaneously212328
M4 - People who experience stigma around using HIV prevention262831
M4 - People who are concerned about taking pills every day273135
M4 - People who experience stress of anxiety over adherence of a daily pill regimen253134
M4 - People who live in areas with high HIV prevalence262932
M4 - People who inject drugs212930
M4 - People who have more chaotic lifestyles192126
M4 - People who have more structured lifestyles222026
M4 - People who have difficulty planning or organizing212026
M4 - People who have stable income and stable housing211626
M4 - People who experience homelessness or are unstably housed232129
M4 - People who have psychiatric comorbidities212025
M4 - People who are incarcerated, temporarily incarcerated, or recently released from incarceration212123
M4 - Other001
M12 - People who have been sexually active with 1 or more partners in the last 6 months252430
M12 - People who have sex without a condom262331
M12 - People who engage in anal sex252028
M12 - People who have a sexual partner living with HIV252632
M12 - People who are in monogamous relationships171120
M12 - People who have sex with a person/people who inject drugs252528
M12 - People who have sex with someone who has recently been in jail/prison242226
M12 - People who currently have or had an STI other than HIV within the past 6 months252429
M12 - People who are currently adherent on daily oral PrEP191424
M12 - Adherent daily oral PrEP users preferring a long-acting option222229
M12 - People who are non-adherent on daily oral PrEP212125
M12 - People who use oral PrEP on demand (i.e., event-based PrEP, PrEP 2-1-1)211623
M12 - People who could benefit from PrEP but do not want to use daily oral PrEP242029
M12 - People who have previously used and discontinued oral PrEP241926
M12 - People who feel stigmatized about taking oral PrEP232027
M12 - request APRETUDE spontaneously221825
M12 - People who experience stigma around using HIV prevention242127
M12 - People who are concerned about taking pills every day242127
M12 - People who experience stress of anxiety over adherence of a daily pill regimen242427
M12 - People who live in areas with high HIV prevalence242129
M12 - People who inject drugs202127
M12 - People who have more chaotic lifestyles181423
M12 - People who have more structured lifestyles221524
M12 - People who have difficulty planning or organizing201621
M12 - People who have stable income and stable housing221623
M12 - People who experience homelessness or are unstably housed211723
M12 - People who have psychiatric comorbidities211220
M12 - People who are incarcerated, temporarily incarcerated, or recently released from incarceration191521
M12 - Other100
SecondaryNumber of SSPs Reporting That APRETUDE is More Appropriate for Specific Demographic Groups Assessed by ISQ

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. The number of SSPs reporting in the ISQ that APRETUDE is more appropriate for specific patient demographic groups is displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs Reporting That APRETUDE is More Appropriate for Specific Demographic Groups Assessed by ISQ
ParticipantsSI - SSPEI - SSPECI - SSP
At Baseline — Yes243522
At Baseline — No161718
At Month 4 — Yes162220
At Month 4 — No131018
At Month 12 — Yes111415
At Month 12 — No151217
SecondaryNumber of SSPs Reporting Specific Demographic Groups for Which APRETUDE May be More Appropriate Assessed by ISQ

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions of the appropriateness of APRETUDE for specific patient demographics groups as reported in the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs Reporting Specific Demographic Groups for Which APRETUDE May be More Appropriate Assessed by ISQ
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Patients <35 years old223121
BL - Patients 35-50 years old182518
BL - Patients >50 years old142312
BL - Black patients233021
BL - White patients182319
BL - Hispanic/Latinx patients222721
BL - Patients of other races/ethnicities182817
BL - Cis-women (assigned female at birth, identify as female)212719
BL - Trans-women (assigned male at birth, identify as female)233321
BL - Trans-men (assigned female at birth, identify as male)192617
BL - Cis-men (assigned male at birth, identify as male)202319
BL - Non-binary individuals192115
BL - Heterosexual women202418
BL - Bisexual/pansexual women222720
BL - Lesbian women121812
BL - Heterosexual men192218
BL - Men who have sex with men213420
BL - None of the above100
BL - Other000
M4 - Patients <35 years old141918
M4 - Patients 35-50 years old131715
M4 - Patients >50 years old12149
M4 - Black patients141916
M4 - White patients121313
M4 - Hispanic/Latinx patients121816
M4 - Patients of other races/ethnicities111313
M4 - Cis-women (assigned female at birth, identify as female)131716
M4 - Trans-women (assigned male at birth, identify as female)142118
M4 - Trans-men (assigned female at birth, identify as male)131416
M4 - Cis-men (assigned male at birth, identify as male)131615
M4 - Non-binary individuals121214
M4 - Heterosexual women141914
M4 - Bisexual/pansexual women151715
M4 - Lesbian women10910
M4 - Heterosexual men121511
M4 - Men who have sex with men152118
M4 - None of the above000
M4 - Other110
M12 - Patients <35 years old101214
M12 - Patients 35-50 years old81112
M12 - Patients >50 years old61111
M12 - Black patients91214
M12 - White patients81112
M12 - Hispanic/Latinx patients81213
M12 - Patients of other races/ethnicities7911
M12 - Cis-women (assigned female at birth, identify as female)91013
M12 - Trans-women (assigned male at birth, identify as female)91113
M12 - Trans-men (assigned female at birth, identify as male)81013
M12 - Cis-men (assigned male at birth, identify as male)81012
M12 - Non-binary individuals81012
M12 - Heterosexual women91011
M12 - Bisexual/pansexual women91112
M12 - Lesbian women677
M12 - Heterosexual men8811
M12 - Men who have sex with men101313
M12 - None of the above000
M12 - Other110
SecondaryNumber of SSPs Reporting Appropriateness of APRETUDE Via Level of Concern Surrounding Patient Beliefs and Experiences Assessed by ISQ

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this outcome measure, appropriateness of APRETUDE for patients was reported by SSPs by rating in the ISQ their level of concern (ranging from "Not at all concerned" to "Extremely concerned") surrounding patients' belief in the efficacy of APRETUDE and experience with pain.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs Reporting Appropriateness of APRETUDE Via Level of Concern Surrounding Patient Beliefs and Experiences Assessed by ISQ
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Patients' injection-related pain/soreness — Extremely concerned260
BL - Patients' injection-related pain/soreness — Moderately concerned5125
BL - Patients' injection-related pain/soreness — Somewhat concerned777
BL - Patients' injection-related pain/soreness — Slightly concerned152117
BL - Patients' injection-related pain/soreness — Not at all concerned11611
M4 - Patients' injection-related pain/soreness — Extremely concerned410
M4 - Patients' injection-related pain/soreness — Moderately concerned240
M4 - Patients' injection-related pain/soreness — Somewhat concerned6510
M4 - Patients' injection-related pain/soreness — Slightly concerned141017
M4 - Patients' injection-related pain/soreness — Not at all concerned31211
M12 - Patients' injection-related pain/soreness — Extremely concerned400
M12 - Patients' injection-related pain/soreness — Moderately concerned342
M12 - Patients' injection-related pain/soreness — Somewhat concerned968
M12 - Patients' injection-related pain/soreness — Slightly concerned7612
M12 - Patients' injection-related pain/soreness — Not at all concerned31010
BL - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned360
BL - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned443
BL - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned798
BL - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned121310
BL - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned142019
M4 - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned100
M4 - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned410
M4 - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned343
M4 - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned101212
M4 - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned111523
M12 - Patient lack of belief in the efficacy of APRETUDE — Extremely concerned201
M12 - Patient lack of belief in the efficacy of APRETUDE — Moderately concerned411
M12 - Patient lack of belief in the efficacy of APRETUDE — Somewhat concerned459
M12 - Patient lack of belief in the efficacy of APRETUDE — Slightly concerned647
M12 - Patient lack of belief in the efficacy of APRETUDE — Not at all concerned101614
SecondaryNumber of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Baseline

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the appropriateness of APRETUDE gathered during SSIs at baseline are displayed. This outcome measure presents common concepts identified from qualitative analysis of PSPs' perceived appropriateness of APRETUDE. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Belief that injectable has better adherence than pill123
PSPs felt prepared to get APRETUDE181217
PSPs felt unprepared to get APRETUDE313
Concerns about effectiveness502
No concerns about effectiveness181217
Confused about what is required for APRETUDE to work433
No confusion about what is required for APRETUDE to work10510
Expectations for APRETUDE to be effective626
Perceived need for a long-acting injection such as APRETUDE16817
No perceived need for a long-acting injection such as APRETUDE001
APRETUDE is considered a good match for PSPs and women like them151210
SecondaryNumber of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Month 12

Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perception of Appropriateness of APRETUDE Assessed by SSI at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
Intends to continue using APRETUDE14912
APRETUDE is a long-term fit8511
APRETUDE can protect or is convenient763
Facilitators to continued use of APRETUDE1255
Barriers to continued use of APRETUDE533
Endorsed appropriateness of APRETUDE334
APRETUDE is convenient16711
APRETUDE addressed adherence challenges124
APRETUDE perceived as providing an additional layer of protection645
SecondaryNumber of Cis- and Trans Black Women Who Complete a Sexual Health Assessment in ECI Arm

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by gender. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Cis- and Trans Black Women Who Complete a Sexual Health Assessment in ECI Arm
ParticipantsECI - CisgenderECI - Transgender
Yes104
No01
I don't know62
Missing10
SecondaryNumber of PSPs Who Complete a Sexual Health Assessment in ECI Arm

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by clinic type to represent differences across clinical settings. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Who Complete a Sexual Health Assessment in ECI Arm
ParticipantsECI - Women's Health ClinicECI - Primary Care ClinicECI - HIV Specialist Clinic
Yes716
No010
I don't know323
Missing001
SecondaryNumber of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm
ParticipantsSI - PSPEI - PSPECI - PSP
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Study Arm13106
SecondaryNumber of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Number of Black Women (Both Cis- and Trans) Who Initiate APRETUDE by Clinic Setting41015
SecondaryNumber of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm
ParticipantsSI - PSPEI - PSPECI - PSP
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Study Arm321022
SecondaryNumber of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Number of Black Women (Both Cis and Trans) Who Continue APRETUDE Beyond a First Dose by Clinic Setting132229
SecondaryMean Feasibility of Intervention Measure (FIM) Score for PrEP Training Assessed for SSPs

The FIM was used to assess the feasibility of the PrEP training provided only to EI and ECI arms using a four-item measure (1. The PrEP training would be easily implemented as part of my continuing education 2. It would be possible to incorporate the PrEP training into my continuing education efforts 3. The PrEP training was doable as a continuing education activity 4. The PrEP training was easy to use) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI); and was not assessed at baseline as sites had not had time to utilize the tool.

Time frame:
At Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean Feasibility of Intervention Measure (FIM) Score for PrEP Training Assessed for SSPs
Scores on a scaleEI - SSPECI - SSP
Month 44.3 ± 0.623.9 ± 0.73
Month 124.6 ± 0.504.3 ± 0.67
SecondaryChange in FIM Score for PrEP Training Assessed for SSPs

This outcome assesses the change in FIM score for PrEP Training for SSPs over time. The change in FIM score was calculated as the longitudinal mean change from Month 4 to Month 12. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) compared to M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 12 compared to Month 4
Reported as:
Mean · Scores on a scale
Change in FIM Score for PrEP Training Assessed for SSPs
Scores on a scaleEI - SSPECI - SSP
Change in FIM Score for PrEP Training Assessed for SSPs-0.1 ± 0.400.4 ± 0.81
SecondaryNumber of SSPs With Responses to Feasibility and Ease of Clinical Tool Implementation Assessed by SSP Questionnaire Responses at Baseline

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of study tools gathered through the ISQ at BL, M4, and M12 are displayed. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents SSPs'perception of ease of implementation of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility and Ease of Clinical Tool Implementation Assessed by SSP Questionnaire Responses at Baseline
ParticipantsEI - SSPECI - SSP
The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Completely disagree00
The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Disagree00
The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree150
The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Agree190
The PrEP Options Communication Tool will be easy to implement in my clinic/practice (EI Only) — Completely agree140
The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Completely disagree00
The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Disagree01
The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Neither agree nor disagree017
The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Agree017
The Sexual Health Assessment Tool is/will be easy to implement in my clinic/practice (ECI Only) — Completely agree05
SecondaryNumber of SSPs With Responses to Planned Frequency of Use for PrEP Options Communication and Sexual Health Assessment Tools Assessed by SSP Questionnaire Responses at Baseline

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the planned frequency of use of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool among SSPs' clinics.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Planned Frequency of Use for PrEP Options Communication and Sexual Health Assessment Tools Assessed by SSP Questionnaire Responses at Baseline
ParticipantsEI - SSPECI - SSP
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Annually with each patient3—
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Before every visit with each patient5—
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — As needed based on patient demographics5—
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — As needed based on patient behaviors14—
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — I don't know21—
Frequency of clinic plans to use the PrEP Options Communication Tool with each patient (EI Only) — Other0—
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Annually with each patient—1
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Before every visit with each patient—8
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — As needed based on patient demographics—2
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — As needed based on patient behaviors—4
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — I don't know—24
Frequency of clinic plans to use the Sexual Health Assessment Tool with each patient (ECI Only) — Other—1
SecondaryNumber of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 4

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 4
ParticipantsEI - SSPECI - SSP
The PrEP training was easy to use — Completely disagree00
The PrEP training was easy to use — Disagree00
The PrEP training was easy to use — Neither agree nor disagree12
The PrEP training was easy to use — Agree813
The PrEP training was easy to use — Completely agree53
The amount of time involved in using this PrEP training has been fitting for me — Completely disagree00
The amount of time involved in using this PrEP training has been fitting for me — Disagree00
The amount of time involved in using this PrEP training has been fitting for me — Neither agree nor disagree14
The amount of time involved in using this PrEP training has been fitting for me — Agree812
The amount of time involved in using this PrEP training has been fitting for me — Completely agree52
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely disagree0—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Disagree0—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree4—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Agree11—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely agree6—
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Completely disagree—0
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Disagree—0
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Neither agree nor disagree—4
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Agree—7
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI Only) — Completely agree—2
SecondaryNumber of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 12

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility, Ease of Use, and Implementation of PrEP Training and Clinical Tools Assessed at Month 12
ParticipantsEI - SSPECI - SSP
The PrEP training was easy to use — Completely disagree00
The PrEP training was easy to use — Disagree00
The PrEP training was easy to use — Neither agree nor disagree01
The PrEP training was easy to use — Agree69
The PrEP training was easy to use — Completely agree87
The amount of time involved in using this PrEP training has been fitting for me — Completely disagree00
The amount of time involved in using this PrEP training has been fitting for me — Disagree01
The amount of time involved in using this PrEP training has been fitting for me — Neither agree nor disagree23
The amount of time involved in using this PrEP training has been fitting for me — Agree79
The amount of time involved in using this PrEP training has been fitting for me — Completely agree54
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely disagree0—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Disagree0—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Neither agree nor disagree1—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Agree8—
The PrEP Options Communication Tool was easy to implement in my clinic/practice (EI Only) — Completely agree6—
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Completely disagree—0
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Disagree—0
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Neither agree nor disagree—4
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Agree—5
The Sexual Health Assessment Tool was easy to implement in my clinic/practice (ECI only) — Completely agree—3
SecondaryNumber of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 4

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 4
ParticipantsEI - SSPECI - SSP
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Rarely1—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Sometimes8—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Often6—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — All the time6—
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Rarely—2
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Sometimes—4
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Often—2
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — All the time—5
SecondaryNumber of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 12

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Frequency of PrEP Options Communication Tool and Sexual Health Assessment Tool Use Assessed at Month 12
ParticipantsEI - SSPECI - SSP
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Rarely0—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Sometimes5—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — Often5—
Frequency of using the PrEP Options Communication Tool with each patient (EI Only) — All the time5—
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Rarely—0
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Sometimes—6
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — Often—2
Frequency of using the Sexual Health Assessment Tool with each patient (ECI Only) — All the time—4
SecondaryNumber of SSPs With Responses to Current Use of the PrEP Options Communication Tool

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Current Use of the PrEP Options Communication Tool
ParticipantsEI - SSP
M4 - Currently using PrEP Options Communication Tool — Yes21
M4 - Currently using PrEP Options Communication Tool — No6
M4 - Currently using PrEP Options Communication Tool — I don't know5
M12 - Currently using PrEP Options Communication Tool — Yes15
M12 - Currently using PrEP Options Communication Tool — No3
M12 - Currently using PrEP Options Communication Tool — I don't know8
SecondaryNumber of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 4

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 4
ParticipantsEI - SSP
Already have a similar tool1
Do not have time in a clinical visit to use the tool1
Do not understand the information in the tool0
Tool does not provide the right information0
Tool is not needed3
Other1
SecondaryNumber of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 12

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs Indicating Reasons Why the PrEP Options Communications Tool Was Not Used, Assessed at Month 12
ParticipantsEI - SSP
Already have a similar tool2
Do not have time in a clinical visit to use the tool0
Do not understand the information in the tool0
Tool does not provide the right information0
Tool is not needed2
Other0
SecondaryNumber of SSPs With Responses to Current Use of the Sexual Health Assessment Tool

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Current Use of the Sexual Health Assessment Tool
ParticipantsECI - SSP
M4 - Currently using Sexual Health Assessment Tool — Yes13
M4 - Currently using Sexual Health Assessment Tool — No9
M4 - Currently using Sexual Health Assessment Tool — I don't know16
M12 - Currently using Sexual Health Assessment Tool — Yes12
M12 - Currently using Sexual Health Assessment Tool — No6
M12 - Currently using Sexual Health Assessment Tool — I don't know14
SecondaryNumber of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 4

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons the Sexual Health Assessment Tool was not used by a clinic/practice.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 4
ParticipantsECI - SSP
Already have a similar assessment8
Does not integrate with the EMR5
The assessment is difficult to administer0
Concerns about patient privacy0
The assessment does not ask the right questions0
The assessment takes too much time0
The assessment is not needed0
Other1
SecondaryNumber of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 12

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons why the Sexual Health Assessment Tool was not used by a clinic/practice.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs Indicating Reasons Why the Sexual Health Assessment Tool Was Not Used, Assessed at Month 12
ParticipantsECI - SSP
Already have a similar assessment5
Does not integrate with the EMR2
The assessment is difficult to administer0
Concerns about patient privacy0
The assessment does not ask the right questions0
The assessment takes too much time0
The assessment is not needed0
Other1
SecondaryNumber of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 4

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 4
ParticipantsSI - SSPEI - SSPECI - SSP
Guide to Getting Started - Useful9119
Frequently Asked Questions - Useful8107
Dosing and Administration Guide - Useful11710
Injection Education Video - Useful101113
Instructions for Use Flashcard - Useful998
Medication Administration Planner - Useful458
Important Safety Information - Useful999
Readiness Considerations Checklist - Useful576
ViiVConnect Materials - Useful823
GSK Response Center - Useful224
Provider Website - Useful (SI Only)10——
EBONI Spot - Useful (EI/ECI Only)—1215
PrEP are for Black Women Training - Useful (EI/ECI Only)—26
How to Discuss Sexual Health Guidance Document - Useful (EI/ECI Only)—43
Implementation Guidance Video - Useful (EI/ECI Only)—55
PrEP Communications Options Tool - Useful (EI Only)—7—
Medication Acquisition Tracker - Useful (EI Only)—1—
Introduction to ViiVConnect Video - Useful (EI Only)—5—
APRETUDE Payer Information - Useful (EI Only)—4—
Sexual Health Assessment - Useful (ECI Only)——9
Other Tools and Resources1189
SecondaryNumber of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 12

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility and Utility of Implementation Strategies Assessed by SSI at Month 12
ParticipantsSI - SSPEI - SSPECI - SSP
Guide to Getting Started - Useful10710
FAQ Brochure - Useful1069
Dosing and Administration Guide - Useful12911
Injection Education Video - Useful31011
Instructions for Use Flashcard - Useful11810
Medication and Administration Planner - Useful714
Important Safety Information - Useful1387
Readiness Considerations Checklist - Useful444
ViiVConnect Materials - Useful1168
GSK Response Center - Useful244
Provider Website - Useful7——
EBONI Spot - Useful—810
PrEPare for Black Women Training - Useful—83
Sexual Health Guidance Document - Useful—53
Implementation Guidance Video - Useful—97
PrEP Communication Options Tool - Useful—9—
Medication Acquisition Tracker - Useful—2—
Introduction to ViiVConnect Video - Useful—6—
APRETUDE Payer Information - Useful—4—
Sexual Health Assessment - Useful——4
Tools and strategies adequate: No gaps151312
Tools and strategies not needed: Past experience314
Patient-facing resource needs432
Need for guidance on insurance and product acquisition501
SecondaryNumber of SSPs That Respond to PrEP Education Training and Utility of Strategies by Study Arm

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on if study tools were fit for use were gathered. Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Study Arm
ParticipantsSI - SSPEI - SSPECI - SSP
Used Frequently Asked Questions Brochure — Yes161717
Used Frequently Asked Questions Brochure — No668
Used Frequently Asked Questions Brochure — I don't remember437
Used Readiness Considerations Checklist — Yes181713
Used Readiness Considerations Checklist — No449
Used Readiness Considerations Checklist — I don't remember4510
Used Getting Started Guide — Yes171714
Used Getting Started Guide — No658
Used Getting Started Guide — I don't remember3410
Used Injection Education Video — Yes181620
Used Injection Education Video — No577
Used Injection Education Video — I don't remember335
Used Provider Website (SI only) — Yes19——
Used Provider Website (SI only) — No4——
Used Provider Website (SI only) — I don't remember3——
Used Instructions for Use flashcard — Yes201617
Used Instructions for Use flashcard — No468
Used Instructions for Use flashcard — I don't remember247
Used Important Safety Information document — Yes191519
Used Important Safety Information document — No476
Used Important Safety Information document — I don't remember347
Used patient materials (e.g., welcome brochure) — Yes181417
Used patient materials (e.g., welcome brochure) — No576
Used patient materials (e.g., welcome brochure) — I don't remember359
Used Dosing and Administration Guide — Yes181418
Used Dosing and Administration Guide — No587
Used Dosing and Administration Guide — I don't remember347
Used Implementation Guidance Video (ECI/EI only) — Yes—1312
Used Implementation Guidance Video (ECI/EI only) — No—710
Used Implementation Guidance Video (ECI/EI only) — I don't remember—610
Used Medication Administration Planner — Yes12128
Used Medication Administration Planner — No7915
Used Medication Administration Planner — I don't remember759
Used document on how to discuss sexual health (ECI/EI only) — Yes—149
Used document on how to discuss sexual health (ECI/EI only) — No—913
Used document on how to discuss sexual health (ECI/EI only) — I don't remember—310
Used EBONI Spot (ECI/EI only) — Yes—1819
Used EBONI Spot (ECI/EI only) — No—45
Used EBONI Spot (ECI/EI only) — I don't remember—48
Used GSK Response Center — Yes876
Used GSK Response Center — No131725
Used GSK Response Center — I don't remember521
Used ViiV Connect Video — Yes384
Used ViiV Connect Video — No315
Used ViiV Connect Video — I don't remember310
Used Medication Acquisition Tracker (EI only) — Yes—5—
Used Medication Acquisition Tracker (EI only) — No—3—
Used Medication Acquisition Tracker (EI only) — I don't remember—2—
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — Yes—1417
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — No—99
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — I don't remember—36
SecondaryNumber of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Study Arm

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Study Arm
ParticipantsSI - SSPEI - SSPECI - SSP
Helpfulness of Frequently Asked Questions Brochure — Very helpful7108
Helpfulness of Frequently Asked Questions Brochure — Somewhat helpful555
Helpfulness of Frequently Asked Questions Brochure — A little helpful314
Helpfulness of Frequently Asked Questions Brochure — Not at all helpful110
Helpfulness of Readiness Considerations Checklist — Very helpful8119
Helpfulness of Readiness Considerations Checklist — Somewhat helpful643
Helpfulness of Readiness Considerations Checklist — A little helpful321
Helpfulness of Readiness Considerations Checklist — Not at all helpful100
Helpfulness of Getting Started Guide — Very helpful6118
Helpfulness of Getting Started Guide — Somewhat helpful553
Helpfulness of Getting Started Guide — A little helpful513
Helpfulness of Getting Started Guide — Not at all helpful100
Helpfulness of Injection Education Video — Very helpful101415
Helpfulness of Injection Education Video — Somewhat helpful515
Helpfulness of Injection Education Video — A little helpful210
Helpfulness of Injection Education Video — Not at all helpful100
Helpfulness of Provider Website (SI only) — Very helpful7——
Helpfulness of Provider Website (SI only) — Somewhat helpful6——
Helpfulness of Provider Website (SI only) — A little helpful4——
Helpfulness of Provider Website (SI only) — Not at all helpful2——
Helpfulness of Instructions for Use flashcard — Very helpful81215
Helpfulness of Instructions for Use flashcard — Somewhat helpful1032
Helpfulness of Instructions for Use flashcard — A little helpful110
Helpfulness of Instructions for Use flashcard — Not at all helpful100
Helpfulness of Important Safety Information document — Very helpful101012
Helpfulness of Important Safety Information document — Somewhat helpful536
Helpfulness of Important Safety Information document — A little helpful320
Helpfulness of Important Safety Information document — Not at all helpful101
Helpfulness of patient materials (e.g., welcome brochure) — Very helpful9912
Helpfulness of patient materials (e.g., welcome brochure) — Somewhat helpful442
Helpfulness of patient materials (e.g., welcome brochure) — A little helpful412
Helpfulness of patient materials (e.g., welcome brochure) — Not at all helpful101
Helpfulness of Dosing and Administration Guide — Very helpful11913
Helpfulness of Dosing and Administration Guide — Somewhat helpful344
Helpfulness of Dosing and Administration Guide — A little helpful310
Helpfulness of Dosing and Administration Guide — Not at all helpful101
Helpfulness of Implementation Guidance Video (ECI/EI only) — Very helpful—89
Helpfulness of Implementation Guidance Video (ECI/EI only) — Somewhat helpful—32
Helpfulness of Implementation Guidance Video (ECI/EI only) — A little helpful—11
Helpfulness of Implementation Guidance Video (ECI/EI only) — Not at all helpful—10
Helpfulness of Medication Administration Planner — Very helpful765
Helpfulness of Medication Administration Planner — Somewhat helpful253
Helpfulness of Medication Administration Planner — A little helpful210
Helpfulness of Medication Administration Planner — Not at all helpful100
Helpfulness of how to discuss sexual health (ECI/EI only) — Very helpful—96
Helpfulness of how to discuss sexual health (ECI/EI only) — Somewhat helpful—43
Helpfulness of how to discuss sexual health (ECI/EI only) — A little helpful—10
Helpfulness of how to discuss sexual health (ECI/EI only) — Not at all helpful—00
Helpfulness of EBONI Spot (ECI/EI only) — Very helpful—1011
Helpfulness of EBONI Spot (ECI/EI only) — Somewhat helpful—75
Helpfulness of EBONI Spot (ECI/EI only) — A little helpful—13
Helpfulness of EBONI Spot (ECI/EI only) — Not at all helpful—00
Helpfulness of GSK Response Center — Very helpful151
Helpfulness of GSK Response Center — Somewhat helpful524
Helpfulness of GSK Response Center — A little helpful101
Helpfulness of GSK Response Center — Not at all helpful100
Helpfulness of ViiV Connect Video — Very helpful162
Helpfulness of ViiV Connect Video — Somewhat helpful210
Helpfulness of ViiV Connect Video — A little helpful011
Helpfulness of ViiV Connect Video — Not at all helpful001
Helpfulness of Medication Acquisition Tracker (EI only) — Very helpful—3—
Helpfulness of Medication Acquisition Tracker (EI only) — Somewhat helpful—0—
Helpfulness of Medication Acquisition Tracker (EI only) — A little helpful—0—
Helpfulness of Medication Acquisition Tracker (EI only) — Not at all helpful—2—
SecondaryNumber of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Study Arm

PrEP training and tools were only available to selected arms (EI and/or ECI). Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients" (ECI only).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Study Arm
ParticipantsEI - SSPECI - SSP
The PrEP training would be useful for my healthcare practice — Completely disagree00
The PrEP training would be useful for my healthcare practice — Disagree00
The PrEP training would be useful for my healthcare practice — Neither agree nor disagree03
The PrEP training would be useful for my healthcare practice — Agree77
The PrEP training would be useful for my healthcare practice — Completely agree77
The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely disagree00
The PrEP training helped me address my patients' HIV prevention concerns effectively — Disagree01
The PrEP training helped me address my patients' HIV prevention concerns effectively — Neither agree nor disagree01
The PrEP training helped me address my patients' HIV prevention concerns effectively — Agree810
The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely agree65
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely disagree0—
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Disagree0—
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Neither agree nor disagree1—
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Agree8—
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely agree6—
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely disagree—0
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Disagree—0
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Neither agree nor disagree—3
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Agree—6
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely agree—3
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely disagree—0
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Disagree—0
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Neither agree nor disagree—4
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Agree—4
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely agree—4
SecondaryNumber of SSPs That Respond to PrEP Education Training and Utility of Strategies by Clinic Characteristics

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to PrEP Education Training and Utility of Strategies by Clinic Characteristics
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
Used Frequently Asked Questions Brochure — Yes61727
Used Frequently Asked Questions Brochure — No3215
Used Frequently Asked Questions Brochure — I don't remember257
Used Readiness Considerations Checklist — Yes51528
Used Readiness Considerations Checklist — No3311
Used Readiness Considerations Checklist — I don't remember3610
Used Getting Started Guide — Yes61527
Used Getting Started Guide — No3313
Used Getting Started Guide — I don't remember269
Used Injection Education Video — Yes61632
Used Injection Education Video — No4510
Used Injection Education Video — I don't remember137
Used Provider Website (SI only) — Yes0811
Used Provider Website (SI only) — No004
Used Provider Website (SI only) — I don't remember012
Used Instructions for Use flashcard — Yes51830
Used Instructions for Use flashcard — No4311
Used Instructions for Use flashcard — I don't remember238
Used Important Safety Information document — Yes71729
Used Important Safety Information document — No2312
Used Important Safety Information document — I don't remember248
Used patient materials (e.g., welcome brochure) — Yes51529
Used patient materials (e.g., welcome brochure) — No2313
Used patient materials (e.g., welcome brochure) — I don't remember467
Used Dosing and Administration Guide — Yes81527
Used Dosing and Administration Guide — No2414
Used Dosing and Administration Guide — I don't remember158
Used Implementation Guidance Video (ECI/EI only) — Yes5614
Used Implementation Guidance Video (ECI/EI only) — No269
Used Implementation Guidance Video (ECI/EI only) — I don't remember439
Used Medication Administration Planner — Yes41018
Used Medication Administration Planner — No3820
Used Medication Administration Planner — I don't remember4611
Used document on how to discuss sexual health (ECI/EI only) — Yes3515
Used document on how to discuss sexual health (ECI/EI only) — No3613
Used document on how to discuss sexual health (ECI/EI only) — I don't remember544
Used EBONI Spot (ECI/EI only) — Yes61021
Used EBONI Spot (ECI/EI only) — No126
Used EBONI Spot (ECI/EI only) — I don't remember435
Used GSK Response Center — Yes2712
Used GSK Response Center — No91630
Used GSK Response Center — I don't remember017
Used ViiV Connect Video — Yes2211
Used ViiV Connect Video — No144
Used ViiV Connect Video — I don't remember022
Used Medication Acquisition Tracker (EI only) — Yes005
Used Medication Acquisition Tracker (EI only) — No003
Used Medication Acquisition Tracker (EI only) — I don't remember011
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — Yes9616
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — No1611
Completed the PrEP Education Training (PrEPare for Black Women) (ECI/EI only) — I don't remember135
SecondaryNumber of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Clinic Characteristics

Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to Helpfulness for Utilized Implementation Strategies by Clinic Characteristics
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
Helpfulness of Frequently Asked Questions Brochure — Very helpful2815
Helpfulness of Frequently Asked Questions Brochure — Somewhat helpful267
Helpfulness of Frequently Asked Questions Brochure — A little helpful233
Helpfulness of Frequently Asked Questions Brochure — Not at all helpful002
Helpfulness of Readiness Considerations Checklist — Very helpful2917
Helpfulness of Readiness Considerations Checklist — Somewhat helpful355
Helpfulness of Readiness Considerations Checklist — A little helpful015
Helpfulness of Readiness Considerations Checklist — Not at all helpful001
Helpfulness of Getting Started Guide — Very helpful2914
Helpfulness of Getting Started Guide — Somewhat helpful337
Helpfulness of Getting Started Guide — A little helpful135
Helpfulness of Getting Started Guide — Not at all helpful001
Helpfulness of Injection Education Video — Very helpful41124
Helpfulness of Injection Education Video — Somewhat helpful245
Helpfulness of Injection Education Video — A little helpful012
Helpfulness of Injection Education Video — Not at all helpful001
Helpfulness of Provider Website (SI only) — Very helpful—25
Helpfulness of Provider Website (SI only) — Somewhat helpful—42
Helpfulness of Provider Website (SI only) — A little helpful—22
Helpfulness of Provider Website (SI only) — Not at all helpful—02
Helpfulness of Instructions for Use flashcard — Very helpful41120
Helpfulness of Instructions for Use flashcard — Somewhat helpful177
Helpfulness of Instructions for Use flashcard — A little helpful002
Helpfulness of Instructions for Use flashcard — Not at all helpful001
Helpfulness of Important Safety Information document — Very helpful31118
Helpfulness of Important Safety Information document — Somewhat helpful356
Helpfulness of Important Safety Information document — A little helpful014
Helpfulness of Important Safety Information document — Not at all helpful101
Helpfulness of patient materials (e.g., welcome brochure) — Very helpful31017
Helpfulness of patient materials (e.g., welcome brochure) — Somewhat helpful127
Helpfulness of patient materials (e.g., welcome brochure) — A little helpful034
Helpfulness of patient materials (e.g., welcome brochure) — Not at all helpful101
Helpfulness of Dosing and Administration Guide — Very helpful51216
Helpfulness of Dosing and Administration Guide — Somewhat helpful227
Helpfulness of Dosing and Administration Guide — A little helpful013
Helpfulness of Dosing and Administration Guide — Not at all helpful101
Helpfulness of Implementation Guidance Video (ECI/EI only) — Very helpful269
Helpfulness of Implementation Guidance Video (ECI/EI only) — Somewhat helpful203
Helpfulness of Implementation Guidance Video (ECI/EI only) — A little helpful101
Helpfulness of Implementation Guidance Video (ECI/EI only) — Not at all helpful001
Helpfulness of Medication Administration Planner — Very helpful279
Helpfulness of Medication Administration Planner — Somewhat helpful226
Helpfulness of Medication Administration Planner — A little helpful012
Helpfulness of Medication Administration Planner — Not at all helpful001
Helpfulness of how to discuss sexual health (ECI/EI only) — Very helpful159
Helpfulness of how to discuss sexual health (ECI/EI only) — Somewhat helpful205
Helpfulness of how to discuss sexual health (ECI/EI only) — A little helpful001
Helpfulness of how to discuss sexual health (ECI/EI only) — Not at all helpful000
Helpfulness of EBONI Spot (ECI/EI only) — Very helpful2613
Helpfulness of EBONI Spot (ECI/EI only) — Somewhat helpful237
Helpfulness of EBONI Spot (ECI/EI only) — A little helpful211
Helpfulness of EBONI Spot (ECI/EI only) — Not at all helpful000
Helpfulness of GSK Response Center — Very helpful025
Helpfulness of GSK Response Center — Somewhat helpful146
Helpfulness of GSK Response Center — A little helpful110
Helpfulness of GSK Response Center — Not at all helpful001
Helpfulness of ViiV Connect Video — Very helpful027
Helpfulness of ViiV Connect Video — Somewhat helpful003
Helpfulness of ViiV Connect Video — A little helpful101
Helpfulness of ViiV Connect Video — Not at all helpful100
Helpfulness of Medication Acquisition Tracker (EI only) — Very helpful——3
Helpfulness of Medication Acquisition Tracker (EI only) — Somewhat helpful——0
Helpfulness of Medication Acquisition Tracker (EI only) — A little helpful——0
Helpfulness of Medication Acquisition Tracker (EI only) — Not at all helpful——2
SecondaryNumber of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Clinic Characteristics

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of SSPs That Respond to Perceived Utility, Effectiveness, and Facilitation of PrEP Training and Clinical Tools by Clinic Characteristics
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
The PrEP training would be useful for my healthcare practice — Completely disagree000
The PrEP training would be useful for my healthcare practice — Disagree000
The PrEP training would be useful for my healthcare practice — Neither agree nor disagree300
The PrEP training would be useful for my healthcare practice — Agree338
The PrEP training would be useful for my healthcare practice — Completely agree338
The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely disagree000
The PrEP training helped me address my patients' HIV prevention concerns effectively — Disagree100
The PrEP training helped me address my patients' HIV prevention concerns effectively — Neither agree nor disagree100
The PrEP training helped me address my patients' HIV prevention concerns effectively — Agree5310
The PrEP training helped me address my patients' HIV prevention concerns effectively — Completely agree236
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely disagree—00
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Disagree—00
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Neither agree nor disagree—10
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Agree—08
The PrEP Options Communication Tool facilitated PrEP conversations with patients (EI only) — Completely agree—15
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely disagree000
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Disagree000
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Neither agree nor disagree102
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Agree231
The Sexual Health Assessment Tool easily identifies individuals interested in PrEP (ECI only) — Completely agree111
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely disagree000
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Disagree000
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Neither agree nor disagree202
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Agree130
The Sexual Health Assessment Tool facilitates PrEP conversations with patients (ECI only) — Completely agree112
SecondaryNumber of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Study Arm

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Study Arm
ParticipantsSI - PSPEI - PSPECI - PSP
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Not at all useful—02
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Not very useful—30
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Somewhat useful—41
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Useful—83
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Very useful—88
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — I did not use it or it was not provided—119
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI only) — Missing—11
Text reminders about your injection — Not at all useful000
Text reminders about your injection — Not very useful000
Text reminders about your injection — Somewhat useful112
Text reminders about your injection — Useful6102
Text reminders about your injection — Very useful301915
Text reminders about your injection — I did not use it or it was not provided244
Text reminders about your injection — Missing111
Email reminders about your injection — Not at all useful100
Email reminders about your injection — Not very useful220
Email reminders about your injection — Somewhat useful421
Email reminders about your injection — Useful9113
Email reminders about your injection — Very useful191116
Email reminders about your injection — I did not use it or it was not provided483
Email reminders about your injection — Missing111
Phone call reminders about your injection — Not at all useful002
Phone call reminders about your injection — Not very useful010
Phone call reminders about your injection — Somewhat useful043
Phone call reminders about your injection — Useful1194
Phone call reminders about your injection — Very useful241412
Phone call reminders about your injection — I did not use it or it was not provided462
Phone call reminders about your injection — Missing111
Postal mail reminders about your injection — Not at all useful304
Postal mail reminders about your injection — Not very useful252
Postal mail reminders about your injection — Somewhat useful222
Postal mail reminders about your injection — Useful481
Postal mail reminders about your injection — Very useful655
Postal mail reminders about your injection — I did not use it or it was not provided22149
Postal mail reminders about your injection — Missing111
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not at all useful—11
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not very useful—11
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Somewhat useful—43
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Useful—115
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Very useful—79
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — I did not use it or it was not provided—104
EBONI spot: a website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Missing—11
Patient Website: download toolkit materials to support you throughout the study (SI only) — Not at all useful0——
Patient Website: download toolkit materials to support you throughout the study (SI only) — Not very useful0——
Patient Website: download toolkit materials to support you throughout the study (SI only) — Somewhat useful3——
Patient Website: download toolkit materials to support you throughout the study (SI only) — Useful14——
Patient Website: download toolkit materials to support you throughout the study (SI only) — Very useful11——
Patient Website: download toolkit materials to support you throughout the study (SI only) — I did not use it or it was not provided11——
Patient Website: download toolkit materials to support you throughout the study (SI only) — Missing1——
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not at all useful000
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not very useful000
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Somewhat useful110
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Useful9138
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Very useful251813
You and your doctor discuss pros and cons of PrEP options and choose the right one together — I did not use it or it was not provided422
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Missing111
Brochures and other print materials to educate you on APRETUDE — Not at all useful000
Brochures and other print materials to educate you on APRETUDE — Not very useful111
Brochures and other print materials to educate you on APRETUDE — Somewhat useful031
Brochures and other print materials to educate you on APRETUDE — Useful12135
Brochures and other print materials to educate you on APRETUDE — Very useful231212
Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided354
Brochures and other print materials to educate you on APRETUDE — Missing111
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful——0
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful——0
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful——2
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful——4
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful——14
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided——3
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing——1
SecondaryNumber of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Study Arm

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Study Arm
ParticipantsSI - PSPEI - PSPECI - PSP
Brochures and other written materials you received about APRETUDE — Not at all helpful020
Brochures and other written materials you received about APRETUDE — Somewhat helpful672
Brochures and other written materials you received about APRETUDE — Helpful11116
Brochures and other written materials you received about APRETUDE — Very helpful15119
Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided736
Brochures and other written materials you received about APRETUDE — Missing111
Getting Started Brochure: overview of how to start APRETUDE — Not at all helpful010
Getting Started Brochure: overview of how to start APRETUDE — Somewhat helpful432
Getting Started Brochure: overview of how to start APRETUDE — Helpful10125
Getting Started Brochure: overview of how to start APRETUDE — Very helpful191211
Getting Started Brochure: overview of how to start APRETUDE — I did not use it or it was not provided665
Getting Started Brochure: overview of how to start APRETUDE — Missing111
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Not at all helpful010
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Somewhat helpful552
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Helpful8103
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Very helpful181212
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — I did not use it or it was not provided866
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Missing010
Study brochures — Not at all helpful010
Study brochures — Somewhat helpful551
Study brochures — Helpful896
Study brochures — Very helpful181210
Study brochures — I did not use it or it was not provided876
Study brochures — Missing111
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful——1
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful——3
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful——6
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful——10
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided——3
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing——1
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful——2
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful——2
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful——7
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful——9
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided——3
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing——1
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful——1
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful——2
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful——7
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful——10
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided——3
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing——1
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful—0—
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful—4—
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful—9—
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful—10—
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided—11—
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing—1—
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful—12
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful—32
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful—104
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful—88
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided—127
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing—11
Important Safety Information: details safety information relating to APRETUDE — Not at all helpful131
Important Safety Information: details safety information relating to APRETUDE — Somewhat helpful332
Important Safety Information: details safety information relating to APRETUDE — Helpful10114
Important Safety Information: details safety information relating to APRETUDE — Very helpful17911
Important Safety Information: details safety information relating to APRETUDE — I did not use it or it was not provided885
Important Safety Information: details safety information relating to APRETUDE — Missing111
Important facts - This document details important facts relating to APRETUDE — Not at all helpful001
Important facts - This document details important facts relating to APRETUDE — Somewhat helpful452
Important facts - This document details important facts relating to APRETUDE — Helpful9135
Important facts - This document details important facts relating to APRETUDE — Very helpful17109
Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided966
Important facts - This document details important facts relating to APRETUDE — Missing111
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful010
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful351
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful885
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful201110
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided897
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing111
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Not at all helpful——0
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Somewhat helpful——2
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Helpful——5
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Very helpful——11
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — I did not use it or it was not provided——5
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI only) — Missing——1
SecondaryNumber of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Digital calendar for planning APRETUDE injections (EI/ECI only) — Not at all useful002
Digital calendar for planning APRETUDE injections (EI/ECI only) — Not very useful003
Digital calendar for planning APRETUDE injections (EI/ECI only) — Somewhat useful005
Digital calendar for planning APRETUDE injections (EI/ECI only) — Useful038
Digital calendar for planning APRETUDE injections (EI/ECI only) — Very useful628
Digital calendar for planning APRETUDE injections (EI/ECI only) — I did not use it or it was not provided4610
Digital calendar for planning APRETUDE injections (EI/ECI only) — Missing002
Text reminders about your injection — Not at all useful000
Text reminders about your injection — Not very useful000
Text reminders about your injection — Somewhat useful004
Text reminders about your injection — Useful1611
Text reminders about your injection — Very useful82531
Text reminders about your injection — I did not use it or it was not provided136
Text reminders about your injection — Missing012
Email reminders about your injection — Not at all useful010
Email reminders about your injection — Not very useful022
Email reminders about your injection — Somewhat useful025
Email reminders about your injection — Useful0815
Email reminders about your injection — Very useful91819
Email reminders about your injection — I did not use it or it was not provided1311
Email reminders about your injection — Missing012
Phone call reminders about your injection — Not at all useful101
Phone call reminders about your injection — Not very useful001
Phone call reminders about your injection — Somewhat useful115
Phone call reminders about your injection — Useful1914
Phone call reminders about your injection — Very useful71924
Phone call reminders about your injection — I did not use it or it was not provided057
Phone call reminders about your injection — Missing012
Postal mail reminders about your injection — Not at all useful214
Postal mail reminders about your injection — Not very useful135
Postal mail reminders about your injection — Somewhat useful015
Postal mail reminders about your injection — Useful049
Postal mail reminders about your injection — Very useful268
Postal mail reminders about your injection — I did not use it or it was not provided51921
Postal mail reminders about your injection — Missing012
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not at all useful101
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Not very useful101
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Somewhat useful025
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Useful1114
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Very useful646
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — I did not use it or it was not provided149
EBONI spot: website with rewards, messages, and materials about APRETUDE (EI/ECI only) — Missing002
Patient Website: download toolkit materials to support you during the study (SI only) — Not at all useful—00
Patient Website: download toolkit materials to support you during the study (SI only) — Not very useful—00
Patient Website: download toolkit materials to support you during the study (SI only) — Somewhat useful—12
Patient Website: download toolkit materials to support you during the study (SI only) — Useful—59
Patient Website: download toolkit materials to support you during the study (SI only) — Very useful—92
Patient Website: download toolkit materials to support you during the study (SI only) — I did not use it or it was not provided—83
Patient Website: download toolkit materials to support you during the study (SI only) — Missing—10
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not at all useful000
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Not very useful000
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Somewhat useful002
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Useful3918
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Very useful72227
You and your doctor discuss pros and cons of PrEP options and choose the right one together — I did not use it or it was not provided035
You and your doctor discuss pros and cons of PrEP options and choose the right one together — Missing012
Brochures and other print materials to educate you on APRETUDE — Not at all useful000
Brochures and other print materials to educate you on APRETUDE — Not very useful012
Brochures and other print materials to educate you on APRETUDE — Somewhat useful013
Brochures and other print materials to educate you on APRETUDE — Useful11019
Brochures and other print materials to educate you on APRETUDE — Very useful81722
Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided156
Brochures and other print materials to educate you on APRETUDE — Missing012
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful000
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful000
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful002
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful112
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful824
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided111
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing001
SecondaryNumber of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Brochures and other written materials you received about APRETUDE — Not at all helpful011
Brochures and other written materials you received about APRETUDE — Somewhat helpful249
Brochures and other written materials you received about APRETUDE — Helpful2818
Brochures and other written materials you received about APRETUDE — Very helpful51515
Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided169
Brochures and other written materials you received about APRETUDE — Missing012
Getting Started Brochure: overview of starting APRETUDE — Not at all helpful001
Getting Started Brochure: overview of starting APRETUDE — Somewhat helpful216
Getting Started Brochure: overview of starting APRETUDE — Helpful1818
Getting Started Brochure: overview of starting APRETUDE — Very helpful71718
Getting Started Brochure: overview of starting APRETUDE — I did not use it or it was not provided089
Getting Started Brochure: overview of starting APRETUDE — Missing012
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Not at all helpful001
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Somewhat helpful228
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Helpful0714
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Very helpful71718
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — I did not use it or it was not provided1811
Patient Brochure: explains APRETUDE injections, side effects, and insurance info — Missing001
Study brochures — Not at all helpful001
Study brochures — Somewhat helpful128
Study brochures — Helpful3614
Study brochures — Very helpful51718
Study brochures — I did not use it or it was not provided1911
Study brochures — Missing012
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful010
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful300
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful105
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful523
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided111
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing001
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful011
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful200
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful304
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful423
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided111
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing001
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful010
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful200
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful205
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful523
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided111
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing001
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful—00
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful—13
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful—09
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful—37
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided—38
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing—01
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful012
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful212
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful1013
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful538
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided2611
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing002
Important Safety Information: APRETUDE safety details — Not at all helpful041
Important Safety Information: APRETUDE safety details — Somewhat helpful215
Important Safety Information: APRETUDE safety details — Helpful2617
Important Safety Information: APRETUDE safety details — Very helpful61615
Important Safety Information: APRETUDE safety details — I did not use it or it was not provided0714
Important Safety Information: APRETUDE safety details — Missing012
Important facts - This document details important facts relating to APRETUDE — Not at all helpful010
Important facts - This document details important facts relating to APRETUDE — Somewhat helpful245
Important facts - This document details important facts relating to APRETUDE — Helpful2619
Important facts - This document details important facts relating to APRETUDE — Very helpful51516
Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided1812
Important facts - This document details important facts relating to APRETUDE — Missing012
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful010
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful126
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful1416
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful61817
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided2913
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing012
Rewards: earn points for completing APRETUDE journey goals (ECI) — Not at all helpful000
Rewards: earn points for completing APRETUDE journey goals (ECI) — Somewhat helpful101
Rewards: earn points for completing APRETUDE journey goals (ECI) — Helpful104
Rewards: earn points for completing APRETUDE journey goals (ECI) — Very helpful722
Rewards: earn points for completing APRETUDE journey goals (ECI) — I did not use it or it was not provided122
Rewards: earn points for completing APRETUDE journey goals (ECI) — Missing001
SecondaryNumber of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — Yes716
Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — No010
Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — I don't know323
Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only) — Missing001
Did your provider or clinic staff discuss your assessment results with you? (ECI only) — Yes413
Did your provider or clinic staff discuss your assessment results with you? (ECI only) — No002
Did your provider or clinic staff discuss your assessment results with you? (ECI only) — I don't know301
Did your provider or clinic staff discuss your assessment results with you? (ECI only) — Missing000
SecondaryNumber of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question: "Who discussed the results of the assessment with you? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
My healthcare provider/doctor111
A nurse202
A social worker100
A peer educator000
Other000
I don't know000
Missing000
SecondaryNumber of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Very helpful314
Somewhat helpful201
A little helpful100
Not at all helpful101
SecondaryNumber of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Clinic Characteristics010
SecondaryNumber of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies by patient gender subgroups.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs by Fit-for-use Rating of APRETUDE Support Tools and Strategies, by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Digital calendar to plan APRETUDE injections (EI/ECI only) — Not at all useful20
Digital calendar to plan APRETUDE injections (EI/ECI only) — Not very useful30
Digital calendar to plan APRETUDE injections (EI/ECI only) — Somewhat useful14
Digital calendar to plan APRETUDE injections (EI/ECI only) — Useful101
Digital calendar to plan APRETUDE injections (EI/ECI only) — Very useful106
Digital calendar to plan APRETUDE injections (EI/ECI only) — I did not use it or it was not provided155
Digital calendar to plan APRETUDE injections (EI/ECI only) — Missing11
Text reminders about your injection — Not at all useful00
Text reminders about your injection — Not very useful00
Text reminders about your injection — Somewhat useful31
Text reminders about your injection — Useful153
Text reminders about your injection — Very useful5212
Text reminders about your injection — I did not use it or it was not provided64
Text reminders about your injection — Missing21
Email reminders about your injection — Not at all useful10
Email reminders about your injection — Not very useful40
Email reminders about your injection — Somewhat useful52
Email reminders about your injection — Useful194
Email reminders about your injection — Very useful3610
Email reminders about your injection — I did not use it or it was not provided114
Email reminders about your injection — Missing21
Phone call reminders about your injection — Not at all useful02
Phone call reminders about your injection — Not very useful10
Phone call reminders about your injection — Somewhat useful43
Phone call reminders about your injection — Useful222
Phone call reminders about your injection — Very useful428
Phone call reminders about your injection — I did not use it or it was not provided75
Phone call reminders about your injection — Missing21
Postal mail reminders about your injection — Not at all useful43
Postal mail reminders about your injection — Not very useful81
Postal mail reminders about your injection — Somewhat useful42
Postal mail reminders about your injection — Useful103
Postal mail reminders about your injection — Very useful124
Postal mail reminders about your injection — I did not use it or it was not provided387
Postal mail reminders about your injection — Missing21
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Not at all useful20
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Not very useful20
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Somewhat useful52
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Useful115
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Very useful133
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — I did not use it or it was not provided86
EBONI spot: website with rewards, messages, and APRETUDE materials (EI/ECI only) — Missing11
Patient Website: download toolkit materials for study support (SI only) — Not at all useful00
Patient Website: download toolkit materials for study support (SI only) — Not very useful00
Patient Website: download toolkit materials for study support (SI only) — Somewhat useful30
Patient Website: download toolkit materials for study support (SI only) — Useful140
Patient Website: download toolkit materials for study support (SI only) — Very useful83
Patient Website: download toolkit materials for study support (SI only) — I did not use it or it was not provided101
Patient Website: download toolkit materials for study support (SI only) — Missing10
You and your doctor discuss pros and cons of PrEP options and decide together — Not at all useful00
You and your doctor discuss pros and cons of PrEP options and decide together — Not very useful00
You and your doctor discuss pros and cons of PrEP options and decide together — Somewhat useful11
You and your doctor discuss pros and cons of PrEP options and decide together — Useful255
You and your doctor discuss pros and cons of PrEP options and decide together — Very useful4511
You and your doctor discuss pros and cons of PrEP options and decide together — I did not use it or it was not provided53
You and your doctor discuss pros and cons of PrEP options and decide together — Missing21
Brochures and other print materials to educate you on APRETUDE — Not at all useful00
Brochures and other print materials to educate you on APRETUDE — Not very useful21
Brochures and other print materials to educate you on APRETUDE — Somewhat useful22
Brochures and other print materials to educate you on APRETUDE — Useful264
Brochures and other print materials to educate you on APRETUDE — Very useful389
Brochures and other print materials to educate you on APRETUDE — I did not use it or it was not provided84
Brochures and other print materials to educate you on APRETUDE — Missing21
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not at all useful00
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Not very useful00
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Somewhat useful20
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Useful40
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Very useful95
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — I did not use it or it was not provided12
Videos to educate you on HIV, PrEP, APRETUDE materials (ECI only) — Missing10
SecondaryNumber of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials by patient gender subgroups.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs That Respond to Helpfulness of APRETUDE Learning Materials by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Brochures and other written materials you received about APRETUDE — Not at all helpful11
Brochures and other written materials you received about APRETUDE — Somewhat helpful123
Brochures and other written materials you received about APRETUDE — Helpful253
Brochures and other written materials you received about APRETUDE — Very helpful278
Brochures and other written materials you received about APRETUDE — I did not use it or it was not provided115
Brochures and other written materials you received about APRETUDE — Missing21
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Not at all helpful10
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Somewhat helpful72
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Helpful234
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Very helpful339
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — I did not use it or it was not provided125
Getting Started Brochure: overview of starting APRETUDE (ECI/ECI) — Missing21
Patient Brochure: explains APRETUDE injections, side effects, insurance info — Not at all helpful10
Patient Brochure: explains APRETUDE injections, side effects, insurance info — Somewhat helpful102
Patient Brochure: explains APRETUDE injections, side effects, insurance info — Helpful192
Patient Brochure: explains APRETUDE injections, side effects, insurance info — Very helpful3210
Patient Brochure: explains APRETUDE injections, side effects, insurance info — I did not use it or it was not provided146
Patient Brochure: explains APRETUDE injections, side effects, insurance info — Missing01
Study brochures — Not at all helpful10
Study brochures — Somewhat helpful92
Study brochures — Helpful203
Study brochures — Very helpful3010
Study brochures — I did not use it or it was not provided165
Study brochures — Missing21
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Not at all helpful01
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Somewhat helpful30
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Helpful51
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Very helpful64
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — I did not use it or it was not provided21
Let's talk about PrEP video - the video giving key facts about HIV and PrEP options (ECI) — Missing10
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Not at all helpful11
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Somewhat helpful20
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Helpful52
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Very helpful63
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — I did not use it or it was not provided21
The Myths and Facts video - the game show video addressing common myths about APRETUDE (ECI) — Missing10
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Not at all helpful01
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Somewhat helpful20
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Helpful61
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Very helpful64
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — I did not use it or it was not provided21
The What to Expect video which shows you what expect during the APRETUDE process (ECI) — Missing10
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Not at all helpful00
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Somewhat helpful31
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Helpful54
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Very helpful82
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — I did not use it or it was not provided92
The ViiV Connect video, which tells you about insurance for APRETUDE (EI) — Missing01
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Not at all helpful21
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Somewhat helpful50
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Helpful95
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Very helpful106
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — I did not use it or it was not provided154
A digital calendar specifically made for APRETUDE to help you plan your injections (EI/ECI) — Missing11
Important Safety Information: APRETUDE safety details — Not at all helpful32
Important Safety Information: APRETUDE safety details — Somewhat helpful71
Important Safety Information: APRETUDE safety details — Helpful214
Important Safety Information: APRETUDE safety details — Very helpful298
Important Safety Information: APRETUDE safety details — I did not use it or it was not provided165
Important Safety Information: APRETUDE safety details — Missing21
Important facts - This document details important facts relating to APRETUDE — Not at all helpful01
Important facts - This document details important facts relating to APRETUDE — Somewhat helpful92
Important facts - This document details important facts relating to APRETUDE — Helpful234
Important facts - This document details important facts relating to APRETUDE — Very helpful288
Important facts - This document details important facts relating to APRETUDE — I did not use it or it was not provided165
Important facts - This document details important facts relating to APRETUDE — Missing21
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Not at all helpful10
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Somewhat helpful72
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Helpful192
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Very helpful3110
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — I did not use it or it was not provided186
The Ebonistudyinfo.com and brochure- the website that describes the Eboni Study — Missing21
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Not at all helpful00
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Somewhat helpful20
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Helpful41
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Very helpful74
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — I did not use it or it was not provided32
Rewards - Earn points and rewards for completing goals on your APRETUDE journey (ECI) — Missing10
SecondaryNumber of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Sexual Health Assessment Completion and Result Discussion by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — Yes104
Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — No01
Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — I don't know62
Have you completed a Sexual Health Assessment from your provider in last 12 months? (ECI only) — Missing10
Did your provider or clinic discuss your assessment results with you? (ECI only) — Yes53
Did your provider or clinic discuss your assessment results with you? (ECI only) — No11
Did your provider or clinic discuss your assessment results with you? (ECI only) — I don't know40
Did your provider or clinic discuss your assessment results with you? (ECI only) — Missing00
SecondaryNumber of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question regarding the sexual health assessment: "Who discussed the results of the assessment with you? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Personnel for Sexual Health Assessment Discussions by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
My healthcare provider/doctor21
A nurse31
A social worker01
A peer educator00
Other00
I don't know00
SecondaryNumber of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Helpfulness of Discussing Sexual Health Assessment Results by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Very helpful44
Somewhat helpful30
A little helpful10
Not at all helpful20
SecondaryNumber of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Number of PSPs Responding With Reasons Why the Sexual Health Assessment Was Not Used, by Patient Subgroups01
SecondaryNumber of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies Assessed by SSI by Study Arm

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies Assessed by SSI by Study Arm
ParticipantsSI - PSPEI - PSPECI - PSP
Used Getting Started Brochure Tool742
Used Helpfulness of Patient Brochure Tool601
Used Important Facts Document500
Used Important Safety Information1224
Used Helpfulness of GSK Response Center Tool100
Used Patient Website Tool (SI only)1100
Used The EBONI Spot Tool (ECI/EI only)079
Used Intro to ViiVConnect Video Tool (EI only)020
Engaged with SHE Ambassador (ECI only)——4
SecondaryNumber of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies by Patient Subgroups

PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies by patient gender subgroups.

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perceptions of Utility of Implementation Tools and Strategies by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Used Getting Started Brochure Tool121
Used Helpfulness of Patient Brochure Tool70
Used Important Facts Document41
Used Important Safety Information162
Used Helpfulness of GSK Response Center Tool10
Used Patient Website Tool (SI only)101
Used The EBONI Spot Tool (ECI/EI only)124
Used Intro to ViiVConnect Video Tool (EI only)02
Engaged with SHE Ambassador (ECI only)31
SecondaryNumber of Injections Occurring Within the Target Window From Target Date

This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as +/- 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of units · Injections
Number of Injections Occurring Within the Target Window From Target Date
InjectionsSI - PSPEI - PSPECI - PSP
Dose 2514733
Dose 3373624
Dose 4332319
Dose 5281416
Dose 6241312
Dose 724149
SecondaryNumber of PSPs With Responses to Ease of Target Appointment Date Understanding Across Traditional and Non-traditional Settings

PSP perceptions of barriers and facilitators to fidelity to APRETUDE injection windows were gathered via the ISQ. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs responses to the following question: "How easy was it to understand the Target Appointment Date?"

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Ease of Target Appointment Date Understanding Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Easy153652
Somewhat easy1311
Neither easy nor difficult136
Somewhat difficult000
Difficult000
I am not familiar/I don't remember5612
SecondaryNumber of PSPs With Responses to Missed APRETUDE Injection Visits Assessed Traditional and Non-traditional Settings

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Have you missed any of your APRETUDE injection visits in the last 6 months?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Missed APRETUDE Injection Visits Assessed Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Yes134
M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — No173667
M4 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Missing110
M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Yes225
M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — No83247
M12 - Have you missed any of your APRETUDE injection visits in the last 6 months? — Missing012
SecondaryNumber of PSPs With Responses to Planned/Unplanned Nature of Missed Injection Visits Across Traditional and Non-traditional Settings

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Was missing your APRETUDE injection visits planned or unplanned?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Planned/Unplanned Nature of Missed Injection Visits Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
M4 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were planned001
M4 - Was missing your APRETUDE injection visits planned or unplanned? — Some of the injection visits I missed were planned and some were unplanned111
M4 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were unplanned022
M4 - Was missing your APRETUDE injection visits planned or unplanned? — I prefer not to answer000
M12 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were planned101
M12 - Was missing your APRETUDE injection visits planned or unplanned? — Some of the injection visits I missed were planned and some were unplanned000
M12 - Was missing your APRETUDE injection visits planned or unplanned? — All the injection visits I missed were unplanned124
M12 - Was missing your APRETUDE injection visits planned or unplanned? — I prefer not to answer000
SecondaryNumber of PSPs With Responses to Initiation of Oral PrEP Following Missed Visits Across Traditional and Non-traditional Settings

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Did you start oral PrEP after missing any of your injection visit?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Initiation of Oral PrEP Following Missed Visits Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
M4 - Did you start oral PrEP after missing any of your injection visit? — Yes112
M4 - Did you start oral PrEP after missing any of your injection visit? — No022
M12 - Did you start oral PrEP after missing any of your injection visit? — Yes001
M12 - Did you start oral PrEP after missing any of your injection visit? — No224
SecondaryNumber of PSPs With Responses to Ease or Difficulty of Initiating Oral PrEP After a Missed Visit Across Traditional and Non-traditional Settings

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How easy or difficult was it to start oral PrEP after a missed injection visit?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Ease or Difficulty of Initiating Oral PrEP After a Missed Visit Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very easy001
M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat easy000
M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Neither easy nor difficult011
M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat difficult100
M4 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very difficult000
M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very easy001
M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat easy000
M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Neither easy nor difficult000
M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Somewhat difficult000
M12 - How easy or difficult was it to start oral PrEP after a missed injection visit?7 — Very difficult000
SecondaryNumber of PSPs With Responses to Acceptability of Initiating Oral PrEP After a Missed Visit Assessed Across Traditional and Non-traditional Settings

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How acceptable was it to start oral PrEP after a missed injection visit?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of Initiating Oral PrEP After a Missed Visit Assessed Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Very acceptable001
M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Acceptable010
M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Somewhat acceptable101
M4 - How acceptable was it to start oral PrEP after a missed injection visit? — A little acceptable000
M4 - How acceptable was it to start oral PrEP after a missed injection visit? — Not at all acceptable000
M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Very acceptable001
M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Acceptable000
M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Somewhat acceptable000
M12 - How acceptable was it to start oral PrEP after a missed injection visit? — A little acceptable000
M12 - How acceptable was it to start oral PrEP after a missed injection visit? — Not at all acceptable000
SecondaryNumber of PSPs With Responses to Target Appointment Date Understanding and Access Across Traditional and Non-traditional Settings

Data below were collected via SSIs or interviews, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs understanding and access to the target appointment date. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Target Appointment Date Understanding and Access Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Received an explanation of the target appointment date10822
Did not receive an explanation of the target appointment date149
Unsure/don't remember receiving an explanation of the target appointment date238
Found the explanation of the target appointment date was helpful236
Isn't aware of or doesn't understand the target appointment date111
Accurately explains the target appointment date329
Accurately explains the injection window3512
Accurately explains the APRETUDE injection dosing schedule425
SecondaryNumber of PSPs With Responses to APRETUDE Adherence and Barriers/Facilitators to Injection Fidelity Across Traditional and Non-traditional Settings

Data below were collected via SSIs or interviews, and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSP responses to the APRETUDE adherence and the specified barriers and facilitators to injection fidelity.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to APRETUDE Adherence and Barriers/Facilitators to Injection Fidelity Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - PSPPrimary Care Clinic - PSPHIV Specialist Clinic - PSP
Has not missed injection window51018
Understand target injection date2718
Unfamiliar with term specific "target injection date"- more familiar with "injection window"2011
Injection schedule fits with PSP's lifestyle3815
Likes how injections are scheduled1614
Appointment reminders and calendar tracking is helpful4824
Clinic staff work to help keep/maintain treatment schedule2712
Multiple injection visits scheduled at once046
Injection appointments scheduled at the end of each visit4321
Clinic flexibility when (re)scheduling appointments is helpful035
Bimonthly visits allowed screenings, vitals, and sexual health needs to be discussed2411
Unfavorable Injection schedule147
SecondaryNumber of SSPs With Responses to APRETUDE Patient Management Challenges and Injection Fidelity Across Traditional and Non-traditional Settings

Data below were collected by ISQ and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses for the specified items regarding patient management challenges and injection fidelity for APRETUDE.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to APRETUDE Patient Management Challenges and Injection Fidelity Across Traditional and Non-traditional Settings
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
BL - Understanding how to manage patients who miss an injection dose — Extremely concerned014
BL - Understanding how to manage patients who miss an injection dose — Moderately concerned315
BL - Understanding how to manage patients who miss an injection dose — Somewhat concerned3512
BL - Understanding how to manage patients who miss an injection dose — Slightly concerned21416
BL - Understanding how to manage patients who miss an injection dose — Not at all Concerned141430
M4 - Understanding how to manage patients who miss an injection dose — Extremely concerned000
M4 - Understanding how to manage patients who miss an injection dose — Moderately concerned004
M4 - Understanding how to manage patients who miss an injection dose — Somewhat concerned448
M4 - Understanding how to manage patients who miss an injection dose — Slightly concerned5910
M4 - Understanding how to manage patients who miss an injection dose — Not at all Concerned71434
M12 - Understanding how to manage patients who miss an injection dose — Extremely concerned001
M12 - Understanding how to manage patients who miss an injection dose — Moderately concerned404
M12 - Understanding how to manage patients who miss an injection dose — Somewhat concerned162
M12 - Understanding how to manage patients who miss an injection dose — Slightly concerned2411
M12 - Understanding how to manage patients who miss an injection dose — Not at all Concerned41431
BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned004
BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned242
BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned268
BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned41013
BL - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned141540
M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned000
M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned002
M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned448
M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned469
M4 - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned81737
M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Extremely concerned101
M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Moderately concerned321
M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Somewhat concerned126
M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Slightly concerned148
M12 - Understanding how to use oral PrEP medication for a planned missed injection visit — Not at all Concerned51633
BL - Understanding how to restart APRETUDE after a missed injection — Extremely concerned004
BL - Understanding how to restart APRETUDE after a missed injection — Moderately concerned333
BL - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned159
BL - Understanding how to restart APRETUDE after a missed injection — Slightly concerned51414
BL - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned131337
M4 - Understanding how to restart APRETUDE after a missed injection — Extremely concerned000
M4 - Understanding how to restart APRETUDE after a missed injection — Moderately concerned004
M4 - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned437
M4 - Understanding how to restart APRETUDE after a missed injection — Slightly concerned489
M4 - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned81636
M12 - Understanding how to restart APRETUDE after a missed injection — Extremely concerned001
M12 - Understanding how to restart APRETUDE after a missed injection — Moderately concerned212
M12 - Understanding how to restart APRETUDE after a missed injection — Somewhat concerned225
M12 - Understanding how to restart APRETUDE after a missed injection — Slightly concerned2410
M12 - Understanding how to restart APRETUDE after a missed injection — Not at all Concerned51731
BL - HIV monitoring requirements associated with APRETUDE — Extremely concerned003
BL - HIV monitoring requirements associated with APRETUDE — Moderately concerned101
BL - HIV monitoring requirements associated with APRETUDE — Somewhat concerned213
BL - HIV monitoring requirements associated with APRETUDE — Slightly concerned21112
BL - HIV monitoring requirements associated with APRETUDE — Not at all Concerned172348
M4 - HIV monitoring requirements associated with APRETUDE — Extremely concerned001
M4 - HIV monitoring requirements associated with APRETUDE — Moderately concerned002
M4 - HIV monitoring requirements associated with APRETUDE — Somewhat concerned034
M4 - HIV monitoring requirements associated with APRETUDE — Slightly concerned555
M4 - HIV monitoring requirements associated with APRETUDE — Not at all Concerned111944
M12 - HIV monitoring requirements associated with APRETUDE — Extremely concerned001
M12 - HIV monitoring requirements associated with APRETUDE — Moderately concerned111
M12 - HIV monitoring requirements associated with APRETUDE — Somewhat concerned122
M12 - HIV monitoring requirements associated with APRETUDE — Slightly concerned236
M12 - HIV monitoring requirements associated with APRETUDE — Not at all Concerned71839
M4 - How to transition patients off of APRETUDE who want to stop taking it — Extremely concerned001
M4 - How to transition patients off of APRETUDE who want to stop taking it — Moderately concerned114
M4 - How to transition patients off of APRETUDE who want to stop taking it — Somewhat concerned247
M4 - How to transition patients off of APRETUDE who want to stop taking it — Slightly concerned484
M4 - How to transition patients off of APRETUDE who want to stop taking it — Not at all Concerned91440
M12 - How to transition patients off of APRETUDE who want to stop taking it — Extremely concerned012
M12 - How to transition patients off of APRETUDE who want to stop taking it — Moderately concerned022
M12 - How to transition patients off of APRETUDE who want to stop taking it — Somewhat concerned345
M12 - How to transition patients off of APRETUDE who want to stop taking it — Slightly concerned336
M12 - How to transition patients off of APRETUDE who want to stop taking it — Not at all Concerned51434
SecondaryNumber of SSPs With Responses to Injection Visits, Adherence, and Missed Doses Across Traditional and Non-traditional Settings Assessed by SSI

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Data displayed represent injection fidelity topics discussed by SSPs while describing the APRETUDE implementation process. SSIs were not conducted with SSPs at baseline. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Injection Visits, Adherence, and Missed Doses Across Traditional and Non-traditional Settings Assessed by SSI
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
Injection visits101943
Managing patient adherence61724
Managing missed doses91740
SecondaryNumber of SSPs With Responses to Perceived Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings Assessed by SSI

Data below were collected via SSIs, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents topics surrounding managing adherence and missed doses as discussed by SSPs during SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Perceived Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings Assessed by SSI
ParticipantsWomen's Health Clinic - SSPPrimary Care Clinic - SSPHIV Specialist Clinic - SSP
Appointment reminders5721
Scheduling strategies4422
Supporting patient needs217
No missed doses outside of window2510
Yes, missed doses outside of window2517
Have not switched patients to oral PrEP2719
Patients discontinued APRETUDE335
Bridging with oral PrEP until restart235
Having a workflow for missed doses3810
SecondaryNumber of Clinics With Responses to Implementation Monitoring Calls (IMC) Assessed Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings

IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to barriers and facilitators to fidelity to APRETUDE injection windows as discussed during IMC calls. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
Up to Month 12
Reported as:
Count of units · Clinics
Number of Clinics With Responses to Implementation Monitoring Calls (IMC) Assessed Barriers/Facilitators to Injection Window Fidelity Across Traditional and Non-traditional Settings
ClinicsWomen's Health ClinicPrimary Care ClinicHIV Specialist Clinic
Consistent/Regular Communication with Patient115
Past experiences with injectables and/or APRETUDE22—
Established and Clear Protocol and Procedures in Place111
Advance and/or Flexible Scheduling—12
Patient Supportive Resources (i.e., educational brochures, transportation arrangements)2—1
Funding Supports Implementation for AREPTUDE——1
Roles Assigned among Clinic Staff——1
Patient-Clinic Relationship Established and/or strengthened——1
Staff knowledge/perception/motivation/attitudes——2
Lack of training/education——1
Time constraints & care prioritization——1
Issues related to insurance coverage/reimbursement or financial-assistance programs—11
Insufficient staff to work on this—2—
Insufficient time to work on this——1
Challenges reaching patients or patients missing appointments232
Patient scheduling challenges135
Patient requested changes—11
SecondaryNumber of PSPs Completing Target Number of Injections by Patient Subgroups

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
Number of PSPs Completing Target Number of Injections by Patient Subgroups
ParticipantsCisgender - PSPTransgender - PSP
Number of PSPs Completing Target Number of Injections by Patient Subgroups298
SecondaryNumber of SSPs With Responses to APRETUDE Implementation and Patient Management Assessed by Questionnaires

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified APRETUDE implementation and patient management. Only a selection of items are applicable for BL timepoint.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to APRETUDE Implementation and Patient Management Assessed by Questionnaires
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Ability to provide HIV screening at each injection visit and follow up based on results — Extremely concerned120
BL - Ability to provide HIV screening at each injection visit and follow up based on results — Moderately concerned040
BL - Ability to provide HIV screening at each injection visit and follow up based on results — Somewhat concerned323
BL - Ability to provide HIV screening at each injection visit and follow up based on results — Slightly concerned6911
BL - Ability to provide HIV screening at each injection visit and follow up based on results — Not at all Concerned303526
BL - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned121
BL - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned142
BL - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned122
BL - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned1398
BL - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned243527
BL - Patients' ability to keep injection appointments — Extremely concerned7102
BL - Patients' ability to keep injection appointments — Moderately concerned8137
BL - Patients' ability to keep injection appointments — Somewhat concerned12813
BL - Patients' ability to keep injection appointments — Slightly concerned71512
BL - Patients' ability to keep injection appointments — Not at all Concerned666
BL - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned293
BL - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned7107
BL - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned10109
BL - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned121012
BL - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned9139
BL - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned260
BL - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned341
BL - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned483
BL - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned91015
BL - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned222421
BL - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned462
BL - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned5118
BL - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned789
BL - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned161515
BL - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned8126
BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned121
BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned332
BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned352
BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned9109
BL - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned243226
M4 - Patients' ability to keep injection appointments — Extremely concerned420
M4 - Patients' ability to keep injection appointments — Moderately concerned756
M4 - Patients' ability to keep injection appointments — Somewhat concerned4812
M4 - Patients' ability to keep injection appointments — Slightly concerned91012
M4 - Patients' ability to keep injection appointments — Not at all Concerned578
M4 - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned422
M4 - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned550
M4 - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned6510
M4 - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned71019
M4 - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned7107
M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned100
M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned201
M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned214
M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned898
M4 - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned162225
M4 - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned201
M4 - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned434
M4 - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned578
M4 - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned81317
M4 - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned1098
M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Extremely concerned000
M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Moderately concerned011
M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Somewhat concerned732
M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Slightly concerned4410
M4 - Ability to provide adherence counseling and support, when injection dosing visits are missed — Not at all Concerned182425
M4 - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned000
M4 - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned310
M4 - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned444
M4 - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned368
M4 - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned192126
M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned100
M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned112
M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned345
M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned546
M4 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned192325
M12 - Patients' ability to keep injection appointments — Extremely concerned511
M12 - Patients' ability to keep injection appointments — Moderately concerned239
M12 - Patients' ability to keep injection appointments — Somewhat concerned7511
M12 - Patients' ability to keep injection appointments — Slightly concerned886
M12 - Patients' ability to keep injection appointments — Not at all Concerned495
M12 - Keeping a patient engaged and motivated to continue APRETUDE — Extremely concerned214
M12 - Keeping a patient engaged and motivated to continue APRETUDE — Moderately concerned542
M12 - Keeping a patient engaged and motivated to continue APRETUDE — Somewhat concerned7311
M12 - Keeping a patient engaged and motivated to continue APRETUDE — Slightly concerned6108
M12 - Keeping a patient engaged and motivated to continue APRETUDE — Not at all Concerned687
M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Extremely concerned201
M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Moderately concerned011
M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Somewhat concerned623
M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Slightly concerned858
M12 - Worried that a patient will feel stigmatized if offered APRETUDE — Not at all Concerned101819
M12 - Patients' willingness to travel every 2 months for an injection appointment — Extremely concerned314
M12 - Patients' willingness to travel every 2 months for an injection appointment — Moderately concerned134
M12 - Patients' willingness to travel every 2 months for an injection appointment — Somewhat concerned1056
M12 - Patients' willingness to travel every 2 months for an injection appointment — Slightly concerned6511
M12 - Patients' willingness to travel every 2 months for an injection appointment — Not at all Concerned6127
M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Extremely concerned100
M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Moderately concerned201
M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Somewhat concerned322
M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Slightly concerned124
M12-Ability to provide HIV screening at each injection visit & provide rapid intervention/follow-up — Not at all Concerned192225
M12 - Provider time to discuss HIV prevention with all eligible patients — Extremely concerned100
M12 - Provider time to discuss HIV prevention with all eligible patients — Moderately concerned102
M12 - Provider time to discuss HIV prevention with all eligible patients — Somewhat concerned314
M12 - Provider time to discuss HIV prevention with all eligible patients — Slightly concerned565
M12 - Provider time to discuss HIV prevention with all eligible patients — Not at all Concerned161921
M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Extremely concerned200
M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Moderately concerned203
M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Somewhat concerned218
M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Slightly concerned545
M12 - Staff preparation (i.e., education, training, in-services) to implement APRETUDE — Not at all Concerned152116
SecondaryNumber of SSPs With Responses to Clinic Climate and Change Readiness Assessed by Questionnaires

Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs response to the specified items regarding to the clinic climate and change readiness as implementation barriers and facilitators.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Clinic Climate and Change Readiness Assessed by Questionnaires
ParticipantsSI - SSPEI - SSPECI - SSP
BL - People at all levels openly talk about what is and isn't working — Completely disagree010
BL - People at all levels openly talk about what is and isn't working — Disagree210
BL - People at all levels openly talk about what is and isn't working — Neither agree nor disagree884
BL - People at all levels openly talk about what is and isn't working — Agree192017
BL - People at all levels openly talk about what is and isn't working — Completely agree112219
BL - Most people in this clinic are willing to change their practices based on feedback — Completely disagree000
BL - Most people in this clinic are willing to change their practices based on feedback — Disagree343
BL - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree785
BL - Most people in this clinic are willing to change their practices based on feedback — Agree202322
BL - Most people in this clinic are willing to change their practices based on feedback — Completely agree101710
BL - It is hard to get things to change in our clinic — Completely disagree887
BL - It is hard to get things to change in our clinic — Disagree152417
BL - It is hard to get things to change in our clinic — Neither agree nor disagree1177
BL - It is hard to get things to change in our clinic — Agree577
BL - It is hard to get things to change in our clinic — Completely agree162
BL - People in this clinic operate as a real team — Completely disagree000
BL - People in this clinic operate as a real team — Disagree220
BL - People in this clinic operate as a real team — Neither agree nor disagree772
BL - People in this clinic operate as a real team — Agree142120
BL - People in this clinic operate as a real team — Completely agree172218
BL - Staff members often show signs of stress and strain — Completely disagree291
BL - Staff members often show signs of stress and strain — Disagree12138
BL - Staff members often show signs of stress and strain — Neither agree nor disagree121216
BL - Staff members often show signs of stress and strain — Agree101314
BL - Staff members often show signs of stress and strain — Completely agree451
BL - We regularly take time to consider ways to improve how we do things — Completely disagree000
BL - We regularly take time to consider ways to improve how we do things — Disagree221
BL - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree671
BL - We regularly take time to consider ways to improve how we do things — Agree181927
BL - We regularly take time to consider ways to improve how we do things — Completely agree142411
BL - Leadership strongly supports clinic change efforts — Completely disagree000
BL - Leadership strongly supports clinic change efforts — Disagree221
BL - Leadership strongly supports clinic change efforts — Neither agree nor disagree1194
BL - Leadership strongly supports clinic change efforts — Agree101622
BL - Leadership strongly supports clinic change efforts — Completely agree172513
M4 - People at all levels openly talk about what is and isn't working — Completely disagree111
M4 - People at all levels openly talk about what is and isn't working — Disagree301
M4 - People at all levels openly talk about what is and isn't working — Neither agree nor disagree637
M4 - People at all levels openly talk about what is and isn't working — Agree101520
M4 - People at all levels openly talk about what is and isn't working — Completely agree9139
M4 - Most people in this clinic are willing to change their practices based on feedback — Completely disagree110
M4 - Most people in this clinic are willing to change their practices based on feedback — Disagree101
M4 - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree449
M4 - Most people in this clinic are willing to change their practices based on feedback — Agree161520
M4 - Most people in this clinic are willing to change their practices based on feedback — Completely agree7128
M4 - It is hard to get things to change in our clinic — Completely disagree766
M4 - It is hard to get things to change in our clinic — Disagree51210
M4 - It is hard to get things to change in our clinic — Neither agree nor disagree8710
M4 - It is hard to get things to change in our clinic — Agree737
M4 - It is hard to get things to change in our clinic — Completely agree245
M4 - People in this clinic operate as a real team — Completely disagree000
M4 - People in this clinic operate as a real team — Disagree011
M4 - People in this clinic operate as a real team — Neither agree nor disagree554
M4 - People in this clinic operate as a real team — Agree181417
M4 - People in this clinic operate as a real team — Completely agree61216
M4 - Staff members often show signs of stress and strain — Completely disagree261
M4 - Staff members often show signs of stress and strain — Disagree465
M4 - Staff members often show signs of stress and strain — Neither agree nor disagree6915
M4 - Staff members often show signs of stress and strain — Agree9712
M4 - Staff members often show signs of stress and strain — Completely agree845
M4 - We regularly take time to consider ways to improve how we do things — Completely disagree101
M4 - We regularly take time to consider ways to improve how we do things — Disagree202
M4 - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree465
M4 - We regularly take time to consider ways to improve how we do things — Agree151420
M4 - We regularly take time to consider ways to improve how we do things — Completely agree71210
M4 - Leadership strongly supports clinic change efforts — Completely disagree101
M4 - Leadership strongly supports clinic change efforts — Disagree012
M4 - Leadership strongly supports clinic change efforts — Neither agree nor disagree1065
M4 - Leadership strongly supports clinic change efforts — Agree81318
M4 - Leadership strongly supports clinic change efforts — Completely agree101212
M12 - People at all levels openly talk about what is and isn't working — Completely disagree100
M12 - People at all levels openly talk about what is and isn't working — Disagree211
M12 - People at all levels openly talk about what is and isn't working — Neither agree nor disagree434
M12 - People at all levels openly talk about what is and isn't working — Agree10822
M12 - People at all levels openly talk about what is and isn't working — Completely agree9145
M12 - Most people in this clinic are willing to change their practices based on feedback — Completely disagree101
M12 - Most people in this clinic are willing to change their practices based on feedback — Disagree100
M12 - Most people in this clinic are willing to change their practices based on feedback — Neither agree nor disagree724
M12 - Most people in this clinic are willing to change their practices based on feedback — Agree10922
M12 - Most people in this clinic are willing to change their practices based on feedback — Completely agree7155
M12 - It is hard to get things to change in our clinic — Completely disagree763
M12 - It is hard to get things to change in our clinic — Disagree4813
M12 - It is hard to get things to change in our clinic — Neither agree nor disagree657
M12 - It is hard to get things to change in our clinic — Agree527
M12 - It is hard to get things to change in our clinic — Completely agree452
M12 - People in this clinic operate as a real team — Completely disagree101
M12 - People in this clinic operate as a real team — Disagree100
M12 - People in this clinic operate as a real team — Neither agree nor disagree422
M12 - People in this clinic operate as a real team — Agree11817
M12 - People in this clinic operate as a real team — Completely agree91612
M12 - Staff members often show signs of stress and strain — Completely disagree261
M12 - Staff members often show signs of stress and strain — Disagree457
M12 - Staff members often show signs of stress and strain — Neither agree nor disagree888
M12 - Staff members often show signs of stress and strain — Agree8413
M12 - Staff members often show signs of stress and strain — Completely agree433
M12 - We regularly take time to consider ways to improve how we do things — Completely disagree111
M12 - We regularly take time to consider ways to improve how we do things — Disagree204
M12 - We regularly take time to consider ways to improve how we do things — Neither agree nor disagree715
M12 - We regularly take time to consider ways to improve how we do things — Agree91116
M12 - We regularly take time to consider ways to improve how we do things — Completely agree7136
M12 - Leadership strongly supports clinic change efforts — Completely disagree101
M12 - Leadership strongly supports clinic change efforts — Disagree201
M12 - Leadership strongly supports clinic change efforts — Neither agree nor disagree1137
M12 - Leadership strongly supports clinic change efforts — Agree4714
M12 - Leadership strongly supports clinic change efforts — Completely agree8169
SecondaryNumber of SSPs With Responses to Perceived Benefits of Bi-monthly Injections Assessed by Questionnaires

Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs perception of the bi-monthly injection benefits.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Perceived Benefits of Bi-monthly Injections Assessed by Questionnaires
ParticipantsSI - SSPEI - SSPECI - SSP
No benefits for every two months injections (exclusive)132
Confirmation of PrEP use211521
Confirmation of HIV testing221716
More opportunities to discuss medication concerns or manage side effect181518
More opportunities to screen for other comorbidities161312
Additional opportunity to screen for STIs202021
Additional change to provide other health or psychological care1389
Another benefit001
Missing010
SecondaryNumber of PSPs With Responses to Prior Knowledge of HIV/PrEP Assessed by Questionnaires

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified questions regarding prior knowledge of HIV/PrEP. For each timepoint assessed for this outcome measure only specific questions were applied.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Prior Knowledge of HIV/PrEP Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
BL - Do you personally know of someone or some people living with HIV? — Yes333426
BL - Do you personally know of someone or some people living with HIV? — No172014
BL - Do you personally know of someone or some people living with HIV? — I don't know222
BL - Do you personally know of someone or some people living with HIV? — Missing100
BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — Yes312523
BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — No213019
BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — I don't know110
BL - Before enrolling, had you heard of APRETUDE, the long-acting injectable form of PrEP? — Missing000
BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — Yes394133
BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — No11137
BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — I don't know322
BL - Before enrolling, had you heard of people without HIV taking daily oral PrEP? — Missing000
BL - Do you personally know of a person or people who have ever taken oral PrEP? — Yes302325
BL - Do you personally know of a person or people who have ever taken oral PrEP? — No9187
BL - Do you personally know of a person or people who have ever taken oral PrEP? — I don't know001
BL - Do you personally know of a person or people who have ever taken oral PrEP? — Missing000
M4 - Do you personally know of someone or some people living with HIV? — Yes362719
M4 - Do you personally know of someone or some people living with HIV? — No111115
M4 - Do you personally know of someone or some people living with HIV? — I don't know352
M4 - Do you personally know of someone or some people living with HIV? — Missing001
M12 - Do you personally know of someone or some people living with HIV? — Yes272116
M12 - Do you personally know of someone or some people living with HIV? — No10126
M12 - Do you personally know of someone or some people living with HIV? — I don't know311
M12 - Do you personally know of someone or some people living with HIV? — Missing011
SecondaryNumber of PSPs With Responses to HIV Knowledge and Misconceptions Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified items regarding HIV knowledge and misconceptions.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to HIV Knowledge and Misconceptions Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
BL - A person who has HIV can look healthy — True525542
BL - A person who has HIV can look healthy — False110
BL - A person who has HIV can look healthy — Missing000
BL - There is a vaccine that can stop you from getting HIV — True343523
BL - There is a vaccine that can stop you from getting HIV — False192119
BL - There is a vaccine that can stop you from getting HIV — Missing000
BL - A person will NOT get HIV if they are taking antibiotics — True777
BL - A person will NOT get HIV if they are taking antibiotics — False464935
BL - A person will NOT get HIV if they are taking antibiotics — Missing000
BL - If you only have sex once with a partner, you cannot get HIV from them — True023
BL - If you only have sex once with a partner, you cannot get HIV from them — False535439
BL - If you only have sex once with a partner, you cannot get HIV from them — Missing000
BL - People on HIV medications cannot spread HIV — True172318
BL - People on HIV medications cannot spread HIV — False363324
BL - People on HIV medications cannot spread HIV — Missing000
BL - Everybody who has HIV knows that they have HIV — True422
BL - Everybody who has HIV knows that they have HIV — False495440
BL - Everybody who has HIV knows that they have HIV — Missing000
BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True368
BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False505034
BL - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing000
BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True434135
BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False10157
BL - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing000
M4 - A person who has HIV can look healthy — True504236
M4 - A person who has HIV can look healthy — False010
M4 - A person who has HIV can look healthy — Missing001
M4 - There is a vaccine that can stop you from getting HIV — True292220
M4 - There is a vaccine that can stop you from getting HIV — False212116
M4 - There is a vaccine that can stop you from getting HIV — Missing001
M4 - A person will NOT get HIV if they are taking antibiotics — True534
M4 - A person will NOT get HIV if they are taking antibiotics — False454032
M4 - A person will NOT get HIV if they are taking antibiotics — Missing001
M4 - If you only have sex once with a partner, you cannot get HIV from them — True001
M4 - If you only have sex once with a partner, you cannot get HIV from them — False504335
M4 - If you only have sex once with a partner, you cannot get HIV from them — Missing001
M4 - People on HIV medications cannot spread HIV — True191318
M4 - People on HIV medications cannot spread HIV — False313018
M4 - People on HIV medications cannot spread HIV — Missing001
M4 - Everybody who has HIV knows that they have HIV — True332
M4 - Everybody who has HIV knows that they have HIV — False474034
M4 - Everybody who has HIV knows that they have HIV — Missing001
M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True454
M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False463832
M4 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing001
M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True403431
M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False1095
M4 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing001
M12 - A person who has HIV can look healthy — True403423
M12 - A person who has HIV can look healthy — False000
M12 - A person who has HIV can look healthy — Missing011
M12 - There is a vaccine that can stop you from getting HIV — True232111
M12 - There is a vaccine that can stop you from getting HIV — False171312
M12 - There is a vaccine that can stop you from getting HIV — Missing011
M12 - A person will NOT get HIV if they are taking antibiotics — True121
M12 - A person will NOT get HIV if they are taking antibiotics — False393222
M12 - A person will NOT get HIV if they are taking antibiotics — Missing011
M12 - If you only have sex once with a partner, you cannot get HIV from them — True100
M12 - If you only have sex once with a partner, you cannot get HIV from them — False393423
M12 - If you only have sex once with a partner, you cannot get HIV from them — Missing011
M12 - People on HIV medications cannot spread HIV — True121514
M12 - People on HIV medications cannot spread HIV — False28199
M12 - People on HIV medications cannot spread HIV — Missing011
M12 - Everybody who has HIV knows that they have HIV — True211
M12 - Everybody who has HIV knows that they have HIV — False383322
M12 - Everybody who has HIV knows that they have HIV — Missing011
M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — True152
M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — False392921
M12 - A natural skin [lamb skin] condom works better against HIV than does a latex condom — Missing011
M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — True342622
M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — False681
M12 - It is safer to use water-based lubricants than oil-based lubricants when using condoms — Missing011
SecondaryNumber of PSPs With Responses on Social Support, Stigma, and Personal Attitudes Towards PrEP Use Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement regarding the social and personal perceptions (support, stigma, attitude) towards PrEP use.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Social Support, Stigma, and Personal Attitudes Towards PrEP Use Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
BL - My friends would be supportive of me taking PrEP — Completely disagree321
BL - My friends would be supportive of me taking PrEP — Disagree221
BL - My friends would be supportive of me taking PrEP — Neither agree nor disagree10106
BL - My friends would be supportive of me taking PrEP — Agree131611
BL - My friends would be supportive of me taking PrEP — Completely agree252623
BL - My friends would be supportive of me taking PrEP — Missing000
BL - My family would be supportive of me taking PrEP — Completely disagree820
BL - My family would be supportive of me taking PrEP — Disagree432
BL - My family would be supportive of me taking PrEP — Neither agree nor disagree81410
BL - My family would be supportive of me taking PrEP — Agree14109
BL - My family would be supportive of me taking PrEP — Completely agree192721
BL - My family would be supportive of me taking PrEP — Missing000
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree687
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree13117
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree212314
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree81211
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree523
BL - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing000
BL - People experience negative judgment because they take PrEP — Completely disagree486
BL - People experience negative judgment because they take PrEP — Disagree896
BL - People experience negative judgment because they take PrEP — Neither agree nor disagree182114
BL - People experience negative judgment because they take PrEP — Agree171713
BL - People experience negative judgment because they take PrEP — Completely agree613
BL - People experience negative judgment because they take PrEP — Missing000
BL - People taking PrEP receive praise for being responsible — Completely disagree112
BL - People taking PrEP receive praise for being responsible — Disagree574
BL - People taking PrEP receive praise for being responsible — Neither agree nor disagree222413
BL - People taking PrEP receive praise for being responsible — Agree171613
BL - People taking PrEP receive praise for being responsible — Completely agree8810
BL - People taking PrEP receive praise for being responsible — Missing000
BL - I would feel ashamed to take PrEP in front of others — Completely disagree272226
BL - I would feel ashamed to take PrEP in front of others — Disagree15198
BL - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree793
BL - I would feel ashamed to take PrEP in front of others — Agree463
BL - I would feel ashamed to take PrEP in front of others — Completely agree002
BL - I would feel ashamed to take PrEP in front of others — Missing000
BL - Someone taking PrEP may be seen as having sex with many different people — Completely disagree346
BL - Someone taking PrEP may be seen as having sex with many different people — Disagree7134
BL - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree181614
BL - Someone taking PrEP may be seen as having sex with many different people — Agree191911
BL - Someone taking PrEP may be seen as having sex with many different people — Completely agree647
BL - Someone taking PrEP may be seen as having sex with many different people — Missing000
BL - People on PrEP are taking care of their health — Completely disagree110
BL - People on PrEP are taking care of their health — Disagree100
BL - People on PrEP are taking care of their health — Neither agree nor disagree561
BL - People on PrEP are taking care of their health — Agree14209
BL - People on PrEP are taking care of their health — Completely agree322932
BL - People on PrEP are taking care of their health — Missing000
BL - People taking PrEP experience verbal harassment — Completely disagree779
BL - People taking PrEP experience verbal harassment — Disagree12156
BL - People taking PrEP experience verbal harassment — Neither agree nor disagree322421
BL - People taking PrEP experience verbal harassment — Agree275
BL - People taking PrEP experience verbal harassment — Completely agree031
BL - People taking PrEP experience verbal harassment — Missing000
BL - I would not want others to know if I was taking PrEP — Completely disagree161519
BL - I would not want others to know if I was taking PrEP — Disagree201410
BL - I would not want others to know if I was taking PrEP — Neither agree nor disagree14167
BL - I would not want others to know if I was taking PrEP — Agree284
BL - I would not want others to know if I was taking PrEP — Completely agree132
BL - I would not want others to know if I was taking PrEP — Missing000
BL - Someone taking PrEP should keep their pills hidden — Completely disagree161217
BL - Someone taking PrEP should keep their pills hidden — Disagree171510
BL - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree19227
BL - Someone taking PrEP should keep their pills hidden — Agree165
BL - Someone taking PrEP should keep their pills hidden — Completely agree013
BL - Someone taking PrEP should keep their pills hidden — Missing000
BL - I would feel proud to take PrEP — Completely disagree210
BL - I would feel proud to take PrEP — Disagree000
BL - I would feel proud to take PrEP — Neither agree nor disagree765
BL - I would feel proud to take PrEP — Agree192510
BL - I would feel proud to take PrEP — Completely agree252427
BL - I would feel proud to take PrEP — Missing000
BL - I would have sex with someone who is taking PrEP — Completely disagree100
BL - I would have sex with someone who is taking PrEP — Disagree010
BL - I would have sex with someone who is taking PrEP — Neither agree nor disagree796
BL - I would have sex with someone who is taking PrEP — Agree182412
BL - I would have sex with someone who is taking PrEP — Completely agree272224
BL - I would have sex with someone who is taking PrEP — Missing000
M4 - My friends would be supportive of me taking PrEP — Completely disagree114
M4 - My friends would be supportive of me taking PrEP — Disagree120
M4 - My friends would be supportive of me taking PrEP — Neither agree nor disagree1057
M4 - My friends would be supportive of me taking PrEP — Agree14177
M4 - My friends would be supportive of me taking PrEP — Completely agree241818
M4 - My friends would be supportive of me taking PrEP — Missing001
M4 - My family would be supportive of me taking PrEP — Completely disagree321
M4 - My family would be supportive of me taking PrEP — Disagree322
M4 - My family would be supportive of me taking PrEP — Neither agree nor disagree8710
M4 - My family would be supportive of me taking PrEP — Agree13157
M4 - My family would be supportive of me taking PrEP — Completely agree231716
M4 - My family would be supportive of me taking PrEP — Missing001
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree837
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree687
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree222014
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree1286
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree242
M4 - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing001
M4 - People experience negative judgment because they take PrEP — Completely disagree827
M4 - People experience negative judgment because they take PrEP — Disagree697
M4 - People experience negative judgment because they take PrEP — Neither agree nor disagree181712
M4 - People experience negative judgment because they take PrEP — Agree15127
M4 - People experience negative judgment because they take PrEP — Completely agree333
M4 - People experience negative judgment because they take PrEP — Missing001
M4 - People taking PrEP receive praise for being responsible — Completely disagree213
M4 - People taking PrEP receive praise for being responsible — Disagree342
M4 - People taking PrEP receive praise for being responsible — Neither agree nor disagree251514
M4 - People taking PrEP receive praise for being responsible — Agree141511
M4 - People taking PrEP receive praise for being responsible — Completely agree686
M4 - People taking PrEP receive praise for being responsible — Missing001
M4 - I would feel ashamed to take PrEP in front of others — Completely disagree211519
M4 - I would feel ashamed to take PrEP in front of others — Disagree14177
M4 - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree788
M4 - I would feel ashamed to take PrEP in front of others — Agree730
M4 - I would feel ashamed to take PrEP in front of others — Completely agree102
M4 - I would feel ashamed to take PrEP in front of others — Missing001
M4 - Someone taking PrEP may be seen as having sex with many different people — Completely disagree437
M4 - Someone taking PrEP may be seen as having sex with many different people — Disagree9127
M4 - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree141210
M4 - Someone taking PrEP may be seen as having sex with many different people — Agree141210
M4 - Someone taking PrEP may be seen as having sex with many different people — Completely agree942
M4 - Someone taking PrEP may be seen as having sex with many different people — Missing001
M4 - People on PrEP are taking care of their health — Completely disagree011
M4 - People on PrEP are taking care of their health — Disagree010
M4 - People on PrEP are taking care of their health — Neither agree nor disagree350
M4 - People on PrEP are taking care of their health — Agree212012
M4 - People on PrEP are taking care of their health — Completely agree261623
M4 - People on PrEP are taking care of their health — Missing001
M4 - People taking PrEP experience verbal harassment — Completely disagree888
M4 - People taking PrEP experience verbal harassment — Disagree10137
M4 - People taking PrEP experience verbal harassment — Neither agree nor disagree261915
M4 - People taking PrEP experience verbal harassment — Agree535
M4 - People taking PrEP experience verbal harassment — Completely agree101
M4 - People taking PrEP experience verbal harassment — Missing001
M4 - I would not want others to know if I was taking PrEP — Completely disagree19817
M4 - I would not want others to know if I was taking PrEP — Disagree9177
M4 - I would not want others to know if I was taking PrEP — Neither agree nor disagree13109
M4 - I would not want others to know if I was taking PrEP — Agree773
M4 - I would not want others to know if I was taking PrEP — Completely agree210
M4 - I would not want others to know if I was taking PrEP — Missing001
M4 - Someone taking PrEP should keep their pills hidden — Completely disagree151015
M4 - Someone taking PrEP should keep their pills hidden — Disagree14118
M4 - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree17179
M4 - Someone taking PrEP should keep their pills hidden — Agree452
M4 - Someone taking PrEP should keep their pills hidden — Completely agree002
M4 - Someone taking PrEP should keep their pills hidden — Missing001
M4 - I would feel proud to take PrEP — Completely disagree112
M4 - I would feel proud to take PrEP — Disagree020
M4 - I would feel proud to take PrEP — Neither agree nor disagree533
M4 - I would feel proud to take PrEP — Agree191815
M4 - I would feel proud to take PrEP — Completely agree251916
M4 - I would feel proud to take PrEP — Missing001
M4 - I would have sex with someone who is taking PrEP — Completely disagree011
M4 - I would have sex with someone who is taking PrEP — Disagree010
M4 - I would have sex with someone who is taking PrEP — Neither agree nor disagree896
M4 - I would have sex with someone who is taking PrEP — Agree161614
M4 - I would have sex with someone who is taking PrEP — Completely agree261615
M4 - I would have sex with someone who is taking PrEP — Missing001
M12 - My friends would be supportive of me taking PrEP — Completely disagree011
M12 - My friends would be supportive of me taking PrEP — Disagree100
M12 - My friends would be supportive of me taking PrEP — Neither agree nor disagree1265
M12 - My friends would be supportive of me taking PrEP — Agree13135
M12 - My friends would be supportive of me taking PrEP — Completely agree141412
M12 - My friends would be supportive of me taking PrEP — Missing011
M12 - My family would be supportive of me taking PrEP — Completely disagree111
M12 - My family would be supportive of me taking PrEP — Disagree300
M12 - My family would be supportive of me taking PrEP — Neither agree nor disagree1296
M12 - My family would be supportive of me taking PrEP — Agree1194
M12 - My family would be supportive of me taking PrEP — Completely agree131512
M12 - My family would be supportive of me taking PrEP — Missing011
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely disagree634
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Disagree324
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Neither agree nor disagree21179
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Agree876
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Completely agree250
M12 - People experience problems when they tell their sex partner(s) they are taking PrEP — Missing011
M12 - People experience negative judgment because they take PrEP — Completely disagree535
M12 - People experience negative judgment because they take PrEP — Disagree533
M12 - People experience negative judgment because they take PrEP — Neither agree nor disagree13153
M12 - People experience negative judgment because they take PrEP — Agree15511
M12 - People experience negative judgment because they take PrEP — Completely agree281
M12 - People experience negative judgment because they take PrEP — Missing011
M12 - People taking PrEP receive praise for being responsible — Completely disagree100
M12 - People taking PrEP receive praise for being responsible — Disagree612
M12 - People taking PrEP receive praise for being responsible — Neither agree nor disagree20159
M12 - People taking PrEP receive praise for being responsible — Agree8108
M12 - People taking PrEP receive praise for being responsible — Completely agree584
M12 - People taking PrEP receive praise for being responsible — Missing011
M12 - I would feel ashamed to take PrEP in front of others — Completely disagree191416
M12 - I would feel ashamed to take PrEP in front of others — Disagree14145
M12 - I would feel ashamed to take PrEP in front of others — Neither agree nor disagree751
M12 - I would feel ashamed to take PrEP in front of others — Agree000
M12 - I would feel ashamed to take PrEP in front of others — Completely agree011
M12 - I would feel ashamed to take PrEP in front of others — Missing011
M12 - Someone taking PrEP may be seen as having sex with many different people — Completely disagree457
M12 - Someone taking PrEP may be seen as having sex with many different people — Disagree870
M12 - Someone taking PrEP may be seen as having sex with many different people — Neither agree nor disagree1376
M12 - Someone taking PrEP may be seen as having sex with many different people — Agree1299
M12 - Someone taking PrEP may be seen as having sex with many different people — Completely agree361
M12 - Someone taking PrEP may be seen as having sex with many different people — Missing011
M12 - People on PrEP are taking care of their health — Completely disagree100
M12 - People on PrEP are taking care of their health — Disagree000
M12 - People on PrEP are taking care of their health — Neither agree nor disagree230
M12 - People on PrEP are taking care of their health — Agree13114
M12 - People on PrEP are taking care of their health — Completely agree242019
M12 - People on PrEP are taking care of their health — Missing011
M12 - People taking PrEP experience verbal harassment — Completely disagree777
M12 - People taking PrEP experience verbal harassment — Disagree785
M12 - People taking PrEP experience verbal harassment — Neither agree nor disagree241410
M12 - People taking PrEP experience verbal harassment — Agree231
M12 - People taking PrEP experience verbal harassment — Completely agree020
M12 - People taking PrEP experience verbal harassment — Missing011
M12 - I would not want others to know if I was taking PrEP — Completely disagree16916
M12 - I would not want others to know if I was taking PrEP — Disagree1462
M12 - I would not want others to know if I was taking PrEP — Neither agree nor disagree9123
M12 - I would not want others to know if I was taking PrEP — Agree011
M12 - I would not want others to know if I was taking PrEP — Completely agree161
M12 - I would not want others to know if I was taking PrEP — Missing011
M12 - Someone taking PrEP should keep their pills hidden — Completely disagree13310
M12 - Someone taking PrEP should keep their pills hidden — Disagree13125
M12 - Someone taking PrEP should keep their pills hidden — Neither agree nor disagree12136
M12 - Someone taking PrEP should keep their pills hidden — Agree211
M12 - Someone taking PrEP should keep their pills hidden — Completely agree051
M12 - Someone taking PrEP should keep their pills hidden — Missing011
M12 - I would feel proud to take PrEP — Completely disagree010
M12 - I would feel proud to take PrEP — Disagree010
M12 - I would feel proud to take PrEP — Neither agree nor disagree660
M12 - I would feel proud to take PrEP — Agree1386
M12 - I would feel proud to take PrEP — Completely agree211817
M12 - I would feel proud to take PrEP — Missing011
M12 - I would have sex with someone who is taking PrEP — Completely disagree010
M12 - I would have sex with someone who is taking PrEP — Disagree022
M12 - I would have sex with someone who is taking PrEP — Neither agree nor disagree752
M12 - I would have sex with someone who is taking PrEP — Agree12125
M12 - I would have sex with someone who is taking PrEP — Completely agree211414
M12 - I would have sex with someone who is taking PrEP — Missing011
SecondaryNumber of PSPs With Responses on Community Attitude Towards PrEP Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs response to the following question: "In general, what kind of attitude do you think your community has toward PrEP?".

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Community Attitude Towards PrEP Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
Positive101710
Somewhat positive899
Neither negative nor positive1088
Somewhat negative1065
Negative111
SecondaryNumber of PSPs With Responses to Worry Regarding APRETUDE Disclosure Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs response to the following question: "How often are you worried that people may find out that you are taking APRETUDE?".

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Worry Regarding APRETUDE Disclosure Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How often are you worried that people may find out that you are taking APRETUDE? — Never373129
M4 - How often are you worried that people may find out that you are taking APRETUDE? — Rarely673
M4 - How often are you worried that people may find out that you are taking APRETUDE? — Sometimes753
M4 - How often are you worried that people may find out that you are taking APRETUDE? — Often001
M4 - How often are you worried that people may find out that you are taking APRETUDE? — All the time000
M4 - How often are you worried that people may find out that you are taking APRETUDE? — Missing001
M12 - How often are you worried that people may find out that you are taking APRETUDE? — Never302719
M12 - How often are you worried that people may find out that you are taking APRETUDE? — Rarely844
M12 - How often are you worried that people may find out that you are taking APRETUDE? — Sometimes230
M12 - How often are you worried that people may find out that you are taking APRETUDE? — Often000
M12 - How often are you worried that people may find out that you are taking APRETUDE? — All the time000
M12 - How often are you worried that people may find out that you are taking APRETUDE? — Missing011
SecondaryNumber of PSPs With Responses to Sources of Pre-enrollment APRETUDE Information Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the sources of information for APRETUDE pre-enrollment. This outcome measure presents the PSPs response to the following question: "If you have questions about APRETUDE, where do you find information?" The answer "the study app/website" was inconsistently displayed to study arms at different time points due to a programming error.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Sources of Pre-enrollment APRETUDE Information Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Product website15711
M4 - Written materials such as the study handbook from my healthcare provider2177
M4 - Speaking to a healthcare provider272624
M4 - Social Media101
M4 - Internet search797
M4 - Friends210
M4 - Family111
M4 - The study app/website (EI/ECI)—78
M4 - I have not had any questions so far844
M4 - I did not find answers to my questions120
M4 - Missing111
M12 - Product website13910
M12 - Written materials such as the study handbook from my healthcare provider1569
M12 - Speaking to a healthcare provider252314
M12 - Social Media301
M12 - Internet search879
M12 - Friends211
M12 - Family100
M12 - The study app/website1039
M12 - I have not had any questions so far341
M12 - I did not find answers to my questions010
M12 - Missing111
SecondaryNumber of PSPs With Responses to Perceived Benefits of In-person APRETUDE Injection Visits

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the PSPs perception of the benefits of in-person APRETUDE injection visits.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perceived Benefits of In-person APRETUDE Injection Visits
ParticipantsSI - PSPEI - PSPECI - PSP
I have more opportunities to discuss APRETUDE concerns or manage side effects272219
I can discuss other sexual health issues like STIs or contraception during visits231812
I have more opportunities to discuss non-sexual healthcare issues or concerns11128
I have more opportunities for health screenings like diabetes and high blood pressure121012
I am more engaged in my sexual health21157
I feel like I have a better relationship with my care provider15189
Another benefit000
There are no benefits201
I have only received injections at home or an alternative site (e.g., infusion center)010
Missing111
SecondaryNumber of PSPs With Responses to Overall Feelings to APRETUDE Assessed by Questionnaires

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Overall, how are you feeling about getting APRETUDE?".

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Overall Feelings to APRETUDE Assessed by Questionnaires
ParticipantsSI - PSPEI - PSPECI - PSP
BL - Overall, how are you feeling about getting APRETUDE? — Very positive474438
BL - Overall, how are you feeling about getting APRETUDE? — Somewhat positive3103
BL - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative320
BL - Overall, how are you feeling about getting APRETUDE? — Somewhat negative000
BL - Overall, how are you feeling about getting APRETUDE? — Very negative001
BL - Overall, how are you feeling about getting APRETUDE? — Missing000
M4 - Overall, how are you feeling about getting APRETUDE? — Very positive453631
M4 - Overall, how are you feeling about getting APRETUDE? — Somewhat positive423
M4 - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative021
M4 - Overall, how are you feeling about getting APRETUDE? — Somewhat negative010
M4 - Overall, how are you feeling about getting APRETUDE? — Very negative010
M4 - Overall, how are you feeling about getting APRETUDE? — Missing112
M12 - Overall, how are you feeling about getting APRETUDE? — Very positive362821
M12 - Overall, how are you feeling about getting APRETUDE? — Somewhat positive342
M12 - Overall, how are you feeling about getting APRETUDE? — Neither positive nor negative020
M12 - Overall, how are you feeling about getting APRETUDE? — Somewhat negative000
M12 - Overall, how are you feeling about getting APRETUDE? — Very negative000
M12 - Overall, how are you feeling about getting APRETUDE? — Missing111
SecondaryNumber of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 4

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 4
ParticipantsSI - SSPEI - SSPECI - SSP
Structural Characteristics as Facilitators389
Structural Characteristics as Barriers429
Climate-Culture as Facilitators232125
Climate-Culture as Barriers7716
Staff Ed and Training as a Facilitator458
Supportive key players3127
Engaging participants242225
SecondaryNumber of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12
ParticipantsSI - SSPEI - SSPECI - SSP
Staff generally supportive161010
Specific roles supportive785
Alignment with clinic priorities835
Supportive clinic leadership633
Strain of new workflow328
Strain of insurance and acquisition processes414
Injection aversion1046
Patient beliefs721
Comfort with oral PrEP224
Injection schedule unappealing141
Injection side effects1276
Adhering to bimonthly visits456
Lack of resources616
Absence of daily pill regimen12812
Privacy542
Perceived protection from HIV351
Good experience: no challenges957
Convenience of appointments332
Routine clinic visits131111
Print outreach1276
Community partnerships-events674
Social media-web636
Patients ask about it614
Directed outreach321
Communication efforts successful131110
No challenges engaging Black women458
Challenge: risk awareness944
Challenge: Misconceptions321
Challenge: small population402
Need: community and provider education743
Patients drive decision-making724
Shared decision-making633
Providing information for patients to decide325
Increase provider understanding525
Educate Black women about risk344
Increase trust, decrease stigma324
Community outreach and representation204
Offer HIV prevention to all women511
SecondaryNumber of Clinics With Responses to Facilitators and Barriers to Implementation Assessed by IMCs

IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to overall SSP perceptions of facilitators and barriers to APRETUDE implementation discussed during IMC calls. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to qualitative data collection.

Time frame:
Up to Month 12
Reported as:
Count of units · Clinics
Number of Clinics With Responses to Facilitators and Barriers to Implementation Assessed by IMCs
ClinicsSI - ClinicsEI - ClinicsECI - Clinics
Practice Preparations - Past experiences with injectables and/or APRETUDE123
Practice Preparations - Leadership Support/Staff buy in for APRETUDE2—2
Practice Preparations - Staff Expertise and Role Specialization1—2
Practice Preparations - Workflow tools developed (i.e., tracking tools)2——
Practice Preparations - Building patient rapport——1
Practice Preparations - Training and Capacity Building——1
Practice Preparations - Support from SMA/Viiv—1—
Practice Preparations - Current workflows will need to be restructured——3
Practice Preparations - Need to develop certain tools/documentation from scratch—12
Practice Preparations - Need to develop new processes——1
Practice Preparations - Staff knowledge/perception/motivation/attitudes1—2
Practice Preparations - Lack of leadership support——1
Practice Preparations- Insufficient staff to work on setting up practice operations—12
Practice Preparations - Insufficient time to work on setting up practice operations1—3
Patient Selection - Clinic tools and strategies234
Patient Selection - Community outreach event/partnerships with community organizations575
Patient Selection - Dedicated Staff and Role Assignment353
Patient Selection - EBONI tools (e.g., health questionnaire, SHE Ambassadors, videos, etc.)1—1
Patient Selection - External Support and Collaboration with other clinics222
Patient Selection - Marketing APRETUDE335
Patient Selection - Past experiences with injectables and/or APRETUDE335
Patient Selection - Patient Supportive Resources254
Patient-Clinic Trust or Relationship established and/or strengthened141
Patient Selection - Trained or knowledgeable staff323
Patient Selection - Staff knowledge/perception/motivation/attitudes—31
Patient Selection - Lack of training/education321
Patient Selection - Time constraints and care prioritization among providers114
Patient Selection - Insufficient staff to work on this222
Patient Selection - Insufficient time to work on this—12
Patient Selection - Insufficient resources/funding to work on this212
Patient Selection - APRETUDE product concerns3—1
Patient Selection - Patient factors (e.g., lack of interest, historical adherence to appointments)796
Injection Visits - Assigned staff roles—23
Injection visits - Pre-established protocols or experience with injectables/APRETUDE112
Injection Visits - Scheduling and injection visit coordination111
Injection Visits - Site's engagement and support with patients111
Injection Visits - Iterative learning and adapting——2
Injection Visits - Training Staff——1
Injection Visits - Space/length of visits for patients—12
Injection Visits - Staff knowledge/perception/motivation/attitudes——2
Injection Visits - Lack of training/education——1
Injection Visits - Lack of established process or workflow concerns——1
Injection Visits - Time constraints & care prioritization—1—
Injection visits - Insurance, reimbursement, or financial assistance issues——3
Injection Visits - Insufficient staff to work on this—11
Injection Visits - Lack of coordination between pharmacy and clinic/practice——1
Injection Visits - Insufficient time to work on this——2
Injection Visits - Challenges reaching patients or patients missing appointments—32
Injection Visits - Patient scheduling challenges213
Injection Visits - Patient requested changes—1—
SecondaryNumber of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Baseline

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
PSP had a low awareness of PrEP254
PSP was aware of PrEP171015
Knowledge about HIV protection: safe sex does not protect against STIs12910
Did not want to take oral PrEP anymore144
More individuals should be on PrEP111
There needs to be more info shared about PrEP103
PSP was aware of APRETUDE13109
PSP was unaware of APRETUDE243
Knowledge of the ease and convenience of injection151215
Knowledge that APRETUDE protects against HIV101112
Learned about APRETUDE from provider526
APRETUDE provider is not the same as general medical care provider18512
APRETUDE provider is the same as general medical care provider488
APRETUDE suggested by clinic staff/provider knowledgeable about PrEP71318
PSP asked provider/initiated discussions about APRETUDE753
Provider involved in decision-making13811
Provider not involved in decision-making766
Received counselling on sexual health services and HIV prevention options available12912
Was not counselled on sexual health services and HIV prevention options available877
Discussed HIV prevention with provider659
Was only counselled about sexual health services after PSP mentioned APRETUDE023
Said they did not receive counseling, but described counseling services220
Noted that they already know a lot about sexual health/PrEP231
Found counselling on sexual health services and HIV prevention helpful for questions9611
Did not find counselling on sexual health services and HIV prevention helpful000
Discussed counselling from non-study providers212
Discussed condoms with provider746
Discussed both oral and injectable PrEP with provider406
Only discussed APRETUDE during counseling003
Discussed abstinence or celibacy with provider102
Discussed STD/STI testing services available to them200
More public awareness and knowledge of APRETUDE033
Assistance with insurance coverage and APRETUDE costs422
Support from peers and community members320
More time between injections322
Ability to receive injections at more location/self-administer222
More information about APRETUDE's efficacy, how it works, and side effects233
Learning about the experiences of other APRETUDE patients111
PrEP is known in PSPs community8913
PrEP is not well known in PSPs community181110
APRETUDE is known in PSPs community456
APRETUDE is not known in PSPs community151015
Believes APRETUDE is a good fit for many members of their community033
Discussed APRETUDE with peers/community members022
High PrEP awareness due to community engagement247
Lack of community knowledge about PrEP021
There is PrEP/HIV stigma in Black community and among Black women123
Experienced stigma from medical staff210
Mentioned belief that PrEP can give HIV or is for people who already have HIV111
Mentioned personal efforts to reduce stigma in their community122
Mentioned stigma associated with going to a specialty clinic to receive APRETUDE122
Discussed the existing sentiment that PrEP is only for gay people102
SecondaryNumber of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Facilitators and Barriers to Implementation Assessed by SSIs at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
Sees another healthcare provider at least once or twice a year345
APRETUDE appointments do not conflict with other medical appointments14311
Confusion/ misunderstanding from other providers about APRETUDE311
Primary interaction is with nurse/doctor during appointments204
Doctor/nurse as the point of contact for questions/concerns576
Believe that providers should be informing patients about APRETUDE212
Stigma associated with APRETUDE and HIV423
Discretion with APRETUDE323
Misinformation and stigma about HIV prevention can affect perceptions of APRETUDE323
SecondaryMean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs

The AIM was used to assess among PSPs the acceptability of APRETUDE using a four-item measure (1. I believe APRETUDE will meet my approval for preventing HIV, 2. APRETUDE for the prevention of HIV is appealing to me, 3. I think I will like APRETUDE for the prevention of HIV, 4. I welcome APRETUDE for the prevention of HIV) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI)

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs
Scores on a scaleSI - PSPEI - PSPECI - PSP
At Baseline4.3 ± 0.784.3 ± 0.674.6 ± 0.51
At Month 44.6 ± 0.524.3 ± 0.594.7 ± 0.47
At Month 124.7 ± 0.424.5 ± 0.604.7 ± 0.40
SecondaryMean FIM Score Assessed for PSPs

The FIM was used to assess among PSPs the feasibility of APRETUDE using a four-item measure (1. Receiving APRETUDE injections every 2 months seems workable in my life, 2. Receiving APRETUDE injections every 2 months seems possible for me, 3. Receiving APRETUDE injections every 2 months seems doable in my life, 4. Receiving APRETUDE injections every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean FIM Score Assessed for PSPs
Scores on a scaleSI - PSPEI - PSPECI - PSP
At Baseline4.3 ± 0.734.3 ± 0.754.6 ± 0.49
At Month 44.5 ± 0.594.4 ± 0.644.7 ± 0.49
At Month 124.5 ± 0.644.3 ± 0.764.7 ± 0.45
SecondaryMean AIM Score Assessed for SSPs

The AIM was used to assess the acceptability of APRETUDE using a four-item measure (1. APRETUDE in our clinic/practice meets my approval, 2. APRETUDE in our clinic/practice is appealing to me, 3. I like APRETUDE in our clinic/practice, 4. I welcome APRETUDE in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean AIM Score Assessed for SSPs
Scores on a scaleSI - SSPEI - SSPECI - SSP
At Baseline4.6 ± 0.574.6 ± 0.544.5 ± 0.61
At Month 44.3 ± 0.844.5 ± 0.524.4 ± 0.58
At Month 124.4 ± 0.864.7 ± 0.444.4 ± 0.61
SecondaryMean FIM Score Assessed for SSPs

The FIM was used to assess the feasibility of APRETUDE using a four-item measure (1. APRETUDE seems implementable in our clinic/practice, 2. APRETUDE seems possible in our clinic/practice, 3. APRETUDE seems doable in our clinic/practice, 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean FIM Score Assessed for SSPs
Scores on a scaleSI - SSPEI - SSPECI - SSP
At Baseline4.4 ± 0.764.6 ± 0.504.4 ± 0.59
At Month 44.2 ± 0.864.6 ± 0.554.2 ± 0.63
At Month 124.4 ± 0.914.6 ± 0.464.3 ± 0.58
SecondaryNumber of SSPs With Responses to Feasibility of APRETUDE Implementation

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding feasibility of APRETUDE implementation.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Feasibility of APRETUDE Implementation
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Difficulty of giving the gluteal medial injection — Extremely concerned420
BL - Difficulty of giving the gluteal medial injection — Moderately concerned053
BL - Difficulty of giving the gluteal medial injection — Somewhat concerned153
BL - Difficulty of giving the gluteal medial injection — Slightly concerned475
BL - Difficulty of giving the gluteal medial injection — Not at all Concerned313329
BL - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned121
BL - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned054
BL - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned334
BL - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned8912
BL - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned283319
BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned221
BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned056
BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned453
BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned111010
BL - Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned233020
BL - Staff time for counseling and support, including answering questions and motivation — Extremely concerned243
BL - Staff time for counseling and support, including answering questions and motivation — Moderately concerned321
BL - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned438
BL - Staff time for counseling and support, including answering questions and motivation — Slightly concerned12913
BL - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned193415
M4 - Difficulty of giving the gluteal medial injection — Extremely concerned100
M4 - Difficulty of giving the gluteal medial injection — Moderately concerned200
M4 - Difficulty of giving the gluteal medial injection — Somewhat concerned334
M4 - Difficulty of giving the gluteal medial injection — Slightly concerned447
M4 - Difficulty of giving the gluteal medial injection — Not at all Concerned192527
M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned000
M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned112
M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned425
M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned877
M4 - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned162224
M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned011
M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned224
M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned425
M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned965
M4 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned142123
M4 - Staff time for counseling and support, including answering questions and motivation — Extremely concerned000
M4 - Staff time for counseling and support, including answering questions and motivation — Moderately concerned125
M4 - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned435
M4 - Staff time for counseling and support, including answering questions and motivation — Slightly concerned888
M4 - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned161920
M12 - Difficulty of giving the gluteal medial injection — Extremely concerned300
M12 - Difficulty of giving the gluteal medial injection — Moderately concerned002
M12 - Difficulty of giving the gluteal medial injection — Somewhat concerned325
M12 - Difficulty of giving the gluteal medial injection — Slightly concerned229
M12 - Difficulty of giving the gluteal medial injection — Not at all Concerned182216
M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Extremely concerned100
M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Moderately concerned103
M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Somewhat concerned324
M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Slightly concerned4610
M12 - Managing scheduling of injection appointments every 2 months within dosing windows — Not at all Concerned171815
M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Extremely concerned200
M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Moderately concerned303
M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Somewhat concerned124
M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Slightly concerned458
M12 -Ability to schedule or reschedule missed APRETUDE visits within dosing windows — Not at all Concerned161917
M12 - Staff time for counseling and support, including answering questions and motivation — Extremely concerned202
M12 - Staff time for counseling and support, including answering questions and motivation — Moderately concerned103
M12 - Staff time for counseling and support, including answering questions and motivation — Somewhat concerned314
M12 - Staff time for counseling and support, including answering questions and motivation — Slightly concerned678
M12 - Staff time for counseling and support, including answering questions and motivation — Not at all Concerned141815
SecondaryNumber of SSPs With Responses to Clinic Capacity for APRETUDE Patient Management

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding clinic capacity for APRETUDE patient management (i.e. "Number of APRETUDE patients that the clinic can manage per week").

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Clinic Capacity for APRETUDE Patient Management
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients172218
BL - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients15139
BL - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients484
BL - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients202
BL - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients000
BL - Number of APRETUDE patients that the clinic can manage per week — > 200 patients000
BL - Number of APRETUDE patients that the clinic can manage per week — Does not know297
M4 - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients631
M4 - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients458
M4 - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients489
M4 - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients7610
M4 - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients241
M4 - Number of APRETUDE patients that the clinic can manage per week — > 200 patients532
M4 - Number of APRETUDE patients that the clinic can manage per week — Does not know137
M12 - Number of APRETUDE patients that the clinic can manage per week — 0-10 patients724
M12 - Number of APRETUDE patients that the clinic can manage per week — 11-25 patients638
M12 - Number of APRETUDE patients that the clinic can manage per week — 26-50 patients296
M12 - Number of APRETUDE patients that the clinic can manage per week — 51-100 patients125
M12 - Number of APRETUDE patients that the clinic can manage per week — 101-200 patients732
M12 - Number of APRETUDE patients that the clinic can manage per week — > 200 patients225
M12 - Number of APRETUDE patients that the clinic can manage per week — Does not know152
SecondaryMean Number of Staff Needed to Incorporate APRETUDE Into Clinics Per Week

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This endpoint presents the results on mean number of staff needed to incorporate APRETUDE into clinics per week.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Mean · Number of participants per week
Mean Number of Staff Needed to Incorporate APRETUDE Into Clinics Per Week
Number of participants per weekSI - SSPEI - SSPECI - SSP
At Baseline3.9 ± 1.935.0 ± 7.984.5 ± 1.90
At Month 43.0 ± 1.782.8 ± 1.234.1 ± 2.48
At Month 122.8 ± 1.384.8 ± 5.874.3 ± 2.81
SecondaryNumber of SSPs With Responses to Staff Time/Full-time Equivalent Hours (FTE) Requirements Per Week

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to staff time/FTE requirements per week to incorporate APRETUDE.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Staff Time/Full-time Equivalent Hours (FTE) Requirements Per Week
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time784
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time101510
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time134
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time503
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff420
BL - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know132419
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time851
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time797
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time535
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time212
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff312
M4 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know41321
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 1-20% FTE or 0.4-8hrs of staff time842
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 21-40% FTE or 8.4-16hrs of staff time625
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 41-60% FTE or 16.4-24hrs of staff time213
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 61-80% FTE or 24.4-32hrs of staff time210
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — 81%-100% FTE or 32.4-40hrs of staff215
M12 - Staff time/FTE hours needed weekly to incorporate APRETUDE into your clinic — Does not know61717
SecondaryNumber of SSPs With Responses to Clinic/Practice Methods for Patient Tracking

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods for patient tracking.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Clinic/Practice Methods for Patient Tracking
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Use a spreadsheet such as MS Excel201920
BL - Assign specific staff to track patients192414
BL - Have providers track their own patients114
BL - Create alerts in electronic medical records (EMRs)131216
BL - Other106
BL - Does not know7169
M4 - Use a spreadsheet such as MS Excel171519
M4 - Assign specific staff to track patients121614
M4 - Have providers track their own patients354
M4 - Create alerts in electronic medical records (EMRs)8912
M4 - Other203
M4 - Does not know248
M12 - Use a spreadsheet such as MS Excel141119
M12 - Assign specific staff to track patients91214
M12 - Have providers track their own patients235
M12 - Create alerts in electronic medical records (EMRs)101013
M12 - Other300
M12 - Does not know257
SecondaryNumber of SSPs With Responses to Clinic/Practice Methods to Remind Patients of an Upcoming Appointment

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods to remind patients of an upcoming appointment

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Clinic/Practice Methods to Remind Patients of an Upcoming Appointment
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Phone call from Staff353420
BL - Automated phone call142525
BL - Text message292430
BL - Email20820
BL - Postal Mail340
BL - Phone app notification6108
BL - Other011
BL - Does not know173
M4 - Phone call from Staff242424
M4 - Automated phone call141326
M4 - Text message192221
M4 - Email11914
M4 - Postal Mail101
M4 - Phone app notification626
M4 - Other001
M4 - Does not know145
M12 - Phone call from Staff222022
M12 - Automated phone call111327
M12 - Text message141725
M12 - Email3812
M12 - Postal Mail011
M12 - Phone app notification136
M12 - Other001
M12 - Does not know230
M12 - Missing010
SecondaryNumber of SSPs With Responses to Clinic/Practice Approaches for Offering Injection Appointments

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice approaches for offering injection appointments.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Clinic/Practice Approaches for Offering Injection Appointments
ParticipantsSI - SSPEI - SSPECI - SSP
BL - Appointments each day of the week242018
BL - Appointments only on certain days of the week11168
BL - Appointments spread out over the month475
BL - Injection-only appointments172020
BL - Allow patients to drop-in for injections on any day without an appointment512
BL - Allow patients to drop-in with little advance notice (e.g., 24 hr notice)985
BL - Allow patients to drop-in on a specific injection day without an appointment411
BL - After hours appointments882
BL - Before hours appointment631
BL - Weekend appointments454
BL - Home nursing appointments010
BL - Mobile clinic option100
BL - Alternate site appointments222
BL - Depends on the schedule of the injection nurse864
BL - Depends on the schedule of the APRETUDE provider543
BL - Other001
BL - Don't know1157
M4 - Appointments each day of the week202021
M4 - Appointments only on certain days of the week877
M4 - Appointments spread out over the month224
M4 - Injection-only appointments131514
M4 - Allow patients to drop-in for injections on any day without an appointment132
M4 - Allow patients to drop-in with little advance notice (e.g., 24 hr notice)537
M4 - Allow patients to drop-in on a specific injection day without an appointment112
M4 - After hours appointments322
M4 - Before hours appointment201
M4 - Weekend appointments054
M4 - Home nursing appointments000
M4 - Mobile clinic option000
M4 - Alternate site appointments133
M4 - Depends on the schedule of the injection nurse312
M4 - Depends on the schedule of the APRETUDE provider234
M4 - Other001
M4 - Unsure149
M12 - Appointments each day of the week161624
M12 - Appointments only on certain days of the week967
M12 - Appointments spread out over the month432
M12 - Injection-only appointments91116
M12 - Allow patients to drop-in for injections on any day without an appointment235
M12 - Allow patients to drop-in with little advance notice (e.g., 24 hr notice)367
M12 - Allow patients to drop-in on a specific injection day without an appointment013
M12 - After hours appointments045
M12 - Before hours appointment003
M12 - Weekend appointments035
M12 - Home nursing appointments010
M12 - Mobile clinic option000
M12 - Alternate site appointments011
M12 - Depends on the schedule of the injection nurse221
M12 - Depends on the schedule of the APRETUDE provider123
M12 - Other000
M12 - Unsure120
SecondaryNumber of SSPs With Responses to Perceived Ease/Difficulty of Implementing APRETUDE in Clinics

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived ease/difficulty of implementing APRETUDE in clinics.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Perceived Ease/Difficulty of Implementing APRETUDE in Clinics
ParticipantsSI - SSPEI - SSPECI - SSP
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy132211
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy141416
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult111310
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult133
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult100
BL - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing000
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy10157
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy121013
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult378
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult3010
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult100
M4 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing000
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very easy7136
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat easy14814
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Neither easy nor difficult226
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Somewhat difficult225
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Very difficult101
M12 - How easy or difficult has it been to implement APRETUDE into your current workflow? — Missing010
SecondaryNumber of SSPs With Responses to Acceptability of APRETUDE Implementation

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to acceptability of APRETUDE implementation.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Acceptability of APRETUDE Implementation
ParticipantsSI - SSPEI - SSPECI - SSP
BL- Risk of drug resistance for patients not adherent to injection visits — Extremely concerned7127
BL- Risk of drug resistance for patients not adherent to injection visits — Moderately concerned7125
BL- Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned10711
BL- Risk of drug resistance for patients not adherent to injection visits — Slightly concerned91610
BL- Risk of drug resistance for patients not adherent to injection visits — Not at all concerned757
BL - Cost of APRETUDE — Extremely concerned9166
BL - Cost of APRETUDE — Moderately concerned5811
BL - Cost of APRETUDE — Somewhat concerned10149
BL - Cost of APRETUDE — Slightly concerned759
BL - Cost of APRETUDE — Not at all concerned995
BL - Cost of ancillary services to provide APRETUDE — Extremely concerned584
BL - Cost of ancillary services to provide APRETUDE — Moderately concerned5116
BL - Cost of ancillary services to provide APRETUDE — Somewhat concerned71510
BL - Cost of ancillary services to provide APRETUDE — Slightly concerned12711
BL - Cost of ancillary services to provide APRETUDE — Not at all concerned11119
BL - Staff belief in the efficacy of APRETUDE — Extremely concerned120
BL - Staff belief in the efficacy of APRETUDE — Moderately concerned020
BL - Staff belief in the efficacy of APRETUDE — Somewhat concerned432
BL - Staff belief in the efficacy of APRETUDE — Slightly concerned665
BL - Staff belief in the efficacy of APRETUDE — Not at all concerned293933
M4 - Risk of drug resistance for patients not adherent to injection visits — Extremely concerned525
M4 - Risk of drug resistance for patients not adherent to injection visits — Moderately concerned634
M4 - Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned5810
M4 - Risk of drug resistance for patients not adherent to injection visits — Slightly concerned6910
M4 - Risk of drug resistance for patients not adherent to injection visits — Not at all concerned7109
M4 - Cost of APRETUDE — Extremely concerned858
M4 - Cost of APRETUDE — Moderately concerned382
M4 - Cost of APRETUDE — Somewhat concerned369
M4 - Cost of APRETUDE — Slightly concerned469
M4 - Cost of APRETUDE — Not at all concerned11710
M4 - Cost of ancillary services to provide APRETUDE — Extremely concerned435
M4 - Cost of ancillary services to provide APRETUDE — Moderately concerned651
M4 - Cost of ancillary services to provide APRETUDE — Somewhat concerned3810
M4 - Cost of ancillary services to provide APRETUDE — Slightly concerned4711
M4 - Cost of ancillary services to provide APRETUDE — Not at all concerned12911
M4 - Staff belief in the efficacy of APRETUDE — Extremely concerned000
M4 - Staff belief in the efficacy of APRETUDE — Moderately concerned010
M4 - Staff belief in the efficacy of APRETUDE — Somewhat concerned304
M4 - Staff belief in the efficacy of APRETUDE — Slightly concerned333
M4 - Staff belief in the efficacy of APRETUDE — Not at all concerned232831
M12 - Risk of drug resistance for patients not adherent to injection visits — Extremely concerned407
M12 - Risk of drug resistance for patients not adherent to injection visits — Moderately concerned347
M12 - Risk of drug resistance for patients not adherent to injection visits — Somewhat concerned637
M12 - Risk of drug resistance for patients not adherent to injection visits — Slightly concerned865
M12 - Risk of drug resistance for patients not adherent to injection visits — Not at all concerned5136
M12 - Cost of APRETUDE — Extremely concerned8310
M12 - Cost of APRETUDE — Moderately concerned624
M12 - Cost of APRETUDE — Somewhat concerned575
M12 - Cost of APRETUDE — Slightly concerned246
M12 - Cost of APRETUDE — Not at all concerned5107
M12 - Cost of ancillary services to provide APRETUDE — Extremely concerned524
M12 - Cost of ancillary services to provide APRETUDE — Moderately concerned519
M12 - Cost of ancillary services to provide APRETUDE — Somewhat concerned549
M12 - Cost of ancillary services to provide APRETUDE — Slightly concerned565
M12 - Cost of ancillary services to provide APRETUDE — Not at all concerned6135
M12 - Staff belief in the efficacy of APRETUDE — Extremely concerned100
M12 - Staff belief in the efficacy of APRETUDE — Moderately concerned200
M12 - Staff belief in the efficacy of APRETUDE — Somewhat concerned211
M12 - Staff belief in the efficacy of APRETUDE — Slightly concerned345
M12 - Staff belief in the efficacy of APRETUDE — Not at all concerned182126
SecondaryNumber of SSPs With Responses to Perceived Positive Perception of Implementing APRETUDE

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived positive perception of implementing APRETUDE.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Perceived Positive Perception of Implementing APRETUDE
ParticipantsSI - SSPEI - SSPECI - SSP
BL - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive253017
BL - How do you feel about implementing APRETUDE at your clinic/practice? — Positive141918
BL - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive113
BL - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive021
BL - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive001
BL - How do you feel about implementing APRETUDE at your clinic/practice? — Missing000
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive192014
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Positive71018
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive324
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive002
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive000
M4 - How do you feel about implementing APRETUDE at your clinic/practice? — Missing000
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Extremely positive121810
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Positive12717
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Somewhat positive104
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — A little positive001
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Not at all positive100
M12 - How do you feel about implementing APRETUDE at your clinic/practice? — Missing010
SecondaryNumber of SSPs With Responses to Patient Time in Waiting Room and Exam Room for APRETUDE Injection Visits

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to patient time in waiting room and exam room for APRETUDE injection visits.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Patient Time in Waiting Room and Exam Room for APRETUDE Injection Visits
ParticipantsSI - SSPEI - SSPECI - SSP
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — Up to 20 minutes241822
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 21-40 minutes022
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 41-60 minutes001
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — 61- 90 minutes (1hr-1.5hrs)000
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — More than 90 minutes (more than 1.5hrs)000
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — I don't know257
On average, how long does an APRETUDE patient spend in the waiting room prior to an injection visit? — Missing010
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — Up to 20 minutes181617
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 21-40 minutes4311
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 41-60 minutes210
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — 61- 90 minutes (1hr-1.5hrs)000
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — More than 90 minutes (more than 1.5hrs)000
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — I don't know254
On average, how long does an APRETUDE patient spend in the exam room during an injection visit? — Missing010
SecondaryNumber of SSPs With Responses to Post-injection Observation Period for Patients After APRETUDE

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to post-injection observation period for patients after APRETUDE.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses to Post-injection Observation Period for Patients After APRETUDE
ParticipantsSI - SSPEI - SSPECI - SSP
No observation period448
Up to 10 minutes1883
11 to 20 minutes3615
21-30 minutes001
More than 30 minutes000
I don't know175
Missing010
SecondaryNumber of PSPs With Responses to Convenience Level of Clinic Hours

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to convenience level of clinic hours.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Convenience Level of Clinic Hours
ParticipantsSI - PSPEI - PSPECI - PSP
BL - How convenient are your clinic's hours? — Very convenient213326
BL - How convenient are your clinic's hours? — Convenient13169
BL - How convenient are your clinic's hours? — Somewhat Convenient1354
BL - How convenient are your clinic's hours? — A little Convenient523
BL - How convenient are your clinic's hours? — Not at all Convenient100
BL - How convenient are your clinic's hours? — Missing000
M4 - How convenient are your clinic's hours? — Very convenient292525
M4 - How convenient are your clinic's hours? — Convenient11116
M4 - How convenient are your clinic's hours? — Somewhat Convenient633
M4 - How convenient are your clinic's hours? — A little Convenient331
M4 - How convenient are your clinic's hours? — Not at all Convenient101
M4 - How convenient are your clinic's hours? — Missing010
M12 - How convenient are your clinic's hours? — Very convenient211716
M12 - How convenient are your clinic's hours? — Convenient1384
M12 - How convenient are your clinic's hours? — Somewhat Convenient262
M12 - How convenient are your clinic's hours? — A little Convenient311
M12 - How convenient are your clinic's hours? — Not at all Convenient010
M12 - How convenient are your clinic's hours? — Missing100
SecondaryNumber of PSPs With Responses to Sources of First Injection Appointment Reminders at Baseline

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to sources of first injection appointment reminders at baseline.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Sources of First Injection Appointment Reminders at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Phone calls313227
Texts/SMS messages423124
Existing clinic app reminder1248
E-mails232419
Reminder in the postal mail101
Face-to-face reminder from a healthcare provider357
Written reminder/appointment card with date and time165
The study app (ECI)000
I did not receive reminders110
SecondaryNumber of PSPs With Responses to Sources of Injection Appointment Reminders at Month 12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to sources of injection appointment reminders at Month 12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Sources of Injection Appointment Reminders at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
Phone calls191611
Text/SMS messages332313
Existing clinic app reminder1136
E-mails9711
Reminder in the postal mail110
Face-to-face reminder from a healthcare provider461
Written reminder/appointment card with date and time025
The study app/website000
Another type of reminder110
I have not received any reminders101
Missing111
SecondaryNumber of PSPs With Responses to Preferred Appointment Reminder Types at Baseline

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to preferred appointment reminder types at baseline (Month 1).

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Preferred Appointment Reminder Types at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Phone calls252816
Texts/SMS messages494734
Existing clinic app reminder1048
App notifications966
E-mails252721
Reminder in the postal mail110
Face-to-face reminder from a healthcare provider133
Written reminder/appointment card with date and time241
Another type of reminder010
I do not wish to receive reminders010
SecondaryNumber of PSPs With Responses to Most Helpful Types of Appointment Reminders at M4 and M12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to most helpful types of appointment reminders at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Most Helpful Types of Appointment Reminders at M4 and M12
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - I have not received any reminders110
M4 - Phone calls212319
M4 - Text/SMS messages383527
M4 - Existing clinic app reminder12137
M4 - E-mails141714
M4 - Reminder in the mail000
M4 - Face-to-face reminder from a healthcare provider144
M4 - Written reminder/appointment card with date and time532
M4 - The study app/website (EI/ECI)011
M4 - Another type of reminder000
M4 - I did not think any of the reminders were helpful000
M4 - Missing211
M12 - Phone calls161515
M12 - Text/SMS messages362317
M12 - Existing clinic app reminder734
M12 - E-mails101312
M12 - Reminder in the mail100
M12 - Face-to-face reminder from a healthcare provider362
M12 - Written reminder/appointment card with date and time121
M12 - The study app/website (EI/ECI)000
M12 - Another type of reminder221
M12 - I did not think any of the reminders were helpful000
M12 - Missing000
SecondaryNumber of PSPs With Responses to Need for Additional Care for Injection Visits

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to need for additional care for injection visits.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Need for Additional Care for Injection Visits
ParticipantsSI - PSPEI - PSPECI - PSP
BL - Will you need additional childcare, eldercare, or other care for injection visits? — Yes264
BL - Will you need additional childcare, eldercare, or other care for injection visits? — No443426
BL - Will you need additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A)71612
BL - Will you need additional childcare, eldercare, or other care for injection visits? — Missing000
M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — Yes043
M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — No403122
M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A)10711
M4 - Have you needed additional childcare, eldercare, or other care for injection visits? — Missing010
M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — Yes452
M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — No252514
M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — I am not caring for others right now (N/A)1037
M12 - Have you needed additional childcare, eldercare, or other care for injection visits? — Missing100
SecondaryNumber of PSPs With Responses to Anticipated Time Off Work for APRETUDE Injections at Baseline

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to anticipated time off work for APRETUDE injections at baseline.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Anticipated Time Off Work for APRETUDE Injections at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
I am not working right now82613
I will not need to take time off work for injections241115
I will probably need to take a whole day off work for each injection655
I will probably need to take a whole day off work for some injections021
I will probably need to take a partial day off work for each injection864
I will probably need to take a partial day off work for some injections644
Other120
SecondaryNumber of PSPs With Responses to Time Taken Off Work for Injections at M4 and M12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to time off work for APRETUDE injections at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Time Taken Off Work for Injections at M4 and M12
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Have you taken any time off from work to receive your injections? — Yes17107
M4 - Have you taken any time off from work to receive your injections? — No302323
M4 - Have you taken any time off from work to receive your injections? — I am not working right now396
M4 - Have you taken any time off from work to receive your injections? — Missing010
M12 - Have you taken any time off from work to receive your injections? — Yes17125
M12 - Have you taken any time off from work to receive your injections? — No181615
M12 - Have you taken any time off from work to receive your injections? — I am not working right now463
M12 - Have you taken any time off from work to receive your injections? — Missing111
SecondaryNumber of PSPs With Responses to Amount of Time Off Work Taken for Injections at M4 and M12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to amount of time off work taken for injections at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Amount of Time Off Work Taken for Injections at M4 and M12
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for each injection112
M4 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for some injections000
M4 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for each injection872
M4 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for some injections313
M4 - How much time did you take off work to receive your injections? — Other510
M12 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for each injection231
M12 - How much time did you take off work to receive your injections? — I needed to take a whole day off work for some injections022
M12 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for each injection1030
M12 - How much time did you take off work to receive your injections? — I needed to take a partial day off work for some injections431
M12 - How much time did you take off work to receive your injections? — Other111
SecondaryNumber of PSPs With Responses to Status of Time Off Work for Injections at M4 and M12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to status of time off work for injections at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Status of Time Off Work for Injections at M4 and M12
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Was your time off work for injections generally paid or unpaid? — Paid422
M4 - Was your time off work for injections generally paid or unpaid? — Unpaid1284
M4 - Was your time off work for injections generally paid or unpaid? — Other101
M12 - Was your time off work for injections generally paid or unpaid? — Paid513
M12 - Was your time off work for injections generally paid or unpaid? — Unpaid12102
M12 - Was your time off work for injections generally paid or unpaid? — Other010
SecondaryNumber of PSPs With Responses to Frequency of Worry About Forgetting APRETUDE Injections

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to frequency of worry about forgetting APRETUDE injections.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Frequency of Worry About Forgetting APRETUDE Injections
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How often are you worried about forgetting your APRETUDE injections? — Never313026
M4 - How often are you worried about forgetting your APRETUDE injections? — Rarely1255
M4 - How often are you worried about forgetting your APRETUDE injections? — Sometimes554
M4 - How often are you worried about forgetting your APRETUDE injections? — Often221
M4 - How often are you worried about forgetting your APRETUDE injections? — All the time010
M4 - How often are you worried about forgetting your APRETUDE injections? — Missing001
M12 - How often are you worried about forgetting your APRETUDE injections? — Never271713
M12 - How often are you worried about forgetting your APRETUDE injections? — Rarely793
M12 - How often are you worried about forgetting your APRETUDE injections? — Sometimes535
M12 - How often are you worried about forgetting your APRETUDE injections? — Often111
M12 - How often are you worried about forgetting your APRETUDE injections? — All the time041
M12 - How often are you worried about forgetting your APRETUDE injections? — Missing011
SecondaryNumber of PSPs With Responses to Perceived Ease/Difficulty of Scheduling Injection Appointments

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of scheduling injection appointments.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perceived Ease/Difficulty of Scheduling Injection Appointments
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very easy433428
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat easy337
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Neither easy nor difficult440
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat difficult021
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very difficult000
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — I have not scheduled any appointments at the clinic/practice000
M4 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Missing001
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very easy302317
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat easy873
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Neither easy nor difficult111
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Somewhat difficult132
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Very difficult000
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — I have not scheduled any appointments at the clinic/practice000
M12 - How easy or difficult is it to schedule injection appointments at the clinic/practice? — Missing011
SecondaryNumber of PSPs With Responses to Perceived Ease/Difficulty of Rescheduling Injection Appointments

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of rescheduling injection appointments.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Perceived Ease/Difficulty of Rescheduling Injection Appointments
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very easy312724
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat easy545
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Neither easy nor difficult350
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat difficult011
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very difficult001
M4 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — I have not needed to reschedule any appointments1165
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very easy272116
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat easy464
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Neither easy nor difficult410
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Somewhat difficult151
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — Very difficult001
M12 - How easy or difficult is it to reschedule injection appointments at the clinic/practice? — I have not needed to reschedule any appointments411
SecondaryNumber of PSPs With Responses to Acceptability of Attending the Clinic Every 2 Months

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to how easy or difficult it has been to get to the clinic every 2 months at M4 and M12.

Time frame:
At Month 4 and at Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of Attending the Clinic Every 2 Months
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very easy292323
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Easy14128
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Neither easy or difficult753
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Difficult021
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very difficult001
M4 - How easy or difficult was to get to the clinic every 2 months for the injection? — Missing010
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very easy211716
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Easy943
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Neither easy or difficult3103
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Difficult621
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Very difficult000
M12 - How easy or difficult was to get to the clinic every 2 months for the injection? — Missing100
SecondaryNumber of PSPs With Responses to Length of Journey to the Clinic/Practice at M12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to "Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?" at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Length of Journey to the Clinic/Practice at M12
ParticipantsSI - SSPEI - SSPECI - SSP
Up to 20 minutes181011
21-40 minutes111810
41-60 minute721
61- 90 minutes231
More than 90 minutes100
Missing100
SecondaryNumber of PSPs With Responses to Concerns About APRETUDE

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to concerns about APRETUDE.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Concerns About APRETUDE
ParticipantsSI - PSPEI - PSPECI - PSP
BL- Do you have any concerns about APRETUDE — Yes694
BL- Do you have any concerns about APRETUDE — No474738
BL- Do you have any concerns about APRETUDE — Missing000
M4- Do you have any concerns about APRETUDE — Yes774
M4- Do you have any concerns about APRETUDE — No433632
M4- Do you have any concerns about APRETUDE — Missing001
M12- Do you have any concerns about APRETUDE — Yes111
M12- Do you have any concerns about APRETUDE — No393322
M12- Do you have any concerns about APRETUDE — Missing011
SecondaryNumber of PSPs With Responses to Specific Concerns About APRETUDE at Baseline

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at baseline (M1).

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Specific Concerns About APRETUDE at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Pain or soreness from the injection332
Other side effects from APRETUDE472
Fear of needles111
Being approved by my insurance to take it320
Having to take oral PrEP first before I take APRETUDE injections001
Possible long-term effects of the medicine553
How it affects other medications I take320
Scheduling or rescheduling injection visits121
Forgetting my appointment for the injection visits131
Missing an injection visit and then getting HIV020
Missing work for the injection visits120
Making time to go to the clinic/practice for the injection every 2 months121
Travelling to the clinic/practice for the injection visits011
Limited clinic/practice hours for injection visits100
Childcare/caregiver responsibilities during injection visits001
Lack of privacy at injection visits011
My dignity not being respected during injection visits000
People asking why I go to the clinic/doctor every 2 months000
My hectic lifestyle100
My travel or holiday schedules110
Taking medication during times when I am not having sex101
The medication not being effective at preventing HIV120
Worrying that people would think I have HIV311
Worry that people think I have many sexual partners because I use CAB-LA for PrEP111
Worrying about my privacy because I live with someone010
Worrying about my privacy because I'm on my parent's health insurance000
Other120
SecondaryNumber of PSPs With Responses to Specific Concerns About APRETUDE at Month 4

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M4.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 4
ParticipantsSI - PSPEI - PSPECI - PSP
Pain or soreness from the injection411
Other side effects from APRETUDE352
Fear of needles100
Possible long-term effects of the medicine361
The medication not being effective at preventing HIV230
How it affects other medications I take040
Being approved by my insurance to take it211
Scheduling or rescheduling injection visits010
Forgetting my appointment for the injection visits010
Missing an injection visit and then getting HIV101
Missing work for the injection visits110
Making time to go to the clinic/practice for the injection every 2 months020
Travelling to the clinic/practice for the injection visits010
Limited clinic/practice hours for injection visits120
Childcare/caregiver responsibilities during injection visits010
Lack of privacy at injection visits100
My dignity not being respected during injection visits000
People asking why I go to the clinic/doctor every 2 months001
My hectic lifestyle020
My travel or holiday schedules110
Taking medication during times when I am not having sex021
Worrying about forgetting my APRETUDE injection100
Worrying that people would think I have HIV001
Worrying that people would think I have a lot of sexual partners because I am on APRETUDE010
Worrying about my privacy because I live with someone011
Worrying about my privacy because I'm on my parent's health insurance000
Other201
SecondaryNumber of PSPs With Responses to Specific Concerns About APRETUDE at Month 12

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Specific Concerns About APRETUDE at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
Pain or soreness from the injection110
Other side effects from APRETUDE001
Fear of needles100
Possible long-term effects of the medicine001
The medication not being effective at preventing HIV000
How it affects other medications I take011
Change in my insurance coverage for APRETUDE000
Scheduling or rescheduling injection visits000
Forgetting my appointment for the injection visits000
Missing an injection visit and then getting HIV000
Missing work for the injection visits000
Making time to go to the clinic/practice for the injection every 2 months110
Travelling to the clinic/practice for the injection visits010
Limited clinic/practice hours for injection visits000
Childcare/caregiver responsibilities during injection visits000
Lack of privacy at injection visits000
My dignity not being respected during injection visits000
People asking why I go to the clinic/doctor every 2 months000
My hectic lifestyle010
My travel or holiday schedules000
Taking medication during times when I am not having sex000
Worrying about forgetting my APRETUDE injection000
Worrying that people would think I have HIV000
Worrying that people would think I have a lot of sexual partners because I am on APRETUDE000
Worrying about my privacy because I live with someone000
Worrying about my privacy because I'm on my parent's health insurance000
Other000
SecondaryNumber of PSPs With Responses to Acceptability of Bi-monthly Clinic Visits for Injections

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of bi-monthly clinic visits for injections.

Time frame:
At Baseline (Month 1), Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of Bi-monthly Clinic Visits for Injections
ParticipantsSI - PSPEI - PSPECI - PSP
At Baseline — Very acceptable303629
At Baseline — Acceptable191910
At Baseline — Somewhat Acceptable313
At Baseline — A little Acceptable100
At Baseline — Not at all Acceptable000
At Baseline — Missing000
At Month 4 — Very acceptable402428
At Month 4 — Acceptable6145
At Month 4 — Somewhat Acceptable432
At Month 4 — A little Acceptable011
At Month 4 — Not at all Acceptable000
At Month 4 — Missing010
At Month 12 — Very acceptable252017
At Month 12 — Acceptable885
At Month 12 — Somewhat Acceptable441
At Month 12 — A little Acceptable210
At Month 12 — Not at all Acceptable000
At Month 12 — Missing100
SecondaryNumber of PSPs With Responses to Acceptability of HIV and STI Testing Frequency

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of HIV and STI testing frequency.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of HIV and STI Testing Frequency
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Would you say the frequency of HIV testing you have done is — Very acceptable312429
M4 - Would you say the frequency of HIV testing you have done is — Acceptable16156
M4 - Would you say the frequency of HIV testing you have done is — Somewhat acceptable231
M4 - Would you say the frequency of HIV testing you have done is — A little acceptable000
M4 - Would you say the frequency of HIV testing you have done is — Not at all acceptable000
M4 - Would you say the frequency of HIV testing you have done is — Missing111
M4 - Would you say the frequency of STI testing you have done is — Very acceptable312328
M4 - Would you say the frequency of STI testing you have done is — Acceptable15167
M4 - Would you say the frequency of STI testing you have done is — Somewhat acceptable321
M4 - Would you say the frequency of STI testing you have done is — A little acceptable010
M4 - Would you say the frequency of STI testing you have done is — Not at all acceptable000
M4 - Would you say the frequency of STI testing you have done is — Missing111
M12 - Would you say the frequency of HIV testing you have done is — Very acceptable242315
M12 - Would you say the frequency of HIV testing you have done is — Acceptable14116
M12 - Would you say the frequency of HIV testing you have done is — Somewhat acceptable002
M12 - Would you say the frequency of HIV testing you have done is — A little acceptable100
M12 - Would you say the frequency of HIV testing you have done is — Not at all acceptable000
M12 - Would you say the frequency of HIV testing you have done is — Missing111
M12 - Would you say the frequency of STI testing you have done is — Very acceptable232116
M12 - Would you say the frequency of STI testing you have done is — Acceptable14116
M12 - Would you say the frequency of STI testing you have done is — Somewhat acceptable121
M12 - Would you say the frequency of STI testing you have done is — A little acceptable100
M12 - Would you say the frequency of STI testing you have done is — Not at all acceptable000
M12 - Would you say the frequency of STI testing you have done is — Missing111
SecondaryNumber of PSPs With Responses to Local Reactions Following an APRETUDE Injection

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to local reactions following an APRETUDE injection.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Local Reactions Following an APRETUDE Injection
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Did you experience any local reaction(s) following an injection appointment? — Yes211214
M4 - Did you experience any local reaction(s) following an injection appointment? — No272822
M4 - Did you experience any local reaction(s) following an injection appointment? — I don't know120
M4 - Did you experience any local reaction(s) following an injection appointment? — Missing111
M12 - Did you experience any local reaction(s) following an injection appointment? — Yes171011
M12 - Did you experience any local reaction(s) following an injection appointment? — No222311
M12 - Did you experience any local reaction(s) following an injection appointment? — I don't know011
M12 - Did you experience any local reaction(s) following an injection appointment? — Missing111
SecondaryNumber of PSPs With Responses to Acceptability of Local Reactions

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of local reactions following an APRETUDE injection.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of Local Reactions
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Acceptability of local reaction(s) — Totally acceptable133
M4 - Acceptability of local reaction(s) — Very acceptable514
M4 - Acceptability of local reaction(s) — Moderately acceptable776
M4 - Acceptability of local reaction(s) — A little acceptable611
M4 - Acceptability of local reaction(s) — Not at all acceptable200
M12 - Acceptability of local reaction(s) — Totally acceptable424
M12 - Acceptability of local reaction(s) — Very acceptable252
M12 - Acceptability of local reaction(s) — Moderately acceptable931
M12 - Acceptability of local reaction(s) — A little acceptable204
M12 - Acceptability of local reaction(s) — Not at all acceptable000
SecondaryNumber of PSPs With Responses on Return to Daily Activities Post-injection

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses on return to daily activities post-injection (e.g., going back to work, social events, exercise, driving).

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Return to Daily Activities Post-injection
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How often can you return to usual daily activities after an injection appointment? — Never012
M4 - How often can you return to usual daily activities after an injection appointment? — Rarely210
M4 - How often can you return to usual daily activities after an injection appointment? — Sometimes430
M4 - How often can you return to usual daily activities after an injection appointment? — Often1375
M4 - How often can you return to usual daily activities after an injection appointment? — Always303029
M4 - How often can you return to usual daily activities after an injection appointment? — Missing111
M12 - How often can you return to usual daily activities after an injection appointment? — Never011
M12 - How often can you return to usual daily activities after an injection appointment? — Rarely011
M12 - How often can you return to usual daily activities after an injection appointment? — Sometimes131
M12 - How often can you return to usual daily activities after an injection appointment? — Often1176
M12 - How often can you return to usual daily activities after an injection appointment? — Always272214
M12 - How often can you return to usual daily activities after an injection appointment? — Missing111
SecondaryNumber of PSPs Indicating How Bothered by Pain They Were During APRETUDE Injections

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents data indicating how bothered by pain PSPs were during injection.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs Indicating How Bothered by Pain They Were During APRETUDE Injections
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - How bothered were you by pain during the injection? — Not at all17814
M4 - How bothered were you by pain during the injection? — A little172114
M4 - How bothered were you by pain during the injection? — Moderately13105
M4 - How bothered were you by pain during the injection? — Very223
M4 - How bothered were you by pain during the injection? — Extremely010
M4 - How bothered were you by pain during the injection? — Missing111
M12 - How bothered were you by pain during the injection? — Not at all12106
M12 - How bothered were you by pain during the injection? — A little111611
M12 - How bothered were you by pain during the injection? — Moderately1473
M12 - How bothered were you by pain during the injection? — Very213
M12 - How bothered were you by pain during the injection? — Extremely000
M12 - How bothered were you by pain during the injection? — Missing111
SecondaryNumber of PSPs With Responses to Acceptability of Injection-related Pain

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of injection-related pain.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Acceptability of Injection-related Pain
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Acceptability of your pain — Totally acceptable131617
M4 - Acceptability of your pain — Very acceptable16910
M4 - Acceptability of your pain — Moderately acceptable18127
M4 - Acceptability of your pain — A little acceptable132
M4 - Acceptability of your pain — Not at all acceptable120
M4 - Acceptability of your pain — Missing111
M12 - Acceptability of your pain — Totally acceptable16119
M12 - Acceptability of your pain — Very acceptable9139
M12 - Acceptability of your pain — Moderately acceptable974
M12 - Acceptability of your pain — A little acceptable531
M12 - Acceptability of your pain — Not at all acceptable000
M12 - Acceptability of your pain — Missing111
SecondaryNumber of PSPs With Responses to Pain Reduction Strategies Post-injection

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to pain reduction strategies post-injection.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Pain Reduction Strategies Post-injection
ParticipantsSI - PSPEI - PSPECI - PSP
M4 - Took over-the-counter pain relievers201414
M4 - Used a hot compress11118
M4 - Used a cold compress778
M4 - Avoided sitting for long periods of time7124
M4 - Light stretching and exercise6911
M4 - Other322
M4 - None13116
M4 - Missing111
M12 - Took over-the-counter pain relievers161010
M12 - Used a hot compress11811
M12 - Used a cold compress924
M12 - Avoided sitting for long periods of time356
M12 - Light stretching and exercise6125
M12 - Other001
M12 - None1472
M12 - Missing111
SecondaryMean Rating of Pain/Discomfort Following First APRETUDE Injection

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following first APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean Rating of Pain/Discomfort Following First APRETUDE Injection
Scores on a scaleSI - PSPEI - PSPECI - PSP
At Month 44.0 ± 2.994.9 ± 2.933.7 ± 2.80
At Month 124.3 ± 2.554.9 ± 2.935.6 ± 3.20
SecondaryMean Rating of Pain/Discomfort Following Most Recent APRETUDE Injection

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following the most recent APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

Time frame:
At Month 4 and Month 12
Reported as:
Mean · Scores on a scale
Mean Rating of Pain/Discomfort Following Most Recent APRETUDE Injection
Scores on a scaleSI - PSPEI - PSPECI - PSP
At Month 43.3 ± 2.693.8 ± 2.692.3 ± 2.36
At Month 122.2 ± 2.022.6 ± 2.412.8 ± 2.41
SecondaryNumber of SSPs With Influences on and Facilitators/Barriers of Acceptability of APRETUDE Assessed by SSI

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions of the acceptability of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of acceptability of APRETUDE.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Influences on and Facilitators/Barriers of Acceptability of APRETUDE Assessed by SSI
ParticipantsSI - SSPEI - SSPECI - SSP
M4 - Implementation self-efficacy330
M4 - Patient support self-efficacy563
M4 - Enthusiasm about APRETUDE for HIV prevention211822
M4 - Heightened knowledge and awareness887
M12 - Alternative to daily pills10910
M12 - Met expectations15716
M12 - Positive patient reaction12106
M12 - Improved adherence/HIV protection7610
M12 - Bimonthly visits going well421
M12 - More privacy/less stigma510
M12 - Insurance barriers824
M12 - Visit burden/ inconvenience433
M12 - Prevention/ adherence challenges225
M12 - Clinic challenges225
M12 - Injection-site pain322
SecondaryNumber of SSPs With Influences on and Facilitators/Barriers of Feasibility of APRETUDE

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSP perceptions of the feasibility of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of feasibility of APRETUDE.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Influences on and Facilitators/Barriers of Feasibility of APRETUDE
ParticipantsSI - SSPEI - SSPECI - SSP
M12 - Facilitator: Organization of tasks975
M12 - Facilitator: Staffing facilitators241
M12- Facilitator: CABENUVA experience321
M12 - Barrier: Staffing barriers114
M12 - Internal tracking tools323
M12 - Offers injection-only visits548
M12 - Sees prescribing provider on set schedule437
M12 - Sees prescribing provider every visit623
M12 - Prescribing provider is on standby232
M12 - Sees medical assistant most visits534
M12 - Sees nurse most visits414
M12 - Nurses inject748
M12 - Prescribing providers inject454
M12 - Medical assistants inject138
M12 - Visits 30 mins or less1067
M12 - Visits 30 mins to 1 hr354
M12 - Staffing structural limitations171011
M12 - Clinic space limitation646
M12 - Options for appointments limitation562
M12 - Workflow processes limitation412
M12 - Funding and acquisition limitations635
M12 - Increased outreach limitation452
M12 - Cohesive, well-trained staff877
M12 - Organized clinic processes756
M12 - Dedicated staff for key tasks635
M12 - Educating patients545
M12 - Understanding of insurance503
M12 -Materials for patient outreach331
M12 -Improving operations521
M12 - Increasing visit convenience342
M12 - Decreasing cost barriers233
M12 - Nothing they wish they had known352
M12 - Infrastructure needs133
M12 - How to handle insurance and acquisition411
M12 - Fits well with clinic processes15109
M12 - Adjusting and innovating8511
M12 - Fit of bimonthly visits976
M12 - Supportive, well- trained staff767
M12 - Support from ViiV424
M12 - Insurance challenges747
M12 - Challenges initial start-up323
SecondaryNumber of PSPs With Influences of Acceptability of APRETUDE at Baseline

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of acceptability of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Influences of Acceptability of APRETUDE at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Concerns about pain12711
Not concerned about pain141118
Received first injection and experienced pain1487
Has pain management plan181213
Did not receive pain management tips from provider638
PSP concerned about side effect concerns1167
Not concerned about side effects423
Experienced side effects after first APRETUDE injection613
Did not experience side effects after first APRETUDE injection146
Provider discussed side effects313
Provider didn't discuss side effects003
Positive comments about decision to take APRETUDE201317
Negative comments about decision to take APRETUDE433
Positive expectations of APRETUDE331
Negative expectations of APRETUDE110
SecondaryNumber of PSPs With Influences of Acceptability of APRETUDE at Month 12

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of acceptability of APRETUDE at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Influences of Acceptability of APRETUDE at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
APRETUDE as an effective method to help prevent HIV transmission1168
No injection site pain321
Minor injection site pain/discomfort1358
Avoiding contact with injection site or massaging/rubbing the area422
Intense injection site pain131
Managing pain with medication401
Pain management strategies from provider813
Cold or warm compress411
Walking/stretching040
No experienced side effects1126
Endorsed Acceptability of APRETUDE14712
APRETUDE is easier than oral PrEP515
More convenient than daily oral/more convenient way to be protected12511
APRETUDE is confidential/discreet403
APRETUDE is a long-term fit8511
SecondaryNumber of PSPs With Influences of Feasibility of APRETUDE at Baseline

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of feasibility of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Influences of Feasibility of APRETUDE at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Can easily incorporate injections into schedule17118
PSP sees healthcare provider monthly044
PSP sees healthcare provider every 2-4 months520
PSP sees healthcare provider every 6 months812
PSP sees healthcare provider annually200
PSP rarely sees a healthcare provider213
PSP sees healthcare provider only as needed322
Bimonthly appointments have good frequency411
No challenges with accommodating injection schedule764
Identified scheduling challenges, but these will not impact injection schedule846
Identified scheduling challenges will impact injection schedule234
Identified solution to injection scheduling challenges856
Entering appointments into personal calendar431
Using advanced planning to adhere to injection schedule1064
PSP discussed preparedness with clinic staff446
Shared scheduling challenges and preferences with provider232
Working with clinic staff to reschedule appointments when needed321
Expectations for APRETUDE to be more convenient than oral PrEP1189
Expects APRETUDE to be convenient14911
Being able to take time off from work to address work-conflicts332
APRETUDE will be/is a priority522
Work responsibilities are a concern302
Work responsibilities not a concern11611
No transportation challenges201017
Transportation challenges254
Childcare challenges021
No childcare challenges14914
Busy schedule/conflicting responsibilities144
APRETUDE fits well with PSPs' schedule551
Desire for expanded injection availability424
Mentioned injection/appointment reminders312
Mentioned their next APRETUDE related appointment434
Mentioned knowing not to miss doses or appointments111
Received a schedule of all APRETUDE injection appointments111
Received a physical/written appointment schedule200
APRETUDE fits well into other healthcare appointments151210
Discussed factors that increase feasibility3210
Discussed barriers to feasibility032
SecondaryNumber of PSPs With Influences of Feasibility of APRETUDE at Month 12

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of feasibility of APRETUDE at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Influences of Feasibility of APRETUDE at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
APRETUDE is convenient16711
More convenient than daily oral/more convenient way to be protected12511
More people should be aware of APRETUDE convenience312
Positive experience working with clinic staff and provider1576
APRETUDE perceived as providing an additional layer of protection645
Insurance coverage314
Positive injection experience with minimal of side effects432
Receives assistance with transportation023
No challenges or barriers436
Clinic operations: Limited clinic hours and working with staff323
Pain334
Did not have transportation issues505
Had issues with transportation to the clinic743
Substantial traffic and commute to get to clinic521
APRETUDE appointments did not interfere with work schedules1148
Childcare accommodations100
Injection appointments take an hour or less11810
Having to go to specific clinic is inconvenient322
Initially overwhelming injection appointments122
Endorsed feasibility of APRETUDE1267
Appointment reminders and calendar tracking is helpful151011
Clinic staff work to help keep/maintain treatment schedule1245
Clinic flexibility when (re)scheduling appointments is helpful341
APRETUDE appointments do not conflict with other medical appointments14311
Unfavorable Injection schedule633
SecondaryNumber of PSPs Who Had Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Baseline

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of use of oral cabotegravir pills as oral lead-in to APRETUDE injections was gathered using the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs who had OLI before APRETUDE injection.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs Who Had Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Yes10810
No404423
I don't know349
SecondaryNumber of SSPs Reporting Use of Oral lead-in Before APRETUDE Injection on Baseline ISQ

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs who chose OLI before APRETUDE injection at baseline (M1).

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of SSPs Reporting Use of Oral lead-in Before APRETUDE Injection on Baseline ISQ
ParticipantsSI - SSPEI - SSPECI - SSP
No554
Yes, for all patients143
Yes, for some patients863
Not sure152
SecondaryNumber of SSPs Who Chose Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Month 4 and 12

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs who chose OLI before APRETUDE injection at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs Who Chose Oral lead-in Before APRETUDE Injection - Data Collected by ISQ at Month 4 and 12
ParticipantsSI - SSPEI - SSPECI - SSP
M4 - Directly with injection8119
M4 - With optional oral lead-in using oral cabotegravir646
M4 - With oral PrEP (TDF/FTC or TAF/FTC)524
M12 - Directly with injection91110
M12 - With optional oral lead-in using oral cabotegravir436
M12 - With oral PrEP (TDF/FTC or TAF/FTC)225
SecondaryNumber of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions on reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). SSIs were not conducted with SSPs at BL. This outcome measure presents the SSPs with responses on reasons for decision to use OLI assessed by SSI at M4 and M12.

Time frame:
At Month 4 and Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI
ParticipantsSI - SSPEI - SSPECI - SSP
M4 - Use of oral lead-in141318
M12 - Primarily DTI753
M12 - Mix of OLI-DTI330
M12 - DTI is simpler and quicker240
M12 - Lack of clinical justification for OLI231
M12 -Barriers obtaining OLI033
SecondaryNumber of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Baseline

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at baseline (M1).

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Baseline
ParticipantsSI - SSPEI - SSPECI - SSP
The ability to assess the safety/tolerability of APRETUDE in all patients888
Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history10117
The availability of more data from clinical trials using an oral lead-in phase551
The ability to increase drug concentration before starting the injections431
Being cautious with a new medication485
Providing patient with protection against HIV until the injection arrives8113
Patient request1087
Other002
SecondaryNumber of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 4

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M4.

Time frame:
At Month 4
Reported as:
Count of participants · Participants
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 4
ParticipantsSI - SSPEI - SSPECI - SSP
The ability to assess the safety/tolerability of APRETUDE in all patients776
Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history344
The availability of more data from clinical trials using an oral lead-in phase111
The ability to increase drug concentration before starting the injections320
Being cautious with a new medication421
Providing patient with protection against HIV until the injection arrives432
Patient request884
Enough data exists from clinical trials to start patients with injection without oral lead-in455
Provide immediate protection with long-acting PrEP by not using oral lead-in121
Other021
SecondaryNumber of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 12

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of SSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by Surveys at Month 12
ParticipantsSI - SSPEI - SSPECI - SSP
The ability to assess the safety/tolerability of APRETUDE in all patients636
Ability to assess APRETUDE safety/tolerability in patients with allergy or drug intolerance history523
The availability of more data from clinical trials using an oral lead-in phase231
The ability to increase drug concentration before starting the injections210
Being cautious with a new medication322
Providing patient with protection against HIV until the injection arrives353
Patient request664
Enough data exists from clinical trials to start patients with injection without oral lead-in343
Provide immediate protection with long-acting PrEP by not using oral lead-in121
Other013
SecondaryNumber of PSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons for using oral cabotegravir pills as OLI to APRETUDE injections were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs' experiences with and reasons for using OLI or direct-to-injection (DTI) approach, assessed by SSIs.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Reasons for Decision to Use Oral lead-in Assessed by SSI
ParticipantsSI - PSPEI - PSPECI - PSP
Discussed experience of OLI213
Used OLI because PSP was not on oral PrEP to assess side effects or adverse events130
PSP used OLI in case APRETUDE approval was delayed110
PSP used OLI because it was part of the clinic's process012
PSP was unaware of reason for OLI001
OLI experience - positive comments about entire process222
OLI experience - negative comments about entire process020
Confirmed use of DTI11711
Description of DTI process181213
Chose DTI because PSP was already on oral PrEP before737
Chose DTI due to PSPs current sexual behaviors210
PSP decided to use DTI223
PSP was not offered OLI002
PSP unsure why they were DTI101
Chose DTI due to belief that its easier and more convenient than OLI515
Chose DTI to avoid side effects of OLI/oral PrEP112
DTI experience - positive comments about entire process151216
DTI experience - negative comments about entire process812
SecondaryNumber of PSPs With Responses on Decision Making for Use of OLI Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs on reasons for decision to use OLI, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Decision Making for Use of OLI Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
It was primarily my decision765
It was a joint decision between me and my provider313
It was primarily my provider's decision012
Other000
SecondaryNumber of PSPs With Responses on Reasons for Decision for Use of OLI Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses on reasons for decision for use of OLI, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses on Reasons for Decision for Use of OLI Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
The doctor just started me on them447
The doctor wanted to see how I would react to APRETUDE130
I have a history of medication allergies, and the doctor wanted to assess reaction to APRETUDE000
The doctor wanted to be cautious with a new medication010
I wanted to make sure the medication was safe323
I wanted to have protection until the injection arrived after it was ordered212
The doctor wanted me to have protection until the injection arrived after ordering011
Other100
Missing100
SecondaryNumber of PSPs With PrEP History

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. Timeframe for evaluation of this outcome measure is BL.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With PrEP History
ParticipantsSI - PSPEI - PSPECI - PSP
Taken oral PrEP in the last 6 months — Yes342027
Taken oral PrEP in the last 6 months — No173614
Taken oral PrEP in the last 6 months — I prefer not to answer201
Taken oral PrEP in the last 6 months — Missing000
Has ever taken PrEP — Yes452
Has ever taken PrEP — No142813
Has ever taken PrEP — I prefer not to answer000
Has ever taken PrEP — Missing130
SecondaryNumber of PSPs With Responses to Consistency in Oral PrEP Use in Past 6 Months

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to consistency in Oral PrEP use in past 6 months.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Consistency in Oral PrEP Use in Past 6 Months
ParticipantsSI - PSPEI - PSPECI - PSP
I take oral PrEP consistently at least 5 or more days a week each week251017
I take PrEP consistently (at least 5 days a week) off and on which I need to but not every week465
I take oral PrEP for less than 5 days a week each week315
I take oral PrEP on demand/when I need it; this is also called PrEP 2-1-1230
SecondaryNumber of PSPs With Responses to Oral PrEP Duration

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to Oral PrEP duration.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Oral PrEP Duration
ParticipantsSI - PSPEI - PSPECI - PSP
Less than 2 months935
2 to 6 months8910
7 to 12 months512
12 months or more11610
I prefer not to answer000
I don't know110
SecondaryNumber of PSPs Who Completed a SHA and Initiate APRETUDE

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP use of the sexual health assessment (available only to the ECI arm) was gathered via the ISQ. Timeframe for evaluation of this outcome measure is at Baseline (BL) and M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs who completed a SHA and initiate APRETUDE. All PSPs enrolled in the study initiated APRETUDE.

Time frame:
At Baseline (Month 1) and Month 12
Reported as:
Count of participants · Participants
Number of PSPs Who Completed a SHA and Initiate APRETUDE
ParticipantsECI - PSP
BL - Completed a Sexual Health Assessment before being told about this study — Yes27
BL - Completed a Sexual Health Assessment before being told about this study — No6
BL - Completed a Sexual Health Assessment before being told about this study — I don't know8
BL - Completed a Sexual Health Assessment before being told about this study — Missing1
M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — Yes14
M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — No1
M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — I don't know8
M12 - Completed a Sexual Health Assessment in the last 12 months? (ECI only) — Missing1
SecondaryNumber of PSPs With Responses to Experiences With Oral PrEP Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to experiences with Oral PrEP, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Experiences With Oral PrEP Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
Side effects — Yes15810
Side effects — No231719
Insurance issues (e.g., delayed or denial of payment) — Yes651
Insurance issues (e.g., delayed or denial of payment) — No322028
Problems remembering to take oral PrEP — Yes211414
Problems remembering to take oral PrEP — No171115
Concerns about running out of oral PrEP — Yes10137
Concerns about running out of oral PrEP — No281222
Feeling you had to hide oral PrEP from others — Yes987
Feeling you had to hide oral PrEP from others — No291722
Thinking oral PrEP is not convenient for you — Yes181016
Thinking oral PrEP is not convenient for you — No201513
Difficulty paying for oral PrEP — Yes641
Difficulty paying for oral PrEP — No322128
Difficulty swallowing oral PrEP — Yes829
Difficulty swallowing oral PrEP — No302320
Worried about potential interaction with other medicines — Yes1097
Worried about potential interaction with other medicines — No281622
Not liking to take oral PrEP so frequently — Yes251413
Not liking to take oral PrEP so frequently — No131116
Worrying that people may find out you are taking oral PrEP — Yes727
Worrying that people may find out you are taking oral PrEP — No312322
Worrying that people will think you have HIV if they see you taking oral PrEP — Yes13711
Worrying that people will think you have HIV if they see you taking oral PrEP — No251818
Worry that people think you have many sexual partners because you take oral PrEP — Yes15912
Worry that people think you have many sexual partners because you take oral PrEP — No231617
Worrying about your privacy because you live with someone — Yes353
Worrying about your privacy because you live with someone — No352026
Worrying about your privacy because you're on your parent's health insurance plan — Yes212
Worrying about your privacy because you're on your parent's health insurance plan — No362427
Other concerns — Yes634
Other concerns — No322225
SecondaryNumber of PSPs With Responses to Oral PrEP Side Effects Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to Oral PrEP side effects, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Oral PrEP Side Effects Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
Headache762
Diarrhea545
Nausea785
Vomiting322
Rash010
Loss of appetite421
Weight loss010
Stomach pain344
Gas or bloating344
New or worse kidney problems011
Bone problems011
Other111
None202
SecondaryNumber of PSPs With Responses to Frequency of Worry About Oral PrEP Disclosure Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to frequency of worry about Oral PrEP disclosure, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Frequency of Worry About Oral PrEP Disclosure Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
Rarely655
Sometimes725
Often001
All the time000
SecondaryNumber of PSPs With Responses to Reasons for Choosing APRETUDE Assessed by Surveys

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to reasons for choosing APRETUDE, assessed by surveys.

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses to Reasons for Choosing APRETUDE Assessed by Surveys
ParticipantsSI - PSPEI - PSPECI - PSP
I never tried PrEP before, but I want to protect myself from HIV123212
I think APRETUDE is the most effective HIV prevention method available241017
I do not have to worry about HIV every day201211
I will be able to have sex at any moment and I know I am protected16128
I want to keep taking PrEP a secret102
I want a prevention option that is more convenient for my life252218
My sexual partner will not know I am taking PrEP032
My doctor suggested I take APRETUDE10118
My friend, family, acquaintance or co-worker suggested it200
I won't have to remember to take PrEP everyday271317
I often forget to take pills261517
I want to try a new approach and see if it fits into my life141210
I prefer an injection for PrEP because I have difficulty swallowing pills638
I was concerned about the long-term side effects of my oral PrEP473
I do not have to worry or stress about missing a dose like oral PrEP291217
I would feel more comfortable not taking pills when going out with friends775
I would feel more comfortable not taking pills with me when travelling13810
I hope that injections will be easier on my stomach/digestive system15118
Other reasons112
SecondaryNumber of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Baseline

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection. This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at baseline (M1).

Time frame:
At Baseline (Month 1)
Reported as:
Count of participants · Participants
Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Baseline
ParticipantsSI - PSPEI - PSPECI - PSP
Confirmation of previous PrEP history7610
Switched from PrEP - Expects APRETUDE to be convenient14911
Switched from PrEP - Experienced problems with oral PrEP553
Switched from PrEP - Did not experience problems with oral PrEP411
Switched from oral PrEP for convenience946
Switched from oral PrEP specifically due to GI side effects or considerations532
Switched from oral PrEP for fewer side effects442
Switched from oral PrEP for other reasons214
Switched from oral PrEP based on provider recommendation113
Switched from oral PrEP because of the peace of mind APRETUDE provides434
Switched from oral PrEP because of increased privacy that APRETUDE provides202
Switched to APRETUDE due to increased personal perceived HIV risk955
Chose APRETUDE based on experiences from others401
Chose APRETUDE because of busy lifestyle521
Chose APRETUDE because of convenience554
Chose APRETUDE because of adherence concerns (vs. oral)365
Chose APRETUDE due to increased perceived personal HIV risk565
Chose APRETUDE because of side effect considerations210
Chose APRETUDE because of associated peace of mind204
Chose APRETUDE based on provider recommendation.221
Found out about APRETUDE through friends232
Discussed APRETUDE with friends or peers before initiating665
Did not discuss APRETUDE with friends or peers before initiating6511
Did not discuss APRETUDE with friends or peers before starting but would have found it helpful223
Did not discuss APRETUDE with friends or peers before starting and would not find it helpful114
Had a partner who was involved in their decision to take APRETUDE791
Did not involve partner in decision to take APRETUDE16918
Had a partner involved in decision-making who reacted positively to APRETUDE initiation764
Discussed decision to take APRETUDE with family402
Decision to take APRETUDE was supported by their family100
Decision to take APRETUDE received unsupportively by their family102
Used information from provider, clinic, or community to make their choice678
Used information from personal research and past experience to make choice10713
Used information about sexual partners/behavior to make choice233
Used information from provider/clinic to make a choice776
Used information from community members/work to make decision212
Used personal research to make decision7410
Made decision to contribute to research due to positive impact of the study201
Used information from peers/experiences of others to make decision002
Additional information about APRETUDE's efficacy and potential side effects242
Testimonials from people would have been helpful010
Additional information about PrEP in general and APRETUDE112
Insurance details would have been helpful100
Information about administration timeline would have been helpful110
No additional info would have been helpful325
SecondaryNumber of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Month 12

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at M12.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of PSPs With Responses for Choosing or Switching to APRETUDE Assessed by SSI at Month 12
ParticipantsSI - PSPEI - PSPECI - PSP
Challenges remembering daily pill615
APRETUDE is easier than oral PrEP515
Safety and protection8710
Better than the pill332
Confidential/discreet403
APRETUDE addressed adherence challenges124
More education needed for women to choose APRETUDE223
Spoke to friends/ peers about APRETUDE and/or APRETUDE use1065
Talked about APRETUDE and/or APRETUDE use with partner410
Participant talked about APRETUDE and/or APRETUDE use with family623
Believes talking about APRETUDE and sexual health with family is important411
Disclosed APRETUDE use to others967
Feelings about APRETUDE have not changed over time1249
Experience with APRETUDE affirms that it's more convenient than Oral PrEP512
Experience with APRETUDE aligns with initial expectations320
Experience taking APRETUDE was better than initial expectations212
Was initially hesitant about APRETUDE but now feels confident in the decision213
PSP feels more protected from HIV and confident about their sexual health533
Feels encouraged to advocate for APRETUDE/PrEP and has less stigma discussing it210

Adverse events

Collected over Serious adverse events (SAEs) were reported from signing of informed consent (a period starting up to 90 days before the first dose in Month 1) to Month 12 (study completion). Non serious Drug related AEs were reported from Month 1 (first dose) to Month 12 (study completion).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SI - PSP0/56 (0%)1/56 (1.8%)3/56 (5.4%)
EI - PSP0/63 (0%)0/63 (0%)1/63 (1.6%)
ECI - PSP0/44 (0%)1/44 (2.3%)1/44 (2.3%)
Most frequent serious events
Most frequent serious events
EventSI - PSPEI - PSPECI - PSP
Back painMusculoskeletal and connective tissue disorders0/560/631/44
DysarthriaNervous system disorders0/560/631/44
HypoaesthesiaNervous system disorders0/560/631/44
PresyncopeNervous system disorders0/560/631/44
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/560/630/44
Most frequent other events
Most frequent other events
EventSI - PSPEI - PSPECI - PSP
Injection site reactionGeneral disorders0/560/631/44
Influenza like illnessGeneral disorders1/560/630/44
Vulvovaginal candidiasisInfections and infestations1/560/630/44
CyanosisVascular disorders1/560/630/44
MyalgiaMusculoskeletal and connective tissue disorders0/561/630/44
SyncopeNervous system disorders0/561/630/44

Baseline characteristics

Baseline characteristics for SSPs were not collected as it was not required as per study design.

Age, Continuous
Age, Continuous(Years)SI - PSPEI - PSPECI - PSPTotal
Mean38.1 ± 10.8535.9 ± 11.1036.1 ± 8.7336.7 ± 10.41
Sex/Gender, Customized
Sex/Gender, Customized(Participants)SI - PSPEI - PSPECI - PSPTotal
Cisgender Woman493934122
Transgender Woman7241041
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SI - PSPEI - PSPECI - PSPTotal
Black or African American566344163
08

Study locations

22 sites
  • GSK Investigational Site
    Washington D.C., District of Columbia 20005, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20010, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20017-2149, United States
  • GSK Investigational Site
    Miami, Florida 33137, United States
  • GSK Investigational Site
    Orlando, Florida 32808, United States
  • GSK Investigational Site
    Tampa, Florida 33611, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Atlanta, Georgia 30303, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    Bridgeport, Kansas 06605, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89104, United States
  • GSK Investigational Site
    Brooklyn, New York 10001, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19147, United States
  • GSK Investigational Site
    Memphis, Tennessee 38104, United States
  • GSK Investigational Site
    Dallas, Texas 75201, United States
  • GSK Investigational Site
    Houston, Texas 77006, United States
  • GSK Investigational Site
    Houston, Texas 77021, United States
  • GSK Investigational Site
    Norfolk, Virginia 23510, United States
09

References and documents

Publications

  • Nelson KL, Evans Cooper T, Lawson Y, Baker D, Mocherla S, Dieterich M, Hodge T, Dyson A, Sutherland-Philips D, Swygard H, Petty L, Jeffery P, Sutton K, Bonner CP, Andrews SM, Chang S, Budnik P, Smith K, de Ruiter A, Czarnogorski M, Pilgrim N. Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study. J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26497. doi: 10.1002/jia2.26497. PubMed 40600480 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2025, 34 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartActual
Oct 28, 2022
Primary completionActual
Sep 2, 2025
CompletionActual
Sep 2, 2025
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Enrollment
370→295
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMean Intervention Appropriateness Measure (IAM) Score inAssessed for SSPs at Month 12Time frame: Up to Month 13 → At Month 12
Oct 1, 2026
Secondary outcomes
28 edited, 2 added, 152 more
What changed in the outcomes
  • EditedChange fromFrom Baseline in Mean IAM Score inAssessed for SSPs at Month 4, 5, 12 and 13Time frame: Baseline (Month 1) and Month 4, 5, 12 and 13 → At Month 4 and Month 12 compared to Baseline (Month 1)
  • EditedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured interviewInterview (SSI) at Month 4, 5, 12 and 13Time frame: Month 1, 4, 5, 12 and 13 → At Month 4
  • EditedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured interview (SSI) at Month 4, 5, 12 and 13Time frame: Month 4, 5 12 and 13 → At Month 12
  • EditedChange fromFrom Baseline in Mean IAM Score inAssessed for PSPs at Month 4, 5, 12 and 13Time frame: Baseline (Month 1) and Month 4, 5, 12 and 13 → At Month 4 and Month 12 compared to Baseline (Month 1)
  • EditedPerceptionNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by PSP Questionnaire responsesISQs at Month 1, 4, 5, 12 and 13Time frame: Month 1, 4, 5, 12 and 13 → At Month 4
  • EditedPerceptionNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI in PSPsISQs at Month 4, 5, 12 and 13Time frame: Month 4, 5, 12 and 13 → At Month 12
  • EditedNumber of cisCis- and transTrans Black women whoWomen Who Complete a Sexual Health Assessment through Month 13 in ECI Arm based on site-level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
  • EditedNumber of PSPs whoWho Complete a Sexual Health Assessment through Month 13 in ECI Arm based on Site-level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
  • EditedNumber of cis-and trans Black Women who(Both Cis- and Trans) Who Initiate APRETUDE through Month 13 by Study Arm Based on Site level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
  • EditedNumber of cis-and trans Black Women who(Both Cis- and Trans) Who Initiate APRETUDE through Month 13 by Clinic Characteristics Based on Site level PrEP Information QuestionnaireSettingTime frame: Up to Month 13 → Up to Month 12
  • EditedNumber of cis-and trans Black Women who(Both Cis and Trans) Who Continue APRETUDE beyondBeyond a First Dose through Month 13 by study arm based on Site-level PrEP Information QuestionnaireStudy ArmTime frame: Up to Month 13 → Up to Month 12
  • EditedNumber of cis-and trans Black Women who(Both Cis and Trans) Who Continue APRETUDE beyondBeyond a First Dose through Month 13 by Clinic Characteristics based on Site-level PrEP Information QuestionnaireSettingTime frame: Up to Month 13 → Up to Month 12
  • EditedMean Feasibility of Intervention Measure (FIM) score in SSPsScore for Implementation StrategiesPrEP Training Assessed for SSPsTime frame: Month 1 and 4, 5, 12 and 13 → At Month 4 and Month 12
  • EditedNumber of SSPs With Responses to Feasibility and Utility of StrategyImplementation Strategies Assessed in SSPs by SSI at Month 4, 5, 12 and 13Time frame: Month 4, 5, 12 and 13 → At Month 4
  • EditedNumber of PSPs With Responses to Perceptions of Utility of Implementation toolsTools and strategiesStrategies Assessed by SSIs in PSPs through Month 13 based on Patient SubgroupsSSI by Study ArmTime frame: Up to Month 13 → Up to Month 12
  • EditedProportionNumber of Injections Occurring Within the Target Window fromFrom Target Date (+-7 days of target date)Time frame: Up to Month 13 → Up to Month 12
  • EditedProportionNumber of PSPs completing target numberCompleting Target Number of injectionsInjections by Patient SubgroupsTime frame: Up to Month 13 → Up to Month 12
  • EditedPerceptionNumber of SSPs With Responses to Facilitators and Barriers to Implementation in SSPs Assessed by SSISSIs at Month 4Time frame: Month 4, 5, 12 and 13 → At Month 4
  • EditedPerceptionNumber of SSPs With Responses to Facilitators and Barriers to Implementation in SSPs Assessed by IMCSSIs at Month 12Time frame: Month 4, 5, 12 and 13 → At Month 12
  • EditedPerceptionNumber of Clinics With Responses to Facilitators and Barriers to Implementation in PSPs Assessed by SSIIMCsTime frame: Month 1, 12 and 13 → Up to Month 12
  • EditedMean Acceptability of Intervention Measure (AIM) Score Assessed for APRETUDE in SSPs and PSPsTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1), Month 4 and Month 12
  • EditedMean FIM Score Assessed for APRETUDE in SSPs and PSPsTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1), Month 4 and Month 12
  • EditedProportionNumber of PSPs that have oneWho Had Oral lead-in before CABBefore APRETUDE Injection - Data Collected by ISQ at BaselineTime frame: Up to Month 13 → At Baseline (Month 1)
  • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in in SSPs Assessed by SSITime frame: Month 1, 4, 5, 12 and 13 → At Month 4 and Month 12
  • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in SSPs Assessed by Survey responsesSurveys at BaselineTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1)
  • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in PSPs Assessed by SSIsSurveys at Month 4Time frame: Month 1 → At Month 4
  • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in PSPs Assessed by Survey ResponsesSurveys at Month 12Time frame: Month 1 → At Month 12
  • EditedReasonsNumber of PSPs With Responses for Choosing or Switching from Oral PrEP to APRETUDE in PSPs Assessed by SSIsSSI at BaselineTime frame: Up to Month 13 → At Baseline (Month 1)
  • AddedMean IAM Score Assessed for SSPs Over TimeTime frame: At Baseline (Month 1), Month 4 and Month 12
  • AddedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at BaselineTime frame: At Baseline (Month 1)
  • …and 152 more, on the record history on ClinicalTrials.gov ↗
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Enrollment 370→295
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMean Intervention Appropriateness Measure (IAM) Score inAssessed for SSPs at Month 12Time frame: Up to Month 13 → At Month 12
    Secondary outcomes 28 edited, 2 added, 152 more
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Mean IAM Score inAssessed for SSPs at Month 4, 5, 12 and 13Time frame: Baseline (Month 1) and Month 4, 5, 12 and 13 → At Month 4 and Month 12 compared to Baseline (Month 1)
    • EditedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured interviewInterview (SSI) at Month 4, 5, 12 and 13Time frame: Month 1, 4, 5, 12 and 13 → At Month 4
    • EditedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Semi-structured interview (SSI) at Month 4, 5, 12 and 13Time frame: Month 4, 5 12 and 13 → At Month 12
    • EditedChange fromFrom Baseline in Mean IAM Score inAssessed for PSPs at Month 4, 5, 12 and 13Time frame: Baseline (Month 1) and Month 4, 5, 12 and 13 → At Month 4 and Month 12 compared to Baseline (Month 1)
    • EditedPerceptionNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by PSP Questionnaire responsesISQs at Month 1, 4, 5, 12 and 13Time frame: Month 1, 4, 5, 12 and 13 → At Month 4
    • EditedPerceptionNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by SSI in PSPsISQs at Month 4, 5, 12 and 13Time frame: Month 4, 5, 12 and 13 → At Month 12
    • EditedNumber of cisCis- and transTrans Black women whoWomen Who Complete a Sexual Health Assessment through Month 13 in ECI Arm based on site-level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
    • EditedNumber of PSPs whoWho Complete a Sexual Health Assessment through Month 13 in ECI Arm based on Site-level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
    • EditedNumber of cis-and trans Black Women who(Both Cis- and Trans) Who Initiate APRETUDE through Month 13 by Study Arm Based on Site level PrEP Information QuestionnaireTime frame: Up to Month 13 → Up to Month 12
    • EditedNumber of cis-and trans Black Women who(Both Cis- and Trans) Who Initiate APRETUDE through Month 13 by Clinic Characteristics Based on Site level PrEP Information QuestionnaireSettingTime frame: Up to Month 13 → Up to Month 12
    • EditedNumber of cis-and trans Black Women who(Both Cis and Trans) Who Continue APRETUDE beyondBeyond a First Dose through Month 13 by study arm based on Site-level PrEP Information QuestionnaireStudy ArmTime frame: Up to Month 13 → Up to Month 12
    • EditedNumber of cis-and trans Black Women who(Both Cis and Trans) Who Continue APRETUDE beyondBeyond a First Dose through Month 13 by Clinic Characteristics based on Site-level PrEP Information QuestionnaireSettingTime frame: Up to Month 13 → Up to Month 12
    • EditedMean Feasibility of Intervention Measure (FIM) score in SSPsScore for Implementation StrategiesPrEP Training Assessed for SSPsTime frame: Month 1 and 4, 5, 12 and 13 → At Month 4 and Month 12
    • EditedNumber of SSPs With Responses to Feasibility and Utility of StrategyImplementation Strategies Assessed in SSPs by SSI at Month 4, 5, 12 and 13Time frame: Month 4, 5, 12 and 13 → At Month 4
    • EditedNumber of PSPs With Responses to Perceptions of Utility of Implementation toolsTools and strategiesStrategies Assessed by SSIs in PSPs through Month 13 based on Patient SubgroupsSSI by Study ArmTime frame: Up to Month 13 → Up to Month 12
    • EditedProportionNumber of Injections Occurring Within the Target Window fromFrom Target Date (+-7 days of target date)Time frame: Up to Month 13 → Up to Month 12
    • EditedProportionNumber of PSPs completing target numberCompleting Target Number of injectionsInjections by Patient SubgroupsTime frame: Up to Month 13 → Up to Month 12
    • EditedPerceptionNumber of SSPs With Responses to Facilitators and Barriers to Implementation in SSPs Assessed by SSISSIs at Month 4Time frame: Month 4, 5, 12 and 13 → At Month 4
    • EditedPerceptionNumber of SSPs With Responses to Facilitators and Barriers to Implementation in SSPs Assessed by IMCSSIs at Month 12Time frame: Month 4, 5, 12 and 13 → At Month 12
    • EditedPerceptionNumber of Clinics With Responses to Facilitators and Barriers to Implementation in PSPs Assessed by SSIIMCsTime frame: Month 1, 12 and 13 → Up to Month 12
    • EditedMean Acceptability of Intervention Measure (AIM) Score Assessed for APRETUDE in SSPs and PSPsTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1), Month 4 and Month 12
    • EditedMean FIM Score Assessed for APRETUDE in SSPs and PSPsTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1), Month 4 and Month 12
    • EditedProportionNumber of PSPs that have oneWho Had Oral lead-in before CABBefore APRETUDE Injection - Data Collected by ISQ at BaselineTime frame: Up to Month 13 → At Baseline (Month 1)
    • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in in SSPs Assessed by SSITime frame: Month 1, 4, 5, 12 and 13 → At Month 4 and Month 12
    • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in SSPs Assessed by Survey responsesSurveys at BaselineTime frame: Month 1, 4, 5, 12 and 13 → At Baseline (Month 1)
    • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in PSPs Assessed by SSIsSurveys at Month 4Time frame: Month 1 → At Month 4
    • EditedPerceptionNumber of SSPs With Responses on ReasonReasons for Decision to Use Oral lead-in PSPs Assessed by Survey ResponsesSurveys at Month 12Time frame: Month 1 → At Month 12
    • EditedReasonsNumber of PSPs With Responses for Choosing or Switching from Oral PrEP to APRETUDE in PSPs Assessed by SSIsSSI at BaselineTime frame: Up to Month 13 → At Baseline (Month 1)
    • AddedMean IAM Score Assessed for SSPs Over TimeTime frame: At Baseline (Month 1), Month 4 and Month 12
    • AddedNumber of SSPs With Responses to Appropriateness of APRETUDE Assessed by Implementation Science Questionnaire (ISQs) at BaselineTime frame: At Baseline (Month 1)
    • …and 152 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05514509
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Oct 28, 2022
Primary completion
Sep 2, 2025
Completion
Sep 2, 2025
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion